The present invention relates to alkylamines of formula (A) as defined hereafter, to their preparation and to their therapeutic applications.

Antagonists of histamine H3-receptor are known especially to increase synthesis and release of cerebral histamine. Through this mechanism, they induce an extended wakefullness, an improvement in cognitive processes, a reduction in food intake and a normalization of vestibular reflexes (Schwartz et al., Physiol. Rev., 1991,71: 1-51).

Whence these agents are potentially useful in several central nervous system disorders such as Alzheimer disease, mood and attention alterations, cognitive deficits in psychiatric pathologies, obesity, vertigo and motion sickness.

Histamine H3-receptor agonists are known to inhibit the release of several neurotransmitters including histamine, monoamines and neuropeptides and thereby exert sedative and sleep-promoting effects in brain. In peripheral tissues, H3-receptor agonists exert namely anti-inflammatory, anti-nociceptive, gastro-intestinal, antisecretory smooth muscle decontracting activities.

All the H3 receptor antagonist or agonist compounds known so far resemble histamine in possessing an imidazole ring generally monosubstituted in 4 (5)-position (Ganellin et al., Ars Pharmaceutica, 1995,36: 3,455-468; Stark et al., Drug of the Future, 1996,21 (5), 507-520).

Numerous patents and patent applications are directed to antagonist and/or agonist compounds having such structure, in particular EP 197 840, EP 494 010, WO 93/14070, WO 96/29315, WO 92/15 567, WO 93/20061, WO 93/20062, WO 95/11894, US 5 486 526, WO 93/12107, WO 93/12108, WO 95/14007, WO 95/06037, WO 97/29092, EP 680 960, WO 96/38141, WO 96/38142, WO 96/40126.

In the litterature, Plazzi et al., Eur. J. Med. Chem. 1995,30,881, Clitherow et al., Bioorg. & Med. Chem. Lett. 6 (7), 833-838 (1996) Wolin et al., Bioorg. & Med. Chem. Lett; 8,2157 (1998) can be cited also in this respect.

Nevertheless, such imidazole derivatives may show drawbacks such as poor blood-brain barrier penetration, interaction with cytochrome P-450 proteins and/or some hepatic and ocular toxicities.

Non-imidazole known neuro-active compounds such as betahistine (J-M. Arrang et al., Eur. J. Pharmacol. 1985,111: 72-84), phencyclidine (J-M. Arrang et al., Eur. J. Pharmacol. 1988,157: 31-35), dimaprit (J-C Schwartz et al., Agents Actions 1990,30: 13-23), clozapine (M. Kathmann et al., Psychopharmacology 1994,116: 464-468), and sesquiterpenes (M.

Takigawa et al., JP 06 345 642 (20 Dec 1994)) were suggested to display H3- receptor antagonism but all these compounds have only very low potency.

These compounds were previously known as therapeutic agent before the discovery and characterization of the histamine H3-receptor, in particular as neuro-active agents for example as neuroleptic (clozapine) or psychotomimetic (Phencyclidine) agent.

When tested at the H3-receptor, these compounds were shown to display much lower potency than the imidazole-containing compounds described in patent applications quoted above.

Attempts at replacing the imidazole ring was generally not successful and no potent H3-receptor ligands not containing such ring was reported in the literature up to now.

These investigations showed the importance of the 4 (5)-imidazole moiety.

The objective of the invention is to provide new potent H3-receptor ligands which may reduce the above-mentioned drawbacks.

The present invention provides new compounds, the structure of which does not contain an imidazole moiety, which are useful as histamine H3- receptor ligands.

The compounds of the invention have the following general formula (A): in which:

-W is a residue which imparts antagonistic and/or agonistic activity at histamine H3-receptors when attached to an imidazole ring in 4 (5)-position; -R'and R2 may be identical or different and represent each independently . a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a a saturated nitrogen-containing ring with m ranging from 2 to 8, or * a non-aromatic unsaturated nitrogen-containing ring with p and q being from 0 to 3 independently and r being from 0 to 4, provided that p and q are not simulteously 0 and 2 < p + q + r < 8, Ra-d being independently a hydrogen atom or a lower alkyl, cycloalkyl, or carboalkoxy group, or a morpholino group, or a a N-substituted piperazino group: with R being a lower alkyl, cycloalkyl, carboalkoxy, aryl, arylalkyl, an alkanoyl or aroyl group.

The inventors have found, surprisingly, that antagonist and/or agonist compounds can be obtained by substituting a di (alkyl) or (cycloalkyl) amine, or a non-aromatic nitrogen-containing ring-NR1R2 as above- defined for the imidazole ring, in known antagonist and/or agonist imidazole derivatives.

It is also believed that antagonist and/or agonist activity can be foreseen, by equivalence, for compounds according to formula (A) having a W residue of imidazole derivatives which were suggested in the prior art as H3 antagonists or agonists, and further for those W residues which would belong to future imidazole derivatives having substantial H3 antagonist and/or agonist activity.

Moreover, the inventors have observed that such non-imidazole analogues can provide potent antagonist and/or agonist activity.

In this regards, they have prepared novel non-imidazole alkylamines analogues of formula (A) corresponding to known imidazole derivatives in particular from the above-mentioned prior art.

The invention also relates to the addition salts which the compounds form with pharmaceutically acceptable acids. The pharmaceutically acceptable salts comprise the nontoxic salt of inorganic or organic acids.

Examples of these salts include the hydrochloride, the hydrobromide or the hydrogen maleate or hydrogen oxalate.

The present invention also encompasses the hydrates of the compounds, the hydrated salts of these compounds and the polymorphic crystalline structures.

When the compounds can exist in one or a number of isomeric forms according to the number of asymmetric centres in the molecule, the invention relates both to all the optical isomers and to their racemic modifications and the corresponding diastereoisomers. The separation of the diastereoisomers and/or of the optical isomers can be carried out according to methods known per se.

The present invention also encompasses all the possible tautomeric forms of the compounds, whether these tautomers occur in isolated form or in the form of mixtures. * According to the invention, lower alkyl or cycloalkyl is intended to mean a linear or branched alkyl group containing from 1 to 6 carbon atoms, or a saturated carbocycle containing 3 to 6 carbon atoms.

Typically examples of lower alkyl are methyl, ethyl, propyl, isopropyl and butyl groups.

A preferred group of compounds according to the invention comprises those with R'and R2 representing independently a lower alkyl group, especially an ethyl group.

Preferred compounds are also those of formula (A) in which R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring: especially with m being 4,5 or 6, optionally substituted with an alkyl group (Ra), preferably a methyl group.

The groups Ra and Rb are identical or different for each (CRaRb) moiety.

Piperidyl and pyrrolidinyl moieties are especially preferred.

Another preferred group of compounds comprises compounds (A) in which R'and R2 taken together with the nitrogen atom to which they are attached, form a non-aromatic unsaturated nitrogen-containing ring: especially with p, q, and r being independently 1 or 2.

In this group, more preferred compounds are those with p being 2 and q and r each being 1.

A sub-class in this group comprises compounds with Ra-d being each a hydrogen atom.

When NR'R 2 is a nitrogen-containing ring i) or ii) as above- defined, the latter is preferably substituted with one or two lower alkyl group (s), especially a methyl group.

The position for substitution is preferably selected according the followingorder: meta>para>ortho.

In this group, for nitrogen-containing ring bearing only one substituent, this latter is preferably in meta position with respect to the nitrogen- atom.

For nitrogen-containing ring bearing two substituents, meta-meta substitution is preferred, especially when these two substituents are in trans- relation.

According to the invention, piperidyl or pyrrolidinyl moiety substituted in meta or meta-meta position, especially with a methyl group, give particularly preferred compounds.

When NR'R2 represents a N-substituted piperazino group, R may be a lower alkyl e. g. methyl.

Typical examples of group R being an aryl or arylalkyl moiety are phenyl and benzyl.

R may be also an alkanoyl or aroyl group e. g. acetyl or benzol.

In all the possible groups for R, the alkyl moiety refers to a linear or branched chain containing from 1 to 6 carbon atoms.

The cycloalkyl group refers to a saturated carbocycle containing 3 to 7 carbon atoms.

When R represents an aryl or arylalkyl group, the aryl moiety is especially a phenyl group optionally substituted with one or more substituents selected from halogen atoms, advantageously selected from fluorine, chlorine and bromine, or a lower alkyl or cycloalkyl, a trifluoromethyl, aryl, alkoxy, aryloxy, nitro, formyl, alkanoyl, aroyl, arylalkanoyl, amino, carboxamido, cyano, alkyloximino, aryloximino, a-hydroxyalkyl, alkenyl, alkynyl, sulphamido, sulfamoyl, carboxamide, carboalkoxy, arylalkyl or oxime group.

R may be also an optionally substituted benzol, the substituent being as defined above with reference to the phenyl group.

Typical example of-NR'R2 representing a N-substituted piperazino group is N-acetylpiperazino.

According to one aspect, the compounds of the invention have the following general formula (I): in which: -CnH2n is a linear or branched hydrocarbon chain with n ranging from 2 to 8; -X is an oxygen or sulfur atom; -n3 is an integer from 0 to 5; -R3 represents each independently a halogen atom, a lower alkyl or cycloalkyl, a trifluoromethyl, aryl, alkoxy, a- alkyloxyalkyl, aryloxy, nitro, formyl, alkanoyl, aroyl, arylalkanoyl, amino, carboxamido, cyano, alkyloximino, alkylalkoximino, aryloximino, a-hydroxyalkyl, alkenyl, alkynyl, sulphamido, sulfamoyl, sulphonamido, carboxamide, carbonylcycloalkyl, alkylcarbonylalkyl, carboalkoxy, arylalkyl or oxime group, or taken together with the carbon atoms of the phenyl ring to which it is fused, a 5-or 6-membered saturated or unsaturated ring or a benzene ring.

-R1 and R2 are as above-defined in formula (A).

A preferred group of compounds according to the invention is the group composed of compounds of formula (I) in which X is an oxygen atom.

Another preferred group of compounds comprises compounds (I) in which-CnH2n-is a linear chain- (CH2) n- with n being as previously defined.

Preferred compounds are also those with n varying from 3 to 5, and with n being more preferably 3.

A sub-class of compounds according to the invention comprises the compounds of formula (I) with n3 being zero that is those having an unsubstituted phenyl moiety.

Another group of compounds according to the invention is composed of compounds containing one or more substituents R3 which may be identical or different. In this group, the compounds having a mono-or di- substituted (n3 = 1 or 2) phenyl moiety are preferred and those mono- substituted with one group R3 as defined above in para-position are particularly preferred.

Among these compounds, (n3 being 1) R3 is preferably a halogen atom or a cyano, nitro, alkanoyl, alkyloximino or a-hydroxyalkyl group.

Still more preferred compounds are those with R3 being CN, N02, COCH3, COC2H5, H3C-C=N-OH, H3C-CH-OH and cycloalkyl-CO like cyclopropyl-CO.

R3 being a halogen atom may be advantageously selected from fluorine, chlorine and bromine.

R3 being an aryl group, may be especially a phenyl group.

In the other substituents R3, the aryl moiety is advantageously a phenyl moiety.

R3 being an aryloxy group may be especially a phenoxy group.

According to the invention, alkanoyl is intended to mean a group containing an alkyl moiety as defined above.

Typical examples of R3 being an alkanoyl, aroyl or arylalkanoyl group are acetyl, butyryl and propionyl groups, benzoyl group or phenylacetyl group.

Typical examples of R3 forming together with the carbon atoms of the phenyl ring to which it is fused, a saturated ring leads to 5,6,7,8- tetrahydronaphthyl or forming a benzene ring leads to a naphthyl moiety.

According to the invention, alkenyl or alkynyl group may contain advantageously from 1 to 8 carbon atoms, in particular from 1 to 6 carbon atoms and preferably 1 to 4 carbon atoms.

In carboalkoxy, carboxyamido, carbonylcycloalkyl, alkylcarbonylalkyl, or carboxamide groups, the hydrocarbon chain is saturated, linear or branched and contains an alkyl moiety as defined above.

In alkoxy, alkylalkoximino, alkyloximino, a-alkyloxyalkyl, arylalkyl or a-hydroxyalkyl group, the alkyl moiety is as previously defined also.

Particularly preferred compounds are: 1-(5-phenoxypentyl)-piperidine 1- (5-phenoxypentyl)-pyrrolidine N-methyl-N- (5-phenoxypentyl)-ethylamine 1- (5-phenoxypentyl)-morpholine N- (5-phenoxypentyl)-hexamethyleneimine N-ethyl-N- (5-phenoxypentyl)-propylamine 1- (5-phenoxypentyl)-2-methyl-piperidine 1- (5-phenoxypentyl)-4-propyl-piperidine 1- (5-phenoxypentyl)-4-methyl-piperidine 1- (5-phenoxypentyl)-3-methyl-piperidine 1-acetyl-4- (5-phenoxypentyl)-piperazine 1- (5-phenoxypentyl)-3, 5-trans-dimethyl-piperidine 1- (5-phenoxypentyl)-3, 5-cis-dimethyl-piperidine 1- (5-phenoxypentyl)-2, 6-cis-dimethyl-piperidine 4-carboethoxy-1- (5-phenoxypentyl)-piperidine 3-carboethoxy-1- (5-phenoxypentyl)-piperidine 1- 3- (4-cyclopropylcarbonylphenoxy) propyl-piperidine 1- 3- (4-acetylphenoxy)-2-R-methylpropyl piperidine 1- 3- (4-cyanophenoxy) propyl-4-methylpiperidine 1- 3- (4-cyanophenoxy) propyl-3-methylpiperidine 1- 3- (4-acetylphenoxy)-2-S-methylpropyl piperidine 1- {3- 4- (3-oxobutyl) phenoxy] propyl} piperidine 1- 3- (4-cyano-3-fluorophenoxy) propyl piperidine 1- 3- (4-nitrophenoxy) propyl-3-methylpiperidine 1- 3- (4-cyanophenoxy) propyl-2-methylpiperidine 1- 3- (4-nitrophenoxy) propyl-2-methylpiperidine 1- 3- (4-nitrophenoxy) propyl-4-methylpiperidine 1- 3- (4-cyanophenoxy) propyl-2, 6-dimethylpiperidine 1- 3- (4-propionylphenoxy) propyl-3-methylpiperidine

1- 3- (4-cyclobutylcarbonylphenoxy) propyl piperidine 1- 3- (4-cyclopentylcarbonylphenoxy) propyl piperidine 1- 3- (4-cyanophenoxy) propyl-cis-2-methyl-5-ethylpiperidine 1- 3- (4-cyanophenoxy) propyl-trans-2-methyl-5-ethylpiperidine 1- 3- (4-cyanophenoxy) propyl-cis-3, 5-dimethylpiperidine 1- 3- (4-propionylphenoxy) propyl-4-methylpiperidine 1- 3- (4-propionylphenoxy) propyl-2-methylpiperidine 1- {3- 4- (1-hydroxypropyl) phenoxy] propyl}-3-methylpiperidine 1-f3- 4- (l-hydroxypropyl) phenoxy] propyl}-4-methylpiperidine 1- 3- (4-propionylphenoxy) propyl-2-methylpiperidine 1- 3- (4-propionylphenoxy) propyl-4-methylpiperidine methoxime 1- 3- (4-cyanophenoxy) propyl-trans-3, 5-dimethylpiperidine 1- 3- (4-cyclopropyl carbonyl phenoxy) propyl-trans-3,5 -dimethylpiperidine 1- 3- (4-cyclopropyl carbonyl phenoxy) propyl-cis-3,5 -dimethylpiperidine 1- 3- (4-carbomethoxyphenoxy) propyl piperidine 1- 3- (4-propenylphenoxy) propyl-2-methyl piperidine 1- 3- (4-propionylphenoxy) propyl-2-methylpiperidine 1- {3- 4- (1-ethoxypropyl) phenoxy] propyl}-2-methyl piperidine 1- 3- (4-propionylphenoxy) propyl-4-methylpiperidine 1- 3- (4-bromophenoxy) propyl piperidine 1- 3- (4-nitrophenoxy) propyl piperidine 1- 3- (4-N, N-dimethylsulfonamidophenoxy) propyl piperidine 1- 3- (4-isopropylphenoxy) propyl piperidine 1- 3- (4-sec-butylphenoxy) propyl piperidine 1- 3- (4-propylphenoxy) propyl piperidine 1- 3- (4-ethylphenoxy) propyl piperidine 1- (5-phenoxypentyl)-1,2,3,6-tetrahyd ropyrid ine 1- 5- (4-nitrophenoxy)-pentyl-pyrrolid ine 1- 5- (4-chlorophenoxy)-pentyl-pyrrolidine 1- 5- (4-methoxyphenoxy)-pentyl-pyrrolidine

1- 5- (4-methylphenoxy)-pentyl-pyrrolidine 1- 5- (4-cyanophenoxy)-pentyl-pyrrolidine 1- 5- (2-naphthyloxy)-pentyl-pyrrolidine 1- 5- (l-naphthyloxy)-pentyl-pyrrolidine 1- 5- (3-chlorophenoxy)-pentyl-pyrrolidine 1- 5- (4-phenylphenoxy)-pentyl-pyrrolidine 1- {5- 2- (5,6,7,8-tetrahydronaphthyl)-oxy-pentyl}-pyrrolidine 1- 5- (3-phenylphenoxy)-pentyl-pyrrolidine 1- (5-phenoxypentyl)-2, 5-dihydropyrrole 1- {5- 1- (5,6,7,8-tetrahydronaphthyl)-oxy-pentyl}-pyrrolidine 1- (4-phenoxybutyl)-pyrrolidine 1-(6-phenoxyhexyl)-pyrrolidine 1- (5-phenylthiopentyl)-pyrrolid ine 1-(4-phenylthiobutyl)-pyrrolidine 1- (3-phenoxypropyl)-pyrrolidine 1- 5- (3-nitrophenoxy)-pentyl-pyrrolidine 1- 5- (4-fluorophenoxy)-pentyl-pyrrolidine 1- 5- (4-nitrophenoxy)-pentyl-3-methyl-piperidine 1- 5- (4-acetylphenoxy)-pentyl-pyrrolidine 1- 5- (4-aminophenoxy)-pentyl-pyrrolidine 1- 5- (3-cyanophenoxy)-pentyl-pyrrolidine N- 3- (4-nitrophenoxy)-propyl-diethylamine N- 3- (4-cyanophenoxy)-propyl-diethylamine 1- 5- (4-benzoylphenoxy)-pentyl-pyrrolidine 1- {5- 4- (phenylacetyl)-phenoxy-pentyl}-pyrrolidine N- 3- (4-acetylphenoxy)-propyl-diethylamine 1- 5- (4-acetamidophenoxy)-pentyl-pyrrolidine 1- 5- (4-phenoxyphenoxy)-pentyl-pyrrolidine 1- 5- (4-N-benzamidophenoxy)-pentyl-pyrrolidine 1- {5- 4- ( 1-hydroxyethyl)-phenoxy-pentyl}-pyrrolidine 1- 5- (4-cyanophenoxy)-pentyl-diethylamine 1- 5- (4-cyanophenoxy)-pentyl-piperidine

N- 5- (4-cyanophenoxy)-pentyl-dimethylamine N- 2- (4-cyanophenoxy)-ethyl-diethylamine N- 3- (4-cyanophenoxy)-propyl-dimethylamine N- 4- (4-cyanophenoxy)-butyl-diethylamine N- 5- (4-cyanophenoxy)-pentyl-dipropylamine 1- 3- (4-cyanophenoxy)-propyl-pyrrolidine 1- 3- (4-cyanophenoxy)-propyl-piperidine N- 3- (4-cyanophenoxy)-propyl-hexamethyleneimine N- 6- (4-cyanophenoxy)-hexyl-diethylamine N- 3- (4-cyanophenoxy)-propyl-dipropylamine N-3- 4- (l-hydroxyethyl)-phenoxy-propyl-diethylamine 4- (3-diethylaminopropoxy)-acetophenone-oxime 1- 3- (4-acetylphenoxy)-propyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-3-methyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-3, 5-trans-dimethyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-4-methyl-piperidine 1- 3- (4-propionylphenoxy)-propyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-3, 5-cis-dimethyl-piperidine 1- 3- (4-formyl phenoxy)-propyl-piperidine 1- 3- (4-isobutyrylphenoxy)-propyl-piperidine N- 3- (4-propionylphenoxy)-propyl-diethylamine 1- 3- (4-butyrylphenoxy)-propyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-1,2,3,6-tetrahydropyridine More preferred compounds are: 1- 5- (4-nitrophenoxy)-pentyl-pyrrolidine N- 3- (4-cyanophenoxy)-propyl-d iethylamine N- 3- (4-acetylphenoxy)-propyl-diethylamine 1- {5- 4- (1-hyd roxyethyl)-phenoxy-pentyl}-pyrrolid ine N- 4- (4-cyanophenoxy)-butyl-diethylamine 1- 3- (4-cyanophenoxy)-propyl-piperidine N- 3- (4-cyanophenoxy)-propyl-hexamethyleneimine N-3- 4- (l-hyd roxyethyl)-phenoxy-propyl-diethylamine

4- (3-diethylaminopropoxy)-acetophenone-oxime 1- 3- (4-acetylphenoxy)-propyl-3-methyl-piperidine- 1- 3- (4-acetylphenoxy)-propyl-4-methyl-piperidine 1- 3- (4-propionylphenoxy)-propyl-piperidine Compounds of formula (I) in which: -NR1R2 is a pyrrolidinyl group, CnH2n is a linear chain- (CH2) n- and n3 is zero, X being an oxygen atom with n ranging from 3 to 5, or X being a sulfur atom with n being 4 or 5; -NR1R2 is a piperidinyl group, CnH2n is a linear chain- (CH2) n- and X is an oxygen atom, n3 being zero with n being 2,5 or 8 or n3 being 1 with R3 being 4-CN and n being 5; -NR1R2 is a diethylamine group, X is an oxygen atom, CnH2n is a linear chain- (CH2)"- and n3 is 1, R3 being 4-NO2 or 4-COCH3 with n being 3 or R3 being 4-CN with n being 2 to 4; -NR1R2 is a dimethylamine group, X is an oxygen atom, CnH2n is a linear chain- (CH2) n- and n3 is 1, R3 being 4-CN with n being 3, are known in the art.

A subject of the invention is thus the use of these compounds as ligands of the histamine H3-receptors in particular as H3-antagonists, agonists and/or partial agonists, in particular to prepare medicaments acting as ligands for the histamine H3-receptors in particular as H3-antagonists and/or agonists, intended for the treatments detailed below.

According to a second aspect, the object of the present invention is non-imidazole compounds analogous to the compounds disclosed in WO 96/29315 and WO 93/14070.

Thus, a first sub-class of the compounds (A) of the invention is defined by the compounds having the following general formula (Ila) and (llb):

in which -R1 and R2 are as defined with reference to general formula (A); -the chain All represents a saturated or unsaturated, straight or branched hydrocarbon chain containing 1 to 6 carbon atoms, it being possible for the saturated hydrocarbon chain to be interrupted by a hetero atom such as a sulphur atom; X"represents an oxygen or sulphur atom,-NH-, -NHCO-,-N (alkyl) CO-,-NHCONH-,-NH-CS-NH-,-NHCS-,-O-CO-,-CO-O-, -OCONH-,-OCON (alkyl)-,-OCON (alkene),-OCONH-CO-,-CONH-, -CON (alkyl)-,-SO-,-CO-,-CHOH-,-N (saturated or unsaturated alkyl),-S- C (=NY")-NH-Y"-with the Y"identical or different and as defined previously, or -NR"-C (=NR"")-NR'll-, R"and R'll denoting a hydrogen atom or a lower alkyl radical and R"Ii a hydrogen atom or another powerful electronegative group, such as a cyano or COYrIl group, Y1ll denoting an alkoxy group; -the chain B"represents an aryl, arylalkyl or arylalkanoyl group, a straight alkylene chain- (CH2) nil-, n being an integer which can vary between 1 and 5 or a branched alkylene chain containing from 2 to 8 carbon atoms, the alkylene chain being optionally interrupted by one or a number of oxygen or sulphur atoms, or a group- (CH2) nN-0- or- (CH2) n ! !-S- where n is an integer equal to 1 or 2; Y"represents a straight or branched alkyl group containing 1 to 8 carbon atoms; a cycloalkyl containing 3 to 6 carbon atoms; a bicycloalkyl group; a cycloalkenyl group; an aryl group such as an optionally substituted phenyl group; a 5-or 6-membered heterocyclic radical containing one or two heteroatoms chosen from nitrogen and sulphur atoms, the said heterocyclic radical optionally being substituted; or also a bicyclic radical resulting from the fusion of a benzene ring to a heterocycle as defined above.

The chain A can be a straight alkylene chain-(CH2) nil-, n representing an integer between 1 and 6 carbon atoms, preferably between 1 and 4 carbon atoms, or a branched alkylene chain, preferably a chain substituted by one or a number of methyl or ethyl radicals.

The chain All can also be a straight or branched unsaturated alkylene chain, and can be, for example, the allyl group.

When Y"represents a cycloalkyl group, the latter can be, for example, cyclopentyl, cyclohexyl or a bicycloalkyl group.

When Y"represents a substituted phenyl group, the phenyl group can be mono-or polysubstituted, for example, by a halogen, by a lower alkyl, for example CH3, by CF3, CN, COCH3, COORIl1 or OR"i,. R"i representing a lower alkyl, for example COOCH3, the N02 group or the group NRIl2Rll3, Roll2 and R"s representing a hydrogen atom and/or a lower alkyl radical ("lower alkyl"means an alkyl radical containing at most 6 carbon atoms).

When Y"represents a heterocyclic radical, the latter can be, for example, the pyridyl radical, the pyridyl N-oxide radical or the pyrazinyl radical, optionally mono-or polysubstituted by N02, CF3, CH3, NH2, a halogen such as Cl, the COOCH3 group or also the thiazolyl radical.

When Y"represents a polycyclic radical resulting from condensed aromatic or heteroaromatic moieties the radical can be, for example, the benzothiazolyl, quinolinyl, isoquinolinyl radical or related moieties.

A second sub-class of the compounds (A) according to the invention comprises the compounds having the above-formulae (Ila) and (llb) in which: -R'R2 are as defined with reference to general formula (A); -the chain A"represents an unbranched, branched or unsaturated alkyl group- (CH2) nil-where nil is an integer which can vary between 1 and 8 and preferably between 1 and 4; an unbranched or branched alkene group comprising from 1 to 8 carbon atoms and preferably 1 to 4 carbon atoms; an unbranched or branched alkyne group comprising from 1 to 4 carbon atoms; -the group X"represents-OCONH- ;-OCON (alkyl)- ; -OCON (alkene)-;-OCO-;-OCSNH-;-CH2-;-O-;-OCH2CO-;-S-;-CO-;-CS-; amine; saturated or unsaturated alkyl; -the chain B"represents an unbranched, branched or unsaturated lower alkyl comprising from 1 to 8 carbon atoms and preferably 1 to

5 carbon atoms;- (CH2) nn (hetero atom)-where the hetero atom is preferably a sulphur or oxygen atom; nil being an integer which can vary between 1 and 5, preferably between 1 and 4; -the group Y"represents a phenyl group, unsubstituted or mono-or polysubstituted with one or more identical or different substituents selected from halogen atoms, OCF3, CHO, CF3, S02N (alkyl) 2 such as S02N (CH3) 2, N02, S (alkyl), S (aryl), SCH2 (phenyl), an-unbranched or branched alkene, an unbranched or branched alkyne optionally substituted with a trialkylsilyl radical,-O (alkyl),-O (aryl),-CH2CN, a ketone, an aldehyde, a sulphone, an acetal, an alcohol, a lower alkyl,-CH=CH-CHO,-C (alkyl) =N-OH, -C (alkyl) =N-O (alkyl) and other keto derivatives,-CH=NOH,-CH=NO (alkyl), and other aldehyde derivatives,-C (alkyl) =NH-NH-CONH2, an O-phenyl or -OCH2 (phenyl) group,-C (cycloalkyl) =NOH,-C (cycloalkyl) =N-O (alkyl), an optionally substituted heterocycle; a heterocycle comprising a sulphur hetero atom; a cycloalkyl; a bicyclic group and preferably a norbornyl group; a phenyl ring fused to a heterocycle comprising a nitrogen hetero atom or to a carbocycle or a heterocycle bearing a keto function; an unbranched or branched lower alkyl comprising from 1 to 8 carbon atoms; an unbranched or branched alkyne comprising from 1 to 8 carbon atoms and preferably 1 to 5 carbon atoms; a linear or branched alkyl mono-or polysubstituted with phenyl groups which are either unsubstituted or mono-or poiysubstituted; a phenyl alkyl ketone in which the alkyl group is branched or unbranched or cyclic; a substituted or unsubstituted benzophenone; a substituted or unsubstituted, unbranched or branched or cyclic phenyl alcohol; an unbranched or branched alkene; a piperidyl group; a phenylcycloalkyl group; a polycyclic group, in particular a fluorenyl group, a naphthyl or polyhydronaphthyl group or an indanyl group; a phenol group; a ketone or keto derivative; a diphenyl group; a phenoxyphenyl group; a benzyloxyphenyl group.

According to the invention, group X"representing an amine is understood to mean a secondary or tertiary amine.

The alkyl, alkene, alkyne, keto, aldehyde, cycloalkyl, S-alkyl, O- alkyl, phenyl alcohol and phenyl-cycloalkyl groups mentioned above as well as

in the remainder of the description and the claims of the present patent comprise from 1 to 8 carbon atoms, and preferably 1 to 5.

Likewise, keto derivatives are understood to mean any oxime, alkyloxime, hydrazone, acetal, aminal, ketal, thione, carbazone or semicarbazone group and the thio analogues of these derivatives.

Likewise, by mono-or polysubstituted phenyl and/or benzophenone groups, it is understood to mean that these groups are substituted with one or more identical or different substituents selected from halogen atoms, OCF3, CHO, CF3, SOIN (alkyl) 2, S02N (CH3) 2, N02, S (alkyl), S (aryl), SCH2 (phenyl), an unbranched or branched alkene, an unbranched or branched alkyne optionally substituted with a trialkylsilyl radical,-O (alkyl), -O (aryl),-CH2CN, a ketone, an aldehyde, a sulphone, an acetal, an alcohol, a lower alkyl,-CH=CH-CHO,-C (alkyl) =N-OH,-C (alkyl) =N-O (alkyl) an other keto derivatives,-CH=NOH,-CH=NO (alkyl), and other aldehyde derivatives, -C (alkyl) =NH-NH-CONH2, an O-phenyl or-OCH2 (phenyl) group, -C (cycloalkyl) =NOH,-C (cycloalkyl) =N-O (alkyl), an optionally substituted heterocycle.

The keto substituent is preferably selected from a linear-or branched-chain aliphatic ketone, it being possible for the said chain to comprise from 1 to 8 carbon atoms and optionally to bear a hydroxyl group, a cycloalkyl ketone, an aryl alkyl ketone or aryl alkenyl ketone in which the aryl group is unsubstituted or mono-or polysubstituted, or a heteroaryl ketone in which the heteroaryl unit is preferably monocyclic.

The acetal substituent preferably consists of an aliphatic acetal comprising from 1 to 8 carbon atoms and optionally bearing a hydroxyl radical.

Group Y"representing a ketone is understood to mean, in particular, a ketone substituted with an alkyl or aryl group, it being possible for these groups to be substituted or unsubstituted.

As regards the heterocycles, these comprise from 1 to 3 hetero atoms, preferably sulphur, oxygen or nitrogen atoms.

The heterocycle substituent is preferably selected from an oxadiazole or an imidazole.

Preferred compounds (Ila) and (Ilb) are those in which X"is selected from-0-,-NH-,-CH2-,-OCONH-,-NHCO-,-NHCONH-. X"represents more preferably an oxygen atom.

Preferred compounds (Ila) and (llb) are also those in which Y"is selected from a linear or branched alkyl group as above defined; a cycloalkyl group as above-defined, in particular cyclopentyl or cyclohexyl group; a phenyl group unsubstituted or mono-substituted, preferred substituent being halogen atom, in particular chorine; a heterocyclic radical, in particular pyridyl N-oxide or pyrazinyl radicals; a bicyclic radical such as a benzothiazolyl radical.

Y"is preferably a phenyl group at least mono-substituted with -CHO, a ketone, an aldehyde,-CH=CH-CHO,-C (alkyl) =N-OH,-C (alkyl) =N- O (alkyl) and other keto derivatives,-CH=N-OH,-CH=NO (alkyl) and other aldehyde derivatives,-C (cycloalkyl) =NOH,-C (cycloalkyl) =N-O (alkyl).

According to the invention, Y"represents especially a phenyl group at least mono-substituted with a keto-substituent or an oxime-substituent, or an halogen atom.

Particularly preferred keto-substituent is cycloalkylketone.

Other preferred compounds are those wherein Y"represents a phenyl group fused to a carbocycle bearing a keto-function.

Yet other preferred Y"are phenylalkyl ketone in which the alkyl group is branched or unbranched or cyclic; an optionally substituted benzophenone, a ketone.

Particularly preferred group Y"are a phenyl group unsubstituted or mono-substituted as above-defined.

The chain All is preferably a chain- (CH2)"n with nil varying from 1 to 6, preferably from 1 to 4. The chain All represents especially - (CH2) 3-.

Preferred chain B"is- (CH2) 2- or- (CH2) 3-.

Among compounds (Ila) and (Ilb), particularly preferred compounds are those in which X"is an oxygen atom, the chain All represents- (CH2) 3- and, for compounds of formula (Ila), the chain B"represents- (CH2) 3- also.

In this group, Y"is preferably an aryl group.

Preferred group R'and R2 are as above-defined with reference to formula (A).

Examples of compounds (Ila) and (Ilb) are: -3,3-Dimethylbutyl 3-piperidinopropyl ether -3-Phenylpropyl 3-piperidinopropyl ether -3- (4-Chlorophenyl) propyl 3-piperidinopropyl ether -2-Benzothiazolyl 3-piperidinopropyl ether -3-Phenylpropyl 3- (4-methylpiperidino) propyl ether -3-Phenylpropyl 3- (3, 5-cis-dimethylpiperidino) propyl ether -3-Phenylpropyl 3- (3, 5-trans-dimethylpiperidino) propyl ether -3-Phenylpropyl 3- (3-methylpiperidino) propyl ether -3-Phenylpropyl 3-pyrrolidinopropyl ether -3- (4-Chlorophenyl) propyl 3- (4-methylpiperidino) propyl ether -3- (4-Chloro phenyl) propyl 3- (3,5-cis -dimethyl piperidino) propyl ether -3- (4-Chloro phenyl) propyl 3- (3, 5-trans-dimethyl piperidino) propyl ether -3-Phenylpropyl 3- (N, N-diethylamino) propyl ether -N-Phenyl-3-piperidinopropyl carbamate -N-Pentyl-3-piperidinopropyl carbamate - (S)- (+)-N- 2- (3, 3-Dimethyl) butyl-3-piperidinopropyl carbamate -3-Cyclopentyl-N- (3- (1-pyrrolidinyl) propyl) propanamide -N-Cyclohexyl-N'- (1-pyrrolidinyl-3-propyl) urea -2-((2-Piperidinoethyl)((2-Piperidinoethyl) amino) benzothiazole -5-Piperidinopentylamine -2-Nitro-5- (6-piperidinohexyl) pyridine -3-Nitro-2- (6-piperidinohexylamino) pyridine

-2-(6-Piperidinohexylamino) pyrimidine -N-(6-Phenylhexyl)(6-Phenylhexyl) piperidine N- (3- (N, N-Diethylamino) propyl) N'-phenylu rea -N-Cyclohexylmethyl-N'- (3-piperidinopropyl) guanidine According to a third aspect, the object of the present invention is non-imidazole compounds analogous to the compounds disclosed in EP 197 840.

Thus, a sub-class of compounds (A) according to the invention comprises compounds having the following formula (III) inwhich: . NR1R2 is either in 3-position or in 4-position on the piperidyl moiety, R1 and R2 being as defined with reference to formula (A); R2n denotes a linear or branched alkyl group having 1 to 6 carbon atoms; a piperonyl group, a 3- (1-benzimidazolonyl) propyl group; a group of formula

and Rs'"is H, CH3, halogen, CN, CF3 or an acyl group -COR4'", R4... being a linear or branched alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or a phenyl group which can bear a CH3 or F substituent; or alternatively a group of formula in which Z'"denotes an O or S atom or a divalent group NH, N- CH3 or N-CN and R5'"denotes a linear or branched alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms which can bear a phenyl substituent, a (C3-C6 cycloalkyl) (linear or branched, Cl-C3 alkyl) group, a phenyl group which can bear a CH3, halogen or CF3 substituent, a phenyl (linear or branched, Cl-C3 alkyl) group or a naphthyl, adamantyl or p- toluenesulphonyl group.

Preferred compounds (III) are those with Rlil representing the group , Zlll and Rlil5 being as above-defined and Zl"is especially O, S or NH.

Preferred group Rail5 is a (C3-C6) cycloalkyl group.

Preferred R'and R2 groups are as above-described in formula (A).

An example of such compound (III) is N'-Cyclohexylthiocarbamoyl- N-1,4'-bipiperidine (compound 123).

According to a fourth aspect, a sub-class of compounds (A) includes the compounds which have the following formula (IV), analogous to compounds disclosed in EP 494 010:

in which -R'and R2 are as defined with reference to general formula (A); -Rlv represents a hydrogen atom or a group COR3lv, in which Rem represents (a) a linear or branched aliphatic group containing 1 to 11, and in particular 1 to 9, carbon atoms; (b) a cyclane ring-system such as cyclopropane, phenylcyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, norbornane, adamantane, noradamantane, chlorooxonorbornane, chloroethylenedioxynorbornane, bromoethylenedioxynorbornane and the anhydride group of hydroxycarboxy-1,2,2-trimethylcyclopentanecarboxylic acid; (c) a benzene ring, unsubstituted or substituted at the para- position with a linear or branched aliphatic group containing 3 to 5 carbon atoms, as well as with a halogen; (d) a group (CH2) m, vR4'v in which mlv is a number between 1 and 10, and R4lv represents a cyclane ring system such as cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cycloheptane, norbornane, noradamantane, adamantane and 6,6-dimethylbicyclo [3.1.1] heptene; a benzene ring, unsubstituted or monosubstituted with a fluorine atom, a chlorine atom, a methyl group or a methoxy group; a thiophene ring grafted via its ring-position 2 or its ring-position 3; a carboxylic acid ester group COORs, in which R5lv is a cyclane ring-system such as cyclopropane, cyclobutane, cyclopentane, cyclohexane or norbornane; a carboxylic acid amide group of structure CONHR6lv, in which Re represents a cyclane ring-system such as cyclopropane, cyclobutane, cyclopentane, cyclohexane or norbornane; a carboxylic acid amide group of structure in which the group

represents pyrrolidine, piperidine or or an ether group- 0-R7'\ it being possible for R7lv to be a benzene ring, unsubstituted or monosubstituted with a chlorine or fluorine atom or disubstituted with a chlorine atom and with a methyl group; (e) a group-CH=CHR8tV, in which R8'v represents a cyclane ring-system such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, norbomane or norbornene; (f) a secondary amine group-NH (CH2) n, vRglv, in which nlv is a number between 1 and 5 and Rgiv constitutes a cyclane ring-system such as cyclopropane, cyclobutane, cyclopentane, cyclohexane or norbornane, or a benzene ring, unsubstituted, mono-substituted with a fluorine or chlorine atom or with a methoxy group or trisubstituted with methoxy groups; Rlv also represents a hydroxyalkenyl group in which piu is a number between 2 and 9 and Riz'\ represents a benzene ring or a phenoxy group; as well as a group CSNH (CH3) n, vRglv -in which nlv is a number between 1 and 5 and Rgiv has the meaning stated above.

Preferred compounds (IV) are those in which Rlv represents the group COR3'\ R3lv representing especially an aliphatic group a).

An example of compound (IV) is N-Heptanoyl-1,4'-bipiperidine or 1- (5-Cyclohexylpentanoyl)-1, 4-bipiperidine.

According to a fifth aspect, the invention is relative to non- imidazole compounds analogous to those disclosed by Plazzi et al. (Eur. J.

Med. Chem. 1995,30,881).

Thus, another sub-class of compounds (A) comprises compounds having the following formula (V):

in which -R'and R2 are as defined with reference to formula (A) in claim 1; -qVis2tO5 zv represents NH, O or S -Xv represents a heterocycle, optionally condensed, containing one or more heteroatoms like nitrogen, oxygen or sulfur, unsubstituted or substituted by one or more groups like aryl, lower alkyl and halogen.

Preferred compounds are those with xV being an heterocycle like : with yv representing an hydrogen atom, an halogen or a lower alkyl.

Examples of compounds (V) are: 2-((2-Piperidinoethyl)((2-Piperidinoethyl) amino) benzothiazole

2-(6-Piperidinohexylamino)benzothiazole 4- (6-Piperidinohexylamino) quinoline 2-Methyl4- (3-piperidinopropylamino) quinoline 2-Methyl 4-(6-piperidinohexylamino) quinoline 7-Chloro-4- (3-piperidinopropylamino) quinoline 7-Chloro-4- (4-piperidinobutylamino) quinoline 7-Chloro-4- (8-piperidinooctylamino) quinoline 7-Chloro-4- (10-piperidinodecylamino) quinoline 7-Chloro-4- (12-piperidinododecylamino) quinoline 7-Chloro-4- (4- (3-piperidinopropoxy) phenylamino) quinoline 7-Chloro-4- (2- (4- (3-piperidinopropoxy) phenyl) ethylamino) quinoline According to a sixth aspect, the present invention concerns non- imidazole compounds which are analogous to those disclosed in WO 95/14007.

Thus, another subclass of compounds (A) inclues the compounds having the following formula (Vl): wherein: Avl is selected from-O-CO-NR'v,-,-O-CO-,-NR'v,-CO-, -NRVI¹-,-NRvI¹-CO-,-NRvI¹-,-O-,-CO-NRvI¹-, -CO-O-, and -C(=NRvI¹)-NRvI¹-; -the groups R1vl, which may be the same or different when there are two or three such groups in the molecule of formula VI, are selected from hydrogen, and lower alkyl, aryl, cycloalkyl, heterocyclic and heterocyclyl- alkyl groups, and groups of the formula- (CH2) yvl-GVl, where GVI is selected from CO2R3VI, CORVI³VI, CONRVI³RVI4, OR3VI, SRVI³, NRVI³RVI4, heteroaryl and phenyl, which phenyl is optionally substituted by halogen, lower alkoxy or polyhaloloweralkyl, and Yvl is an integer from 1 to 3;

-R2v, is selected from hydrogen and halogen atoms, and alkyl, alkenyl, alkynyl and trifluoromethyl groups, and groups of the formula OR3vI, SR3, and NR VIR VI; -R3VI and R4vl are independently selected from hydrogen, and lower alkyl and cycloalkyl groups, or R3vl and R V, together with the intervening nitrogen atom can form a saturated ring containing 4 to 6 carbon atoms that can be substituted with one or two lower alkyl groups; -the group- nvl-AVl-R1vl is at the 3-or 4-position, and the group R 2vi is at any free position; -mVI is an integer from 1 to 3; -and nv is 0 or an integer from 1 to 3.

When used herein, the following terms have the given meanings: lower alkyl (including the alkyl portions of lower alkoxy)- represents a straight or branched, saturated hydrocarbon chain having from 1 to 6 carbon atoms, preferably from 1 to 4; lower alkenyl (in R2vl)-represents a straight or branched aliphatic hydrocarbon radical having at least one carbon-to-carbon double bond (preferably in conjugation with the benzene ring that the group R2 substitutes) and having from 2 to 6 carbon atoms; lower alkynyl (in R2vl)-represents a straight or branched aliphatic hydrocarbon radical having at least one carbon-to-carbon triple bond (preferably in conjugation with the benzene ring that the group R2 substitutes) and having from 2 to 6 carbon atoms; aryl-represents a carbocyclic group having from 6 to 14 carbon atoms and having at least one benzenoid ring, with all available substitutable aromatic carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted with 1 to 3 Yvl groups, each independently selected from halo, alkyl, hydroxy, loweralkyoxy, phenoxy, amino, loweralkylamino, diloweralkylamino, and polyhaloloweralkyl. Preferred aryl groups include 1-naphthyl, 2-naphthyl and indanyl, and especially phenyl and substituted phenyl;

cycloalkyl-represents a saturated carbocyclic ring having from 3 to 8 carbon atoms, preferably 5 or 6; halogen-represents fluorine, chlorine, bromine and iodine; heterocyclic-represents, in addition to the heteroaryl groups defined below, saturated and unsaturated cyclic organic groups having at least one O, S and/or N atom interrupting a carbocyclic ring structure that consists of one ring or two fused rings, wherein each ring is 5-, 6--or 7-membered and may or may not have double bonds that lack delocalized pi electrons, which ring structure has from 2 to 8, preferably from 3 to 6 carbon atoms; e. g., 2-or 3- piperidinyl, 2-or 3-piperazinyl, 2-or 3-morpholinyl, or 2-or 3-thiomorpholinyl; heteroaryl-represents a cyclic organic group having at least one O, S and/or N atom interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic group having from 2 to 14, preferably 4 or 5 carbon atoms, e. g., 2-, 3-or 4-pyridyl, 2-or 3-furyl, 2-or 3-thienyl, 2-, 4-or 5-thiazolyl, 2-or 2-, 4-or 5-pyrimidinyl, 2-pyrazinyl, or 3-or 4-pyridazinyl, etc.

Preferred heteroaryl groups are 2-, 3-and 4-pyridyl; heterocyclyl-alkyl-represents a heterocyclic group defined above substituting an alkyl group; e. g., 2- (3-piperidinyl)-ethyl, (2-piperazinyl)-methyl, 3- (2-morpholinyl)-propyl, (3-thiomorpholinyl)-methyl, 2- (4-pyridyl)-ethyl, (3- pyridyl)-methyl, or (2-thienyl)-methyl.

Preferably, AVl is-CH2-NR1vl-or especially-C (=NH)-NR1vl- preferred compounds include those wherein mVI is 1 or 2, and nvt is 0,1 or 2.

Other preferred values of A include-O-CO-NRv,-,-O-, and -CO-O-. In all these compounds, the groups R1vl are as defined above, and the side chain is preferably at the 4-position. In compounds of formula VI, one group R1vl is preferably selected from hydrogen, 2-phenylethyl, 4- chlorophenylmethyl, 4-methoxyphenylmethyl, 4-trifluoromethylphenylmethyl and 4-pyridylmethyl, but is especially 4-chlorophenylmethyl; any other group Rlvl that is present is preferably a hydrogen atom or a methyl group.

Particularly preferred compounds are those wherein nez and mv, are each 1, and A'represents an oxygen atom.

Rlvl is preferably an aryl or- (CH2) yvl-GVl with Gel seing a phenyl.

R'and R2 are preferably selected as specified with reference to formula (A).

Another sub-class of compounds (A) comprises compounds of formula (VI) wherein Rlvl represents an aryl group, especially a phenyl optionally substituted with a keto substituent, R VI, nvi, mv, and Aval shaving the above-meaning.

The keto substituent is as above-defined in Y"with reference to compounds (Ila) and (lob).

Preferred compounds are those with nv and mv being each 1 and Avl being an oxygen atom.

Examples of compounds VI are : a- (Acetylphenoxy)-a'-piperidino p-xylol a- (4-Acetylphenoxy)-a'- (1-pyrrolidinyl) p-xylol a- (3-Phenylpropoxy)-a'-piperidino p-xylol a- (4-Acetylphenoxy)-a'- (4-methylpiperidino) p-xylol a- (4-Acetylphenoxy)-a'- (3, 5-cis-dimethylpiperidino) p-xylol a- (4-Acetylphenoxy)-a'- (3, 5-trans-dimethylpiperidino) p-xylol a- (4-Acetylphenoxy)-a'- (2-methylpyrrolidino) p-xylol a- (4-Cyclopropylcarbonylphenoxy)-a'-piperidino-p-xylol a- (4-Cyclopropylcarbonylphenoxy)-a'- (4-methylpiperidino) p -xylol a- (4-Cyclopropylcarbonylphenoxy)-a'-pyrrolidino-p-xylol N- (4-Chlorobenzyl)-2- (4-piperidino methyl) phenyl) ethan -amidine According to a seventh aspect, the present invention is directed to another sub-class of compounds (A) including non-imidazole compounds having the following formula (VII) which are analogous to compounds disclosed in Clitherow et al. (Bioorg. & Med. Chem. Lett., 6 (7), 833,1996):

in which -R1 and R2 are as defined in reference to formula (A); -XVII, YVII and ZVII are identical or different and represent O, N or S; -nvil is varying from 1 to 3; -mail is 1 or 2. nVII is preferably 2 or 3, especially 2 and mv, is preferably 1.

Preferred compounds are those with XVll being 0 and Y'and Z" each being N to represent a 1,2,4-oxadiazolyl group.

An illustrative compound is given in example 130.

According to a eighth aspect, the present invention is directed to another sub-class of compounds (A) including the non-imidazole compounds having the following formula (Vlil), which are analogous to those disclosed in WO 95/06037: wherein R1 and R2 are as defined with reference to formula (A) and wherein A'is 1) a group of the formula (CH2) mvill, wherein mv", = 0-9; or 2) a group of the formula:

wherein RVIII5 represents hydrogen, (Ci-C3) alkyl-, aryl (C1-C3) alkyl-, aryl-, wherein aryl may optionally be substituted, hydroxyl-, (C1-C3) alkoxy-, halogen, amino-, cyano-or nitro; and R VII, represents hydrogen, (Ci-C3) alkyl-, aryl (C1- C3) alkyl-, or aryl-, wherein aryl may optionally be substituted; or 3) a group of the formula: wherein RVIII5 and RVIII6, are as defined above; or 4) a group of the formula: if Bill ils a group of the formula: such that AVIII and BVIII together form a group of the formula: wherein RVIII6 is as defined above; or 5) a group of the formula: wherein Rsvill is as defined above; or 6) a group of the formula: IC -C-C= c-c if BVIll is a group of the formula : R6n such that AVIII and BVIII together form a group of the formula:

wherein RVIII6 is as defined above; or 7) a group of the formula: -(CH2,)XVIII-S-(CH2)YVIII- wherein XVIII + YVIII = mvIII-1; BVIII iS 1) a group of the formula: wherein R5vill is as defined above; or 2) a group of the formula: if A is a group of one of the formulas: such that A and B together form a group of one of the formulas: wherein R6vill is as defined above; or 3) a group of the formula: if XVill is a group of the formula:

such that BVIII and XVIII together form a group of the formula wherein Pvill = 1-3; or xvillis 1) a group of the formula (CH2) nvn wherein nvn = 2-4; or 2) a group of the formula: if Bill ils a group of the formula: such that X'"and B"'together form a group of the formula: wherein Pvill = 1-3; or 3) two hydrogens (one on the carbon and one on the nitrogen); or 4) one hydrogen on the carbon atom and one RVIII7, group on the nitrogen atom, wherein RVIII7 represents hydrogen, (C1-C10)alkyi-, aryl (C1-C10)alkyl-, or aryl, wherein aryl may optionally be substituted; Yvn ; s a group of the formula (CH2) kvm, wherein kvill = 0-2; RVIII4 represents hydrogen, (Ci-Cio) alkyl-, (Ci-C3) alkyl-sulfonamide-, aryl (C1- Ciao) alkyl-, aryl, wherein aryl may optionally be substituted; or a group of the formula: or a group of the formula:

wherein XVlil represents O, S, or NH, R7vlll is as defined as above; R8vill represents (Ci-Cio) alkyl-, aryl (C1-C10) alkyl-or aryl, wherein aryl may optionally be substituted and wherein aryl is phenyl, substituted phenyl, naphtyl, substituted naphtyl, pyridyl.

The present invention comprises both! inear and ringstructured compounds.

The linear compounds have for example one of the formulas Preferred R1 and R2 groups are as defined with reference to formula (A).

A compound (VIII) is described in examples 132 and 169.

According to a ninth aspect, the invention is relative to a sub-class of compounds (A) consisting of compounds having the following formula (IX) which are analogous to those described in WO 97/29092: wherein: R'and R2 are as defined with reference to formula (A) R', X is C4 to C20 hydrocarbyl (in which one or more hydrogen atoms may be replaced by halogen, and up to four carbon atoms [and especially from 0 to 3 carbon atoms may be replaced by oxygen, nitrogen or sulphur atoms, provided that R1lx does not contain an-O-O-group), R2, X identical or different, are H or Ci to C15 hydrocarbyl (in which one or more hydrogen atoms may be replaced by halogen, and up to three

carbon atoms may be replaced by oxygen, nitrogen or sulphur atoms, provided that R2,x does not contain an-O-O-group), mit ils from 1 to 15 (preferably 1 to 10, more preferably 3 to 10, eg.

4to9) each Xlx group is independently or one Xlx group is -N (R41x)-,-O-or-S- (provided that this Xlx group is not adjacent the-NR2, X- group) and the remaining Xlx groups are independently , wherein In ils H, Ci to C6 alkyl, C2 to C6 alkenyl,-C02R5ix,-CON (RS,x) 2,-CR5ix20Rsix or -oR5lx (in which RSix and R6lx are H or Ci to C3 alkyl), and R4, X is H or Ci to C6 alkyl.

The term"hydrocarbyl", as used herein, refers to monovalent groups consisting of carbon and hydrogen. Hydrocarbyl groups thus include alkyl, alkenyl, and alkynyl groups (in both straight and branched chain forms), cycloalkyl (including polycycloalkyl), cycloalkenyl, and aryl groups, and combinations of the foregoing, such as alkylaryl, alkenylaryl, alkynylaryl, cycloalkylaryl, and cycloalkenylaryl groups.

A"carbocyclic"group, as the term is used herein, comprises one or more closed chains or rings, which consist entirely of carbon atoms. Included in such groups are alicyclic groups (such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and adamantyl), groups containing both alkyl and cycloalkyl moieties (such as adamantanemethyl), and aromatic groups (such as phenyl, naphthyl, indanyl, fluorenyl, (1,2,3,4)-tetrahydronaphthyl, indenyl and isoindenyl).

The term"aryl"is used herein to refer to aromatic carbocyclic groups, including those mentioned above.

When reference is made herein to a substituted carbocyclic group (such as substituted phenyl), or a substituted heterocyclic group, the substituents are preferably from 1 to 3 in number and selected from Ci to C6

alkyl, Cl to C6 alkoxy, Ci to C6 alkylthio, carboxy, Ci to C6 carboalkoxy, nitro, trihalomethyl, hydroxy, amino, Cl to C6 alkylamino, di (Ci to C6 alkyl) amino, aryl, Cl to C6 alkylaryl, halo, sulphamoyl and cyano.

The term"halogen", as used herein, refers to any of fluorine, chlorine, bromine and iodine.

Preferably, RIX² is selected from H, Ci to C6 alkyl, C1 to C6 cycloalkyl, C1 to C6 hydroxyalkyl, C1 to C6 alkylhydroxyalkyl, aryl C1 to C6 alkyl and substituted are c to C6 alkyl. For example, RIX² may be H or Ci to C3 alkyl.

In certain embodiments,-Xlxmix-is a Ci to C8 alkylene group, e. g. a butylene group.

Included in the definition of R',lx are aryl-containing groups (such as phenyl, substituted phenyl, naphthyl and substituted naphthyl), and (cycloalkyl) alkyl groups (such as cyclohexylpropyl and adamantylpropyl).

Preferably, R1lx is a group of the formula wherein plx is 0 or 1, RIX¹¹ is H or C1 to C3 alkyl, qlx is from 0 to 4, R'2,x is a carboxyclic, substituted carbocyclic, heterocyclic or substituted heterocyclic group, and R13 Ix is independently selected from H, Cl to C6 alkyl, Ci to C6 cycloalkyl, Cl to C6 hydroxyalkyl, C1 to C6 alkylhydroxyalkyl, aryl C1 to C6 alkyl and substituted aryl Ci to C6 alkyl.

Preferably, R13lx is hydrogen.

Compounds (IX) wherein R',lx is a group-NH-CH2-Ph where Ph represents an optionally substituted phenyl, are preferred.

Preferred groups R'and R2 are as specified with reference to formula (A).

An illustrative example is compound 173.

According to a tenth aspect, the present invention is relative to another sub-class of compounds (A) comprising compounds having the following formula (X), which are analogous to compounds disclosed by Wolin et al. (Bioorg. & Med. Chem. Lett., 8,2157 (1998)): wherein: -R'and R2 are as defined with reference to formula (A); -R1X is H or CH3; -R2X is selected from a phenyl optionally substituted with a halogen atom, preferably chlorine, a (Ci-C4) alkyl, a (Ci-C4) alkoxy, CF3, OCF3, N02, NH2; or a CH2-phenyl optionally substituted as above-specified; -nx is from 0 to 3. nx is preferably 1. R2 is preferably a phenyl group, especially a mono-substituted phenyl group.

Preferred R1 and R2 are as above-specified for formula (A).

Compound 174 is illustrative of compounds (X).

According to a eleventh aspect, the invention is directed to non- imidazole compounds which are analogous to those disclosed in WO 96/38142.

Thus, another sub-class of compounds (A) of the invention is directed to compounds having the following formula (Xl): where R'and R2 are as defined with reference to formula (A);

where AXl is-NHCO-,-N (CH3)-CO-,-NHCH2-,-N (CH3)-CH2-,-CH=CH-, -COCH2-, CH2CH2-,-CH (OH) CH2-, or-C-C- ; XXI is H, CH3, NH2, NH (CH3), N (CH3) 2, OH, OCH3, or SH; R2Xl is hydrogen or a methyl or ethyl group; R3XI is hydrogen or a methyl or ethyl group; nXI is 0, 1,2,3,4,5 or 6; and R1Xl is selected from the group consisting of C3 to C8 cycloalkyl; phenyl or substituted phenyl; decahydronaphthalene and octahydroindene; or Ri'and X'may be taken together to denote a 5,6 or 6,6 saturated bicyclic ring structure when Xxl is NH, O, S, or SO2.

Preferably for compounds of formula (XI): AXl is-NHCO-,-N (CH3)-CO-,-NHCH2-,-N (CH3)-CH2-,-CH=CH-, -COCH2-,-CH2CH2-,-CH (OH) CH2-, or-C=C- ; XXI is H, CH3, NH2, NH (CH3), N (CH3) 2, OH, OCH3, or SH; RXI² is hydrogen or a methyl or ethyl group; R3Xl is hydrogen or a methyl or ethyl gorup; nXlis 0,1,2,3,4,5, or 6; and RiX'is selected from the group consisting of (a) C3 to C8 cycloalkyl; (b) phenyl or substituted phenyl; (d) heterocyclic (e) decahydronaphthalene and (f) octahydroindene; or RXI1 and XXI may be taken together to denote a 5,6 or 6,6 saturated bicyclic ring structure when XXl can be NH, O, or S.

More preferably, the present invention provides compounds where AXl is-NHCH2-,-N (CH3)-CH2-,-CH=CH-, -COCH2-,-CH2CH2,-CH (OH) CH2-, or-C=C-; XX1 is H, CH3, NH2, NH (CH3), N (CH3) 2, OH, OCH3, or SH; RXl2 is hydrogen or a methyl or ethyl group; RXl3 is hydrogen or a methyl or ethyl group; nXlis 0,1,2,3,4,5, or 6; and Rxll is selected from the group consisting of (a) C3 to C8 cycloalkyl; (b) phenyl or substituted phenyl; (d) heterocyclic; (e) decahydronaphthalene and (f) octahydroindene; or

Rxll and XXl may be taken together to denote a 5,6 or 6,6 saturated bicyclic ring structure when XXl can be NH, O, or S.

Most preferably, the present invention provides compounds whereAX1 is -CH=CH or -C#C-; XXl is H, CH3 or NH2; R2x and R3X'are H; nazis 1,2, or 3; Rix'is selected from the group consisting of (a) C3 to C8 cycloalkyl; (b) phenyl or substituted phenyl; (d) heterocyclic; (e) decahydronaphthalene and (f) octahydroindene; or Ri'and X'may be taken together to denote a 5,6 or 6,6 saturated bicyclic ring structure when XXl is NH, O, or S.

The term"substituted phenyl"as used herein refers to a phenyl group substituted by one or more groups such as alkyl, halogen, amino, methoxy and cyano groups.

The term"alkyl"refers to straight or branched chain radicals.

Representative examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl and the like.

Compounds (XI) where Axl is-CH=CH-or-C-C-, XX, R2X'and R3Xl are each H, nx, is 1 and Rix'is a C3-C8 cycloalkyl, are especially preferred.

R1 and R2 are preferably selected as above-indicated in reference to formula (A).

Representative particularly preferred compounds are compounds 177,178 or 179.

According to a twelfth aspect, the invention concerns non- imidazole compounds which are analogous to those disclosed in WO 96/38141.

Thus, the invention is relative to compounds having the following formula (XII):

where R'and R2 are as defined in reference to formula (A), where R2Xll is a hydrogen or a methyl or ethyl group; R3XIl is a hydrogen or a methyl or ethyl group; nXIl is 0,1,2,3,4,5, or 6; and Rixn is selected from the group consisting of (a) C3 to Ce cycloalkyl; (b) phenyl substituted or not by one or more groups such as a halogen atom, a lower alkyl or cycloalkyl, a trifluoromethyl, aryl, alkoxy, cc-alkyloxyalkyl, aryloxy, nitro, formyl, alkanoyl, aroyl, arylalkanoyl, amino, carboxamido, cyano, alkyloximino, alkylalkoximino, aryloximino, o-hydroxyalkyl, alkenyl, alkynyl, sulphamido, sulfamoyl, sulphonamido, carboxamide, carbonylcycloalkyl, alkylcarbonylalkyl, carboalkoxy, arylalkyl or oxime group, or two substituants taken together with the carbon atoms of the phenyl ring to which it is fused form 5-or 6-membered saturated or unsaturated ring or a benzene ring; (c) alkyl; (d) heterocyclic; (e) decahydronaphthalene; and (f) octahydroindene; with the provisos that when XXll is H, AXIl can be-CH2CH2-,-COCH2-,-CONH-,-CON (CH3)-, -CH=CH-,-C-C-,-CH2-NH-,-CH2-N (CH3)-,-CH (OH) CH2-,-NH-CH2-, -N (CH3)-CH2-,-CH20-,-CH2S-, or-NHCOO- ; when XXll is NH2, NH (CH3), N (CH3) 2, OH, OCH3, CH3, SH or SCH3; AXIl can be -NHCO-,-N (CH3)-CO-,-NHCH2-,-N (CH3)-CH2-,-CH=CH-,-COCH2-,-CH2CH2-, -CH (OH) CH2-, or-C-C-; and when Rlxli and Xx"taken together denote a 5,6 or 6,6 saturated bicyclic ring structure XXll can be NH, O, or S.

The term"alkyl"as used herein refers to straight or branched chain radicals derived from saturated hydrocarbons by the removal of one hydrogen atom. Representative examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and the like.

The term"substituted phenyl"as used herein refers to a phenyl group substituted by one or more groups such as alkyl, halogen, amino, methoxy, and cyano groups.

The term"bicyclic alkyl"as used herein refers to an organic compound having two ring structures connected to an alkyl group. They may or may not be the same type of ring and the rings may be substituted by one or more groups. Representative bicyclic alkyl groups include adamanthyl, decahydronaphthalene and norbornane.

The cyclopropane attached to the NR'R 2 moiety is preferably in trans configuration.

More preferably, the present invention provides compounds of the general formula (Xll): where AXIl is-CONH,-CH=CH-,-NHCOO-, or-C-C-; XXll is H or NH2; R2 xii and R3XIl areH; nazis 0,1,2 or 3; Rix is cyclohexyl, phenyl or substituted phenyl.

In compounds (XII), AXIl is especially-CH=CH-or-C-C-; R2XII, R3XII and XXII are each especially a hydrogen atom; non is preferably 1 and R1Xll is especially an alkyl group.

R'and R2 are preferably selected as above-indicated with reference to formula (A).

Representative example of compounds (XII) is compound 180.

According to a thirteenth aspect, the invention is directed to non- imidazole compounds analogous to those disclosed in WO 95/11894.

Thus, the present invention is relative to a sub-class of compounds (A) comprising compounds having the following formula (XIII):

wherein R1 and R2 are as defined with reference to formula (A) wherein Dxl"is CH2 or CH2-CH2, ZXn represents sulfur (S) or oxygen (O), preferably O, Xx"l is 0 or 1, nxi is an integer from 0 to 6, and R2Xn represents a substituted or unsubstituted linear chain or branched chain alkyl group of up to about 20 carbon atoms, a substituted or unsubstituted carbocyclic group of up to about 20 carbon atoms including mono and bicyclic moieties, and a substituted or an unsubstituted aryl group of up to about 20 carbon atoms, or any combination of above-mentioned groups, or salts thereof and with the substituants being represented by one or more groups such as a halogen atom, a lower alkyl or cycloalkyl, a trifluoromethyl, aryl, alkoxy, a- alkyloxyalkyl, aryloxy, nitro, formyi, alkanoyl, aroyl, arylalkanoyl, amino, carboxamido, cyano, alkyloximino, alkylalkoximino, aryloximino, a-hydroxyalkyl, alkenyl, alkynyl, sulphamido, sulfamoyl, sulphonamido, carboxamide, carbonylcycloalkyl, alkylcarbonylalkyl, carboalkoxy, arylalkyl or oxime group, or two substituants taken together with the carbon atoms of the phenyl ring to which it is fused form 5-or 6-membered saturated or unsaturated ring or a benzene ring.

In a specific embodiment, R2Xlil can represents a disubstituted methyl, such as but not limited to dicyclohexyl methyl (-CH (C6H11) 2), diphenyl methyl (-CH (C6H5) 2), and the like. If R2Xlil is tert-butyl, cyclohexyl, or dicyclohexylmethyl, Xxill or nxill must not be 0. If R2xn is adamantane, the sum of xxill and nxill must be greater than 1.

In a preferred embodiment, Dx... is CH2-CH2, resulting in a piperidine ring structure. However, it is contemplated that Dxl"can be CH2, yielding a pyrrolidine ring structure. In yet another embodiment, DXIll can be (CH2) 3, yielding a cycloheptimide (seven membered heterocycle with one nitrogen).

In a specific embodiment, a tetramethylene bound to the amide or carbamate group is used. Preferably a cyclic alkyl or aryl group is linked to the amide or carbamate via the straight chain alkyl group. In a specific embodiment, tetramethylene cyclohexane (cyclohexylbutyl) is bound to an amide. Although specific hydrophobic alkyl and aryl groups have been mentioned, one of

ordinary skill in the art will recognize that there are many possible hydrophobic groups for use in the compounds of the invention. These fall within the scope of the instant invention.

Thus, R2 xiii can be one or more bulky substituent groups. As stated above, in a preferred aspect of the invention, the bulky substituents are removed from the amide or carbamate group on the piperidyl, by increasing nxn. In one embodiment, R2Xn is CHR3xnR4xn, in which nxlll is 3 or 4 and R3 xiii and R4Xn are cyclohexyl, phenyl, or the like. R3Xn and R4Xn can be the same group or different groups. In another embodiment, R2Xlil is decalin or adamantane or the like. If R2Xn is adamantane, preferably nxill is greater than 1, but the sum of xXlil and nxill must be greater than 1.

As used herein, the phrase linear chain or branched chained alkyl groups of up to about 20 carbon atoms means any substituted or unsubstituted acyclic carbon-containing compounds, including alkanes, alkenes and alkynes.

Examples of alkyl groups include lower alkyl, for example, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl; upper alkyl, for example, octyl, nonyl, decyl, and the like; and lower alkylene, for example, ethylene, propylene, propyidiene, butylene, butyidiene, and the like. The ordinary skilled artisan is familiar with numerous linear and branched alkyl groups, which are with the scope of the present invention.

In addition, such alkyl group may also contain various substituents in which one or more hydrogen atoms has been replaced by a functional group.

Functional groups include but are not limited to hydroxyl, amino, carboxyl, amide, ester, ether, and halogen (fluorine, chlorine, bromine and iodine), to mention but a few.

As used herein, substituted and unsubstituted carbocyclic groups of up to about 20 carbon atoms means cyclic carbon-containing compounds, including but not limited to cyclopentyl, cyclohexyl, cycloheptyl, admantyl, and the like. Such cyclic groups may also contain various substituents in which one or more hydrogen atoms has been replaced by a functional group. Such functional groups include those described above, and lower alkyl groups as

describe above. The cyclic groups of the invention may further comprise a heteroatom. For example, in a specific embodiment, R2xn is cyclohexanol.

As used herein, substituted and unsubstituted aryl groups means a hydrocarbon ring bearing a system of conjugated double bonds, usually comprising six or more even number of yT (pi) electons. Examples of aryl groups include, by are not limited to, phenyl, naphthyl, anisyl, toluyl, xylenyl and the like. According to the present invention, aryl also includes heteroaryl groupss, e. g., pyrimidine or thiophene. These aryl groups may also be substituted with any number of a variety of functional groups. In addition to the functional groups described above in connection with substituted alkyl groups and carbocyclic groups, functional groups on the aryl groups can be nitro groups.

As mentioned above, R2"'can also represents any combination of alkyl, carbocyclic or aryl groups, for example, 1-cyclohexylpropyl, benzyl cyclohexylmethyl, 2-cyclohexylpropyl, 2,2-methylcyclohexylpropyl, 2,2- methylphenylpropyl, 2,2-methylphenylbutyl.

In a specific embodiment, R2 represents cyclohexane, and nu", =4 (cyclohexylvaleroyl). In another specific embodiment, R2Xlil represents cinnamoyl.

Particularly preferred are compounds (XIII) wherein zXIII is an oxygen atom and wherein xxill is 0 or 1, nxlll is an integer from 0 to 6, more preferably nx ! h = 3-6, and most preferably nxill=4, and R2x"l is as defined above.

Examples of preferred alkyl groups for R2x"l include but are not limited to cyclopentyl, cyclohexyl, admantane methylene, dicyclohexyl methyl, decanyl and t-butyryl and the like. Examples of preferred aryl and substituted aryl groups include but are not limited to phenyl, aryl cyclohexyl methyl and the like.

Preferred R1 and R2 are selected as indicated with reference to formula (A).

Representative examples are compounds 123 and 176.

According to a fourteenth aspect, the present invention is directed to compounds analogous to those disclosed in WO 93/12107.

Thus, a sub-class of compounds (A) of the invention concerns compounds having the following formula (XIV)

wherein R'and R2 are as defined in reference of formula (A); (A) mxlv is an integer selected from the group consisting of: 1 and 2; (B) nxlv and PXIV are intergers and are each independently selected from the group consisting of: 0,1,2,3, and 4 such that the sum of nxiv and pxlv is 4 and Txlv is a 6-membered ring ; (C) R xiv and R Xiv are each independently bound to the same or different carbon atom of ring Txlv such that there is only one R 3xlv group and one RXIV4 group in ring Txlv, and each RXIV¹, RXIV², RXIV³ and R\v is independently selected from the group consisting of: (1) H; (2) Cl to C6 akyl; and (3)-(CH2) qxlv-R6xlv wherein qxlv is an integer of: 1 to 7, and Rx ! v is selected from the group consisting of: phenyl, substituted phenyl,-OR7XIV, -C(O)ORXIV7, -C(O)RXIV7, -OC (O)RXIV7, -C(O)NRXIV7RXIV8, CN and-SR7Xlv wherein R7XIV and RXIV8 are as defined below, and wherein the substituents on said substituted phenyl are each independently selected from the group consisting of:-OH, -O-(C1 to C6) alkyl, halogen, C1 to C6 alkyl,-CF3,-CN, and -N02, and wherein said substituted phenyl contains from 1 to 3 substituents; (D) R5xiv is selected from the group consisting of: (1) H; (2) Cl to C20 alkyl; (3) C3 to C6 cycloalkyl;

(4)-C(O)ORCIV7' ; wherein R7'XIV is the same as RXIV7 defined below except that R7'XIV is not H; (5)-C(O)RXIV7'; (6)-C(O)NR7'XIVRXIV8; (7) allyl; (8) propargyl; and (9)- (CH2) q-R XIV wherein qxlv and R xiv are as defined above, and when qxlv is equal to 1, then R XIV is not OH or SH; (E) RXIV7 and Raxlv are each independently selected from the group consisting of: H, Cl to C6 alkyl, and C3 to C6 cycloalkyl; (F) the dotted line (--------) represents a double bond that is optionally present when mXIV is 1, and nXIV is not 0, and p is not 0 (i. e., the nitrogen in the ring is not bound directly to the carbon atom bearing the double bond), and when said double bond is present then R2xlv is absent; and (G) when mxm is 2, each RXIV¹ is the same or different substituent for each mxn, and each RXIV² is the same or different substituent for each mx ! v, and at least two of the substituents R1xlv and/or R2xlv are H.

Those skilled in the art will appreciate that the total number of substituents on each of the -(C)nXIV- and -(C)pXIV- groups is two, and that such substituents are independently selected from the group consisting of hydrogen, R3xlv and R4xlv such that there is a total of only one R3xlv and one RXIV4 substituent in ring Txlv.

As used herein the following terms have the following meanings unless indicated otherwise: alkyl-represents a straight or branched, saturated hydrocarbon chain having from 1 to 20 carbon atoms; cycloalkyl-represents a saturated carbocyclic ring having from 3 to 6 carbon atoms; halogen (halo)-represents fluoro, chloro, bromo or iodo.

Preferably, for compounds of formula (XIV) m is 1; R5XIV is selected from the group consisting of H and Cl to C15 alkyl; and RXIV¹ to R4XIV are each independently selected from the group consisting of: H, Cl to C6 alkyl, and -(CH2)qXIV-RXIV6 wherein RXIV6 is phenyl. Most preferably, R XIV is selected from the group consisting of H and Cl to C6 alkyl with H and methyl being even more preferable; and R xiv and R Xiv are each independently selected from the group consisting of: H and methyl.

Representative compounds of this invention include compounds of the formula: For formula (XIVa), (XlVb) or (XlVc), RSxm is preferably H or CH3; R3xlv and R4XIV are preferably each an hydrogen atom.

Preferred R'and R2 are as specified for formula (A).

According to a fifteenth aspect, the invention is directed to compounds analogous to those disclosed in WO 93/12108.

Thus, the invention concerns compounds having the following formula (XV):

wherein R'and R2 are as defined in reference to formula (A) (A) mxv is an integer selected from the group consisting of: 0,1, and 2; (B) nxv and pxv are integers and are each independently selected from the group consisting of: 0,1,2, and 3 such that the sum of nxv and pxv is 2 or 3 such that when the sum of nxv and pxv is 2, TXv is a 4-membered ring and when the sum of nxv and pxv is 3, TXv is a 5-membered ring; (C) each R1XV, R2xv, R3XV, R4xv, R6xv, R'xv and R8xv is independently selected from the group consisting of: (1) H ; (2) Cl to C6 alkyl; (3) C3 to C6 cycloalkyl; and (4)- (CH2) qxv-R9xv wherein qxv is an integer of: 1 to 7, and R9xv is selected from the group consisting of: phenyl, substituted phenyl, -ORXV10, -C(O)ORXV10, -C(O)R10XV, -OC(O)RXV10, -C (O)NRXV10RXV¹¹, CN and -SRXV10 wherein R10xv and R11XV are as defined below, and wherein the substituents on said substituted phenyl are each independently selected from the group consisting of:-OH, -O-(C1 to C6) alkyl, halogen, Ci to C6 alkyl,-CF3, -CN, and-N02, and wherein said substituted phenyl contains from 1 to 3 substituents; examples of - (CH2) qxv-R9xv include benzyl, substituted benzyl and the like, wherein the substitutents on the substituted benzyl are as defined above for said substituted phenyl; (D) Rxv is selected from the group consisting of:

(1) H; (2) Cl to C2o alkyl; (3) C3 to C6 cycloalkyl; (4)-C (O) OR10xv; wherein R13xv is the same as RXV10 defined below except that RXV10' is not H; (5)-C (O) R10xv ; (6)-C (O) NR'°xvR"xv ; (7) allyl; (8) propargyl; and (9) -(CH2)qXV-RXV9, wherein qxv and R9xv are as defined above with the proviso that when qxv is 1 then R9xv is not-OH or -SH; (E) R10XV and RXV¹¹ are each independently selected from the group consisting of: H, Cl to C6 alkyl, and C3 to C6 cycloalkyl; and, for the substituent-C (O) NR'°xvRxv", RXV10 and R11xvs together with the nitrogen to which they are bound, can form a ring having 5,6, or 7 atoms; (F) the dotted line (-----) represents a double bond that is optionally present when mxv is 1, and TXv is a 5-membered ring, and nxv is not 0, and pxv is not 0 (i. e., the nitrogen in the ring is not bound directly to the carbon atom bearing the double bond), and when said double bond is present then RXV² and Rxv are absent; (G) when mxv is 2, each RXV¹ is the same or different substituent for each mXV, and each R2xv is the same or different substituent for each mXV; (H) when nxv is 2 or 3, each R3xv is the same or different substituent for each nxv, and each R4xv is the same or different substituent for each nxv; and (I) when pXV is 2 or 3, each R6xv is the same or different substituent for each p, and each RXV7 is the same or different substituent for each pxv.

As used herein the following terms have the foliowing meanings unless indicated otherwise: alkyl-represents a straight or branched, saturated hydrocarbon chain having from 1 to 20 carbon atoms; cycloalkyl-represents a saturated carbocyclic ring having from 3 to 6 carbon atoms; and halogen (halo)-represents fluoro, chloro, bromo or iodo.

Preferably, for compounds of formula (XV) mxv is 0 or 1; R5xv is selected from the group consisting of H and Cl to C20 alkyl; and R1xv to R4xv and Rxv to R8xv are each independently selected from the group consisting of: H, Cl to C6 alkyl, and- (CH2) qxv-R9xv wherein R9xv is phenyl. Most preferably, xv is selected from the group consisting of H and methyl; and R1XV, R2xv, R3xv, R4xv, Rsxv, R'xv, and Rsxv are each independently selected from the group consisting of: H, methyl, ethyl, pentyl, benzyl, and 2-phenylethyl.

Representative compounds of this invention include compounds of the formula:

wherein mxv and R1xv to Rxv are as defined for formula (XV) Compounds (XVc) or (XVd) are preferred.

Representative compounds (XVa) to (XVd) are those wherein R5XV is H or CH3.

Preferably, only one or two of substituents R3xv, R4xv, Rsxv, R'xv, R8xv is different from H and represents especially CH3.

R1 and R2 are preferably selected as indicated in reference to formula (A).

According to a sixteenth aspect, the invention is directed to compounds analogous to those disclosed in WO 92/15567.

Thus, the invention is relative to a sub-class of compounds (A) consisting of compounds having the following formula (XVI) wherein R'and R2 are as defined in reference to formula (A)

ZXVI is a group of the formula (CH2) mxv wherein mxvl = 1-5 or a group of the formula: , wherein R6xvl = (C1-C3) alkyl R7xvl = (Ci-C3) alkyl; wherein ZXVI may optionally comprise other substituents selected such that the activity of the derivative is not negatively affected, Xxvl represents S, NH or CH2 R1XVI represents hydrogen, (Ci-C3) alkyl-, aryl (C1-C10) alkyl, wherein aryl may optionally be substituted, aryl, (C5-C7) cycloalkyl (C1-C10) alkyl-, or a group of the formula: wherein nXVI = 1-4, RXVI8 is aryl, aryl (Ci-Cio)alkyl-, (C5-C7)cycloalkyl- or (C5-C7) cycloalkyl(C1-C10)alkyl-, and R9xvl is hydrogen, (Ci-Cio) alkyl- or aryl; R2XVI and R5 xvi represent hydrogen, (Ci-C3) alkyl-, aryl or arylalkyl-, wherein aryl may optionally be substituted; wherein aryl is phenyl, substituted phenyl, naphthyl, substituted napththyl, pyridyl or substituted pyridyl; R2 xvi and R5 xvi are preferably a hydrogen atom. mXVI is preferably 2 or 3 XXVI is preferably S or NH R1XVI is preferably selected from H or an optionally substituted aryl.

Preferred R'and R2 are selected as specified for formula A.

According to a seventeenth aspect, a sub-class of compounds (A) of the invention comprises compounds having the following formula (XVII), which can be considered as analogous to those disclosed in EP 680 960:

Wherein mxvil represents an integer of from 4 to 6.

R4xvn represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, a cycloalkylalkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group; and Zxvil represents Vil or AXvll-R5xvll, wherein AXVlI represents S or O, R5Xvl represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group, and R6xvi'represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a substituted or unsubstituted aralkyl group; The lower alkyl groups are preferably linear or branched alkyl groups having 1 to 6 carbon atoms. Specific examples thereof include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl and n- hexyl groups.

The linear or branched alkyl groups are preferably those having 1 to 8 carbon atoms. Specific examples thereof include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, 1,1- dimethylpropyl, 1,2-dimethylpropyl and 1,2,2-trimethylpropyl groups.

The cycloalkyl groups are preferably those having 3 to 10 carbon atoms. The cycloalkyl groups include not only monocycloalkyl groups (for example, cyclopentyl, cyclohexyl and cycloheptyl) but also polycycloalkyl groups (for example, bicycloalkyl and tricycloalkyl). Examples of the bicycloalkyl groups include norbornyl (for example, exo-2-norbornyl and endo-2-norbornyl), 3-pinanyl and bicyclo [2.2.2] oct-2-yl groups, while examples of the tricycloalkyl groups include adamantyl groups (for example, 1-adamantyl and 2-adamantyl).

Such a cycloalkyl group may be substituted by alkyl group (s), etc.

The cycloalkylalkyl groups are preferably those composed of a cycloalkyl group having 3 to 10 carbon atoms with a linear or branched alkyl group having 1 to 3 carbon atoms. Specific examples thereof include 1- cyclohexylethyl and 1-cyclopropylethyl groups.

The lower alkenyl groups are preferably linear or branched alkenyl groups having 3 to 6 carbon atoms. Specific examples thereof include allyl, 1-

methyl-2-propenyl, 2-methyl-2-propenyl, cis-2-butenyi, trans-2-butenyl and 3- methyl-2-butenyl groups.

The lower alkynyl groups are preferably those having 3 to 6 carbon atoms. A specific example thereof includes a 2-propynyl group.

The substituted aryl groups are preferably phenyl and naphthyl groups which may be substituted by halogen atoms and trifluoromethyl, lower alkyl, lower alkoxy, lower alkylthio, cyano and nitro groups.

Specific examples thereof include phenyl, 1-naphthyl, 2- chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, 3- fluorophenyl, 4-fluorophenyl, 2-methoxyphenyl, 4-methoxyphenyl, 2-tolyl and 3- tolyl groups.

The aralkyl groups are preferably benzyl, diarylmethyl and trityl groups.

The substituted aralkyl groups are preferably arylalkyl groups composed of a phenyl or naphthyl group, which may be substituted by halogen atoms and trifluoromethyl, lower alkyl, lower alkoxy, lower alkylthio, cyano and nitro groups, and a linear or branched alkyl group having 1 to 4 carbon atoms.

Specific examples thereof include benzyl, a-methylbenzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 4-chlorobenzyl, 4-fluorobenzyl, 4- methoxybenzyl, 4-chloro-a-methylbenzyl, 4-fluoro-amethylbenzyl and 4- methoxy-a-methylbenzyl groups.

Among the compounds represented by the general formula (XVII) preferable examples include those wherein: mxvil is from 4 to 6; R4XVII is a hydrogen atom; a linear or branched alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkylalkyl group composed of a cycloalkyl moiety having 3 to 10 carbon atoms and an alkyl moiety having 1 to 3 carbon atoms, a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group carrying an alkyl moiety having 1 to 4 carbon atoms; R5xvu is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group or a substituted or

unsubstituted aralkyl group carrying an alkyl moiety having 1 to 4 carbon atoms; and R6XVII is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 3 to 6 carbon atoms, an alkynyl group having 3 to 6 carbon atoms or a substituted or unsubstituted aryl group.

Preferable examples of the compounds represented by the general formula (XVII) are those satisfying the following requirements: (1) A compound wherein mXvil is 5 and R', R2 and R3 are each a hydrogen atom.

(2) A compound wherein R4xvlx is a cycloalkyl group, such as monocycloalkyl, bicycloalkyl and tricycloalkyl groups. A preferable example of the monocycloalkyl group is a cyclohexyl group. A preferable example of the bicycloalkyl group is a norbornyl group, more preferably a 2-exo-norbornyl group. A preferable example of the tricycloalkyl group is an adamantyl group, more preferably a 1-adamantyl group.

(3) A compound wherein R4xvil is a substituted or unsubstituted phenyl group or a substituted or unsubstituted phenylalkyl group.

(4) A compound wherein R5xvil is a hydrogen atom.

(5) A compound wherein Axv"is S and R XVII is a lower alkyl group.

(6) A compound wherein a lower alkyl group is a methyl group.

R'and R2 are preferably selected as specified for the formula (A).

According to a eighteenth aspect, the invention is directed to non imidazole compounds having the following formula (XVIII), analogous to those disclosed in Van der Goot et al. (Eur. J. Med. Chem. (1992) 27,511-517):

in which: -R1 and R2 are as defined with reference to formula (A); -Rexvill is H, alkyl or cycloalkyl; -RfXvlll is H or halogen, in particular Cl, F, Br, or an alkyl ; -txVIll is 1 to 3; -uxvill is 1 to 4.

Preferred groups R'and R2 are as defined with reference to formula (A).

Representative example is compound 122 and 167.

According to the invention, the W residue as defined in formula (A) and in particular as illustrated by formulae (I) to (XVIII), preferably contains no imidazole moiety attached in 4 (5)-position and more preferably W contains no imidazole moiety.

The compounds according to the invention may be prepared according to one of the following schemes: More specifically, compounds of formula (I) can be obtained by the schemes 1 to 5: In these schemes, R', R2, R3, X and n are as defined in general formula (I).

Me and Et are intended to mean methyl and ethyl.

SCHEME 1 (methods A, B, C, D, H and K): BrCnHznBrR3) n HNR1R2 (R3) n 3 3 3 aXH XCnH2nBr XCnH2nNR'R2 SCHEME 2 (methods F and L): HOCnH2nC ! +HNRiR2) ( ) n3 H (C6H5) 3P, THF, N2 3 v s (6 5) 3 s2wOH OCnH2nNRIR2 SCHEME 3 (method E):

SCHEME 4 (method G): SCHEME 5 (method J): SCHEME 6 : RbC (CHRa) P roc (CHR) (CHRd) q O Br- (CHZ),-N Cl- (CHZ),--CN (a) (c) \ 0 liai4 \/ Ra-d = H or lower alkyl RbC (CHRa) P p, q, r = 0-3 (independently) 11 N- (CH2) t-NH2 t=2-8 (CHRd) q For example: (a) KI, K2CO3, EtOH, 6 h, reflux; (b) THF, 3 h, reflux.<BR> <P> (c) Kl, K2C03, EtOH, 3 h, 60 °C; (d) 6N HCI, 2 h, 100 °C. <BR> <BR> <P>SCHEME 7: I 0 Rb (CHRa) p\ 0 N- (CH,)-NH, O roc CI-C-RS (CHRd) q (a) (a) R C /N- (CFiz) t-NH-C-RS SIO=C=N-RS HZN-R5 (CHRd) q (b) l (c) \ RbC (CHRa) P\ OiS C/N-OH2) t NH-C-NH-RS (C H Rd) q \¢ (CHRa) NU N- (CHZ) t-NH-C-NH-Rs Ra-d = H or lower alkyl; R5 = alkyl, cycloalkyl, or aryl. (CHRd) q q p, q, r = 0-3 (independently); t = 2-5.

For example: (a) dioxane/H2O (1+1), 4 h, 0 °C; (b) acetonitrile, 5min, r. t.; (c) N-Boc-diphenylimido carbonate, 10 h, reflux ;<BR> (d) 1N HCI, 0.5 h, reflux.

SCHEME8: Ra = H or lower alkyl; R5 = alkyl, cycloalkyl, or aryl.<BR> p, q, r = 0-3 (independently); t = 2-5.<BR> <P>For example : (a) toluene, 12 h, r. t.; (b) toluene, tetrabutylammonium iodide, 15-crown-5,12 h, 80 °C; (c) acetonitrile, 4<BR> (d) thionyl chloride, THF, 12 h, 50 °C; (e) K2CO3, H20, EtOH, 2 days, reflux. SCHEME 9 : RbC (CHRa) P I I/N N H ROC r (CHR) q /\ O S=C=N-R (a) (b) Cl-C-R5 C (CHRa) P g RbC (CHRa) p C/N N-C-NH-R5 RC/N N-C-RS Rcc (CHRd) q (CHRd)/q R= H or lower alkyl; R5 = alkyl, cycloalkyl, or aryl.<BR> p, q, r = 0-3 (independently).<BR> <P>For example: (a) diethyl ether, 2 h, r. t.; (b) dioxane/H2O (1+1), 4 h, 0 °C.

SCHEME 10: Ra-d= H or lower alkyl.<BR> p, q, r = 0-3 (independently); t = 2-5.<BR> <P>For example : (a) acetone, triethylamine, 8 h, 50 °C; (b) NaH, MeOH, DMF, 6 h, 80 °C.

SCHEME 11: Ra-d = H or lower alkyl; R5 = alkyl, cycloalkyl, or aryl.<BR> p, q, r = 0-3 (independently); t = 0-2 (independently).<BR> <P>For example: (a) toluene, 100 °C, nitrogen atmosphere, 12 h; (b) MeOH, SOC'2; (c) triethylamine, MeOH.

SCHEME 12 <BR> Ra-d = H or lower alkyl; X = Cl, Br, etc.<BR> p, q, r = 0-3 (independently); t = 2-5; u=1-5; w = 0-2.<BR> <P>For example : (a) triethylamine, CH2CI2,24 h, r. t; (b) N, N, N', N'-tetramethylazodicarboxamide, tributylphosphine, MeOH, benzene, 24 h, r. t.;<BR> (c) triethylamine, CH2CI2, argon atmosphere, 0 °C, 18 h; (d) NaH, DMF, argon atmosphere,-15 °C; (e) 1N HCI, MeOH, 18 h, reflux. S9E\8E13 l b t (CHRa) ps 11 N--- (CH2) t-NH2 N (CHR) q N N- 'I/ ( () () s N if X (CHRa) p- 0a) R bC (CHR P\ N : o a g 11H R) q (c) Y ( roc t (CHRa) ps X/RbC< (CHR) P\ N X R C d RcC N--- (C H 2) t-NH (CHR) q (CH) q N Ra-d = H or lower alkyl; X = N02, NH2, OCH3, etc.<BR> p,q, r=0-3(independently) ; t=2-6<BR> For example: (a) triethylamine, CH2CI2,24 h, 50 °C; (b) triethylamine, Kl, EtOH, 6 h, reflux;<BR> (c) thionyl chloride, THF, 2 h, 0 °C; (d) K2CO3, Kl, EtOH, 6 h, reflux.

SCHEME 14: Ra-d = H or lower alkyl; R5= alkyl, cycloalkyl, or aryl. p, q, r = 0-3 (independently); t, u = 0-3.

For example: (a) n-BuLi,-78 °C; (b) THF, CIP (O) OEt2; (c) THF, 4 mole% HMPA; (d)H2, quinoline, ethyl acetate (cis); (d') Na/NH3 (trans); (e) H2, Pd (black), MeOH.

Detailed synthesis procedures are given in the examples.

The compounds of formula (A) according to the invention have antagonistic and/or agonistic properties at the histamine H3-receptors. They affect the synthesis and release of histamine monoamines or neuropeptides in brain and peripheral tissues.

This property makes the compounds of the invention useful derivatives in human or veterinary medicine.

Their therapeutical applications are those known for H3-antagonist and/or agonist compounds and especially relate to the central nervous system disorders.

Regarding antagonistic activity, the compounds according to the invention can be used in the treatment of Alzheimer disease, mood and attention alterations, cognitive deficits in psychiatric pathologies, obesity, vertigo and motion sickness.

Regarding agonistic activity, the compounds according to the invention can be used in the treatment of various allergic and inflammatory diseases and as a sedative agent.

Therefore, the compounds of formula (A) according to the invention are advantageously used as active ingredient of medicaments which act as ligand for H3- receptors of histamine and in particular as an antagonist and/or agonist of H3- receptors of histamine.

The present invention is also directed to the use of at least one following compounds 1-(5-phenoxypentyl)-piperidine 1- (5-phenoxypentyl)-pyrrolidine N-methyl-N- (5-phenoxypentyl)-ethylamine 1- (5-phenoxypentyl)-morpholine N- (5-phenoxypentyl)-hexamethyleneimine N-ethyl-N- (5-phenoxypentyl)-propylamine 1-(5-phenoxypentyl)-2-methyl-piperidine 1-i ne 1-ine 1-ine 1-acetyl-4- (5-phenoxypentyl)-piperazine

1- (5-phenoxypentyl)-3, 5-trans-dimethyl-piperidine 1- (5-phenoxypentyl)-3, 5-cis-dimethyl-piperidine 1- (5-phenoxypentyl)-2, 6-cis-dimethyl-piperidine 4-carboethoxy-1- (5-phenoxypentyl)-piperidine 3-carboethoxy-1- (5-phenoxypentyl)-piperidine 1- 3- (4-cyclopropylcarbonylphenoxy) propyl-piperidine 1- 3- (4-acetylphenoxy)-2-R-methylpropyl piperidine 1- 3- (4-cyanophenoxy) propyl-4-methylpiperidine 1- 3- (4-cyanophenoxy) propyl-3-methylpiperidine 1- 3- (4-acetylphenoxy)-2-S-methylpropyl piperidine 1- {3- 4- (3-oxobutyl) phenoxy] propyl} piperidine 1- 3- (4-cyano-3-fluorophenoxy) propyl piperidine 1- 3- (4-nitrophenoxy) propyl-3-methylpiperidine 1- 3- (4-cyanophenoxy) propyl-2-methylpiperidine 1- 3- (4-nitrophenoxy) propyl-2-methylpiperidine 1- 3- (4-nitrophenoxy) propyl-4-methylpiperidine 1- 3- (4-cyanophenoxy) propyl-2, 6-dimethyl piperidine 1- 3- (4-propionylphenoxy) propyl-3-methylpiperidine 1- 3- (4-cyclobutylcarbonylphenoxy) propyl piperidine 1- 3- (4-cyclopentylcarbonylphenoxy) propyl piperidine 1- 3- (4-cyanophenoxy) propyl-cis-2-methyl-5-ethylpiperidine 1- 3- (4-cyanophenoxy) propyl-trans-2-methyl-5-ethylpiperidine 1- 3- (4-cyanophenoxy) propyl-cis-3, 5-dimethylpiperidine 1- 3- (4-propionylphenoxy) propyl-4-methylpiperidine 1- 3- (4-propionylphenoxy) propyl-2-methylpiperidine 1- {3- 4- (1-hydroxypropyl) phenoxy] propyl}-3-methylpiperidine 1- {3- 4- (l-hyd roxypro pyl) phenoxy] propyl}-4-methyl piperidine 1- 3- (4-propionylphenoxy) propyl-2-methylpiperidine 1- 3- (4-propionylphenoxy) propyl-4-methylpiperidine methoxime 1- 3- (4-cyanophenoxy) propyl-trans-3, 5-dimethyl piperidine 1- 3- (4-cyclopropylcarbonylphenoxy) propyl-trans-3,5 -dimethyl piperidine 1- 3- (4-cyclopropylcarbonylphenoxy) propyl-cis-3,5 -dimethyl piperidine

1- 3- (4-carbomethoxyphenoxy) propyl piperidine 1- 3- (4-propenylphenoxy) propyl-2-methyl piperidine 1- 3- (4-propionylphenoxy) propyl-2-methylpiperidine 1- {3- 4- (1-ethoxypropy !) phenoxy] propyl}-2-methyl piperidine 1- 3- (4-propionylphenoxy) propyl-4-methylpiperidine 1- 3- (4-bromophenoxy) propyl piperidine 1- 3- (4-nitrophenoxy) propyl piperidine 1- 3- (4-N, N-dimethylsulfonamidophenoxy) propyl piperidine 1- 3- (4-isopropylphenoxy) propyl piperidine 1- 3- (4-sec-butylphenoxy) propyl piperidine 1- 3- (4-propylphenoxy) propyl piperidine 1- 3- (4-ethylphenoxy) propyl piperidine 1- (5-phenoxypentyl)-1,2,3,6-tetrahydropyridine 1- 5- (4-nitrophenoxy)-pentyl-pyrrolidine 1- 5- (4-chlorophenoxy)-pentyl-pyrrolidine 1- 5- (4-methoxyphenoxy)-pentyl-pyrrolidine 1- 5- (4-methylphenoxy)-pentyl-pyrrolidine 1- 5- (4-cyanophenoxy)-pentyl-pyrrolidine 1- 5- (2-naphthyloxy)-pentyl-pyrrolidine 1- 5- (1-naphthyloxy)-pentyl-pyrrolidine 1- 5- (3-chlorophenoxy)-pentyl-pyrrolidine 1- 5- (4-phenylphenoxy)-pentyl-pyrrolidine 1- {5- 2- (5,6,7,8-tetrahydronaphthyl)-oxy-pentyl}-pyrrolidine 1- 5- (3-phenylphenoxy)-pentyl-pyrrolidine 1- (5-phenoxypentyl)-2, 5-dihydropyrrole 1-f 5- 1- (5,6,7,8-tetrahydronaphthyl)-oxy-pentyl}-pyrrolidine 1- (4-phenoxybutyl)-pyrrolidine 1-(6-phenoxyhexyl)-pyrrolidine 1- (5-phenylthiopentyl)-pyrrolidine 1- (4-phenylthiobutyl)-pyrrolidine 1- (3-phenoxypropyl)-pyrrolidine 1- 5- (3-nitrophenoxy)-pentyl-pyrrolidine 1- 5- (4-fluorophenoxy)-pentyl-pyrrolidine 1- 5- (4-nitrophenoxy)-pentyl-3-methyl-piperidine

1- 5- (4-acetyl phenoxy)-pentyl-pyrrol idine 1- 5- (4-aminophenoxy)-pentyl-pyrrolidine 1- 5- (3-cyanophenoxy)-pentyl-pyrrolidine N- 3- (4-nitrophenoxy)-propyl-diethylamine N- 3- (4-cyanophenoxy)-propyl-diethylamine 1- 5- (4-benzoylphenoxy)-pentyl-pyrrolidine 1- {5- 4- (phenylacetyl)-phenoxy-pentyl}-pyrrolidine N- 3- (4-acetylphenoxy)-propyl-diethylamine 1- 5- (4-acetamidophenoxy)-pentyl-pyrrolidine 1- 5- (4-phenoxyphenoxy)-pentyl-pyrrolidine 1- 5- (4-N-benzamidophenoxy)-pentyl-pyrrolidine 1- {5- 4- (1-hydroxyethyl)-phenoxy-pentyl}-pyrrolidine 1- 5- (4-cyanophenoxy)-pentyl-diethylamine 1- 5- (4-cyanophenoxy)-pentyl-piperidine N- 5- (4-cyanophenoxy)-pentyl-dimethylamine N- 2- (4-cyanophenoxy)-ethyl-diethylamine N- 3- (4-cyanophenoxy)-propyl-dimethylamine N- 4- (4-cyanophenoxy)-butyl-diethylamine N- 5- (4-cyanophenoxy)-pentyl-dipropylamine 1- 3- (4-cyanophenoxy)-propyl-pyrrolidine 1- 3- (4-cyanophenoxy)-propyl-piperidine N- 3- (4-cyanophenoxy)-propyl-hexamethyleneimine N- 6- (4-cyanophenoxy)-hexyl-diethylamine N- 3- (4-cyanophenoxy)-propyl-dipropylamine N-3- 4- (1-hydroxyethyl)-phenoxy-propyl-diethylamine 4- (3-diethylaminopropoxy)-acetophenone-oxime 1- 3- (4-acetylphenoxy)-propyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-3-methyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-3, 5-trans-dimethyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-4-methyl-piperidine 1- 3- (4-propionylphenoxy)-propyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-3, 5-cis-dimethyl-piperidine 1- 3- (4-formylphenoxy)-propyl-piperidine 1- 3- (4-isobutyrylphenoxy)-propyl-piperidine

N- 3- (4-propionylphenoxy)-propyl-diethylamine 1- 3- (4-butyrylphenoxy)-propyl-piperidine 1- 3- (4-acetylphenoxy)-propyl-1,2,3,6-tetrahydropyridine a- (4-Acetylphenoxy)-a'- (4-methylpiperidino) p-xylol a- (4-Acetylphenoxy)-a'- (3, 5-cis-dimethylpiperidino) p-xylol a- (4-Acetylphenoxy)-a'- (3, 5-trans-dimethylpiperidino) p-xylol a- (4-Acetylphenoxy)-a'- (2-methylpyrrolidino) p-xylol a- (4-Cyclopropylcarbonylphenoxy)-a'-piperidino-p-xylol a- (4-Cyclopropylcarbonylphenoxy)-a'- (4-methylpiperidino) p -xylol a- (4-Cyclopropylcarbonylphenoxy)-a'-pyrrolidino-p-xylol 3-Phenylpropyl 3- (4-methylpiperidino) propyl ether 3-Phenylpropyl 3- (3, 5-cis-dimethylpiperidino) propyl ether 3-Phenylpropyl 3- (3, 5-trans-dimethylpiperidino) propyl ether 3-Phenylpropyl 3- (3-methylpiperidino) propyl ether 3-Phenylpropyl 3-pyrrolidinopropyl ether 3- (4-Chlorophenyl) propyl 3- (4-methylpiperidino) propyl ether 3- (4-Chlorophenyl) propyl 3- (3, 5-cis-dimethylpiperidino) propyl ether 3- (4-Chlorophenyl) propyl3- (3, 5-trans-dimethylpiperidino) propyl ether 4- (6-Piperidinohexylamino) quinoline 2-Methyl 4- (3-piperidinopropylamino) quinoline 2-Methyl 4- (6-piperidinohexylamino) quinoline 7-Chloro-4- (3-piperidinopropylamino) quinoline 7-Chloro-4- (4-piperidinobutylamino) quinoline 7-Chloro-4- (8-piperidinooctylamino) quinoline 7-Chloro-4- (10-piperidinodecylamino) quinoline 7-Chloro-4- (12-piperidinododecylamino) quinoline 7-Chloro-4- (4- (3-piperidinopropoxy) phenylamino) quinoline 7-Chloro-4- (2- (4- (3-piperidinopropoxy) phenyl) ethylamino) quinoline 4- (6-Piperidinohexanoyl) phenyl 3-piperidinopropyl ether 5-Nitro-2- (5-piperidinopentylamino) pyridine 3-Nitro-2- (6-piperidinopentylamino) pyridine 5-Amino-2- (6-piperidinopentylamino) pyridine 2- (6-Piperidinohexylamino) quinoline

N- (4-Chlorobenzyl)-/V'-cyclohexyl-3-piperidinopropyl isothiourea 2- (6-Piperidinohexylamino) benzothiazole 10-Piperidinodecylamine 3-Phenylpropyl 3- (NN-diethylamino) propyl ether N- (3- (N, N-Diethylamino) propyl) N'-phenylurea N-Cyclohexylmethyl-N'- (3-piperidinopropyl) guanidine N- (4-Bromobenzyl)-N'- (4-piperidinobutyl) sulphamide 3-Chloro-N- (4-piperidinobutyl)-N-methyl-benzene sulphonamide N- (4-Chlorobenzyl)-2- (4-piperidinomethyl) phenyl) ethan amidine 1- (5-Cyclohexylpentanoyl)-1, 4-bipiperidine cis-1- (6-Cyclohexyl-3-hexen-1-yl) piperidine trans-1- (6-Cyclohexyl-3-hexen-1-yl) piperidine 1- (2- (5, 5-Dimethyl-1-hexin-1-yl) cyclopropyl) piperidine for the preparation of a medicament acting as a ligand for the histamine H3-receptor and in particular as an antagonist and/or agonist of the histamine H3-receptors.

The antagonists are advantageously used as active ingredient in particular, of medicaments having psychotropic effects, promoting wakefullness, attention, memory and improving mood, in treatment of pathologies such as Alzheimer disease and other cognitive disorders in aged persons, depressive or simply asthenic states.

Their nootropic effects can be useful to stimulate attention and memorization capacity in healthy humans.

In addition, these agents can be useful in treatment of obesity, vertigo and motion sickness.

It can also be useful to associate the compounds of the invention with other psychiatric agents such as neuroleptics to increase their efficiency and reduce their side effects.

Application in certain form of epilepsy is also foreseen.

Their therapeutic applications involve also peripheral organs mainly a stimulant of secretions or gastro-intestinal motricity.

The compounds of the invention are particularly useful for the treatment of CNS disorders of aged persons.

The said compounds may also be used as an agonist or partial agonist action on the said histamine receptors.

H3 receptor agonists and partial agonists, through their cerebral effects, mainly exert sedative, tranquillizing, antistress and analgesic activity, indicating their use as mild sedative psychotropics, in particular in various psychosomatic disorders.

H3 agonists and partial agonists are also indicated in the treatment of migraine states and other headaches.

Through their peripheral effects, H3 receptor agonists and partial agonists will be mainly indicated in the treatment of respiratoy, allergic or inflammatory conditions (asthma, bronchitis, rhinitis, tracheitis, and the like), cardiac conditions (myocardial dysfunction and infarction), gastrointestinal conditions as a result of their antisecretory and anti-inflammatory actions (gastric and duodenal ulcers, ulcerative colitis, Crohn's disease, irritable bowel, faecal incontinence, and the like), conditions of the urogenital system (cystitis, metritis, premenstrual syndrome, prostatic inflammations, urinary incontinence, genital disorders) and conditions of the cutaneous system (urticaria, itching). The anti-inflammatory and analgesic effect may usefully be turned to good account in the treatment of arthritis and other rheumatic conditions, conjunctivitis and other ocular inflammations, and sialorrhoea.

Compounds which are histamine H3 receptor agonists or partial agonists are advantageously used as active principle of medicinal products, in particular having mild sedative, antisecretory, anti-inflammatory, steep-regulating and anticonvulsant effects, regulatory effects on hypothalamohypophyseal secretion, anti- depressant effects, modulatory effects on cerebral circulation, modulatory effects on the immune system, and anti-allergic and antimigraine effects.

Hence the present invention also relates to pharmaceutical compositions which contain as active principle a therapeutically effective amount of one of the agonist or partial agonist compounds of formule (A).

The present invention also relates to medicaments having the above- mentioned effects comprising as active ingredient, a therapeutically effective amount of a compound of formula (A).

The present invention relates more particularly to such medicaments containing a compound of formula (1) to (XVIII).

The present invention also relates to pharmaceutical compositions containing as active ingredient, a therapeutically effective amount of a compound (A) together with a pharmaceutically acceptable vehicle or excipient.

The invention is directed to such pharmaceutical compositions containing as active-ingredient, a compound of formula (I) to (XVIII).

The medicaments or pharmaceutical compositions according to the invention can be administered via oral, parenteral or topical routes, the active ingredient being combined with a therapeutically suitable excipient or vehicle.

According to the invention, oral administration is advantageously used.

Another subject of the present invention is the use of the compounds of formula (A) for the preparation of H3-antagonist and/or agonist medicaments according to the above-mentioned forms.

The invention further relates to the use of the compounds of formula (A) for preparing medicaments having the pre-cited effects.

The invention also concerns the use of a compound of formula (I) to (XVIII).

Still another subject of the invention is a method for the treatment of precited ailments comprising administering a therapeutically effective dose of a compound (I), optionally in combination with a therapeutically acceptable vehicle or excipient.

The invention is also directed to such a method comprising administering a therapeutically effective dose of a compound of formula (I) to (XVIII).

For each of the above-indications, the amount of the active ingredient will depend upon the condition of the patient.

However, a suitable effective dose will be in general in the range of from 10 to 500 mg per day and of from 1 to 10 mg/day for particularly active compounds.

These doses are given on the basis of the compound and should be adapted for the salts, hydrates or hydrated salts thereof.

The invention is now illustrated by the following examples.

EXAMPLES The structure of the synthesized compounds and their method of preparation as well as their melting point, recrystalisation solvant and elemental analysis are summarized in the following Table 1: TABLE 1: N FORMULA mp analysis (calc.) method STRUCTURE (recryst. solv) NAME 1 C16H25NO; C2H204 143-145°C C: 64.06 (64.07) A (absolute ethanol) H: 8.09 (8.16) /\ \ coom N: 4.14 (4.15) O- (CH)-N (COOH) Z N : 4. 14 (4. 15) zs 1-(5-phenoxypentyl)-piperidine hydrogen(5-phenoxypentyl)-piperidine hydrogen oxalate 2 C15H23NO; C2H204 153-155°C C: 63.06 (63.14) A (absolute ethanol) H: 7.78 (7.79) 0- . cnorn N: 4.42 (4 33) vs 1- (5-phenoxypentyl)-pyrrolidine hydrogen oxalate 3 C14H23NO; C2H204 122-124°C C: 61.74 (61.72) A SO (CH2) N'CH3 (COOH) (absolute ethanol) H: 8.24 (8.09) CH2CH3 N : 4. 52 (4. 50) CHZCH3 N: 4.52 (4.50) N-methyl-N- (5-phenoxypentyl)-ethylamine hydrogen oxalate 4 ClsH23No2 ; C2H2°4 166-168°C C: 60.10 (60.16) A (absolute ethanol) H: 7.45 (7.31) N : 4.08 4. 13 0- (CH 2) 5N' 0/ (COOH) Z 1-(5-phenoxypentyl)-morpholine hydrogen(5-phenoxypentyl)-morpholine hydrogen oxalate 5 C17H27No; C2H204 132-134°C C: 64.70 (64.93) A (absolute ethanol) H: 8. 34 (8. 32) N : 3.85 (3.99) vO-(CH 2) 5-Nep(CH 2) 5-Nep (COOH) 2 N : 3. 85 (3. 99) N- (5-phenoxypentyl)-hexamethyleneimine hydrogen oxalate 6 C16H27NO; C2H204 90-91°C C: 63.60 (63.69) B (isopropyl alcohol) H: 8.81 (8.61) CH z CH 3 (COOH) 2 N : 3.97 (4.13) \/0- (CH5 N\ CH 2CH 2CH 3 N-ethyl-N- (5-phenoxypentyl)-propylamine hydrogen oxalate 7 C17H27No; 1.1 C2H204 80-83°C C: 64.15 (63.98) B (isopropyl alcohol) H: 8.42 (8.17) CH 3 N : 3.97 (3.89) 0-(CH 2) 5-N 1. 1 (COOH) 2 1- (5-phenoxypentyl)-2-methyl-piperidine hydrogen oxalate 8 Cl9H31NO; C2H204 165-166°C C: 66.27 (66.46) B (absolute ethanol) H: 8.94 (8.76) N: 3.72 (3.69) aO- (CH 2) 5-ND-nC3H7 (COOH) 2 N : 3. 72 (3. 69) 1- (5-phenoxypentyl)-4-propyl-piperidine hydrogen oxalate 9 C17H27NO; C2H204 151-152°C C: 64.87 (64.93) B 0- (C H2) 5-N~}-C H3 (C 0 0 H) Z (absolute ethanol) H: 8.41 (8.32) N: 4.01 (3.99) 1- (5-phenoxypentyl)-4-methyl-piperidine hydrogen oxalate 10 C17H27NO; C2H204 140-141°C C: 65.35 (64.93) B CH 3 (isopropyl alcohol) H: 8.49 (8.32) /-0- (cH 2) 5-r (COOH) 2 N: 4.00 (3.99) 1- (5-phenoxypentyl)-3-methyl-piperidine hydrogen oxalate 11 C17H26N202 ; C2H204 186-188°C C: 59.78 (59.99) B (absolute ethanol) H: 7.47 (7.42) M(CH2) 5N NCOCH3 (COOH) 2 U N: 7.35 (7.36) 1-acetyl-4- (5-phenoxypentyl)-piperazine hydrogen oxalate ~ ~ 12 C18H29NO; 1.05 C2H204 154-155°C C : 65.16 (65.25) B (absolute ethanol) H: 8.61 (8.47) CH 3 N N : 3.66 (3.79) - (CH 2) 57NQ 3.. 05 (COOH) 2 CH 3 1- (5-phenoxypentyl)-3, 5-trans-dimethyl-piperidine hydrogen oxalate 13 Ci§H29NO; C2H204 154-155°C C: 65.62 (65.73) B CH3 (isopropyl alcohol) H: 8.64 (8.55) J3 N: 3.63 (3.83) v (CH2) 5-N\ (COOH) CH3 1- (5-phenoxypentyl)-3, 5-cis-dimethyl-piperidine hydrogen oxalate 14 C18H2gNo; HC1 135-136°C C: 69.18 (69.32) B (acetone) H: 9.79 (9.70) CHUS N : 4.28 (4.49) O- (CH z) 5N HCI CH 3 1- (5-phenoxypentyl)-2, 6-cis-dimethyl-piperidine hydrochloride 15 Cl9H29NO3; C2H204 149-150°C C: 61.16 (61.60) B (absolute ethanol) H: 7.76 (7.63) 0 I I N: 3.40 (3.42) (CI-I y) 5 COC y H g (COOH) 2 4-carboethoxy-1- (5-phenoxypentyl)-piperidine hydrogen oxalate 16 ClgH29No3; C2H204 117-118°C C: 61.54 (61.60) B (isopropyl alcohol) H: 7.87 (7.63) COOC, H< COOC 2H5 N: 3.29 (3.42) O- (CH z) 5 N-) (COOH) 2 3-carboethoxy-1- (5-phenoxypentyl)-piperidine hydrogen oxalate 17 C16H23NO; C2H204 177-179°C C: 64.19 (64.46) B (methanol) H: 7.49 (7.51) N : 4.25 (4.18) -CH 2) 5 N (COOH) 2 1- (5-phenoxypentyl)-1,2,3,6-tetrahydropyridine hydrogen oxalate 18 C15H22N203; C2H204; 0. 2 H20 145-147°C C: 54.89 (54.89) C (absolute ethanol) H: 6.68 (6.61) (COOH) 2 N : 7. 41 (7.53) 0. 2 H 20 0. 2 H 20 1- 5- (4-nitrophenoxy)-pentyl-pyrrolidine hydrogen oxalate 19 C15H22CINO; C2H204 139-141°C C: 57.00 (57.06) C (absolute ethanol) H: 6.63 (6.76) cl COOH) N: 3.79 (3.91) CI 0- (CH 2) 5 N, z. Cl. Cl : 10.24 (9.91) 1- 5- (4-chlorophenoxy)-pentyl-pyrrolidine hydrogen oxalate 20 C16H25No2; C2H204 115-116°C C: 61.22 (61.17) C (absolute ethanol) H: 7.72 (7.70) H3C0 0-(CH 2) 5-N/3 (COOH) 2 N :(CH 2) 5-N/3 (COOH) 2 N : 4.03 (3.96) 1-5- (4-methoxyphenoxy)-pentyl-pyrrolidine hydrogen oxalate 21 C16H25NO; C2H204 138-140°C C: 64.05 (64.07) C (absolute ethanol) H: 8.00 (8.07) H3C-c-0- COOH) N: 4.10 (4.15) HsC-/)-0- (CH2) 5-N. 2 1- 5- (4-methylphenoxy)-pentyl-pyrrolidine hydrogen oxalate 22 Ci6H22N20 ; l. lC2H204 129-130°C C: 61.24 (61.16) C (absolute ethanol) H: 6.81 (6.82) n N: 7.95 (7.84) NCO0-(CH 2) 5-NX 1. 1(CH 2) 5-NX 1. 1 (COOH) 2 1- 5- (4-cyanophenoxy)-pentyl-pyrrolidine hydrogen oxalate 23 Cl9H25NO; C2H204 166-167°C C: 67.42 (67.54) C (methanol) H: 7.26 (7.29) /\ COOH) 2 N: 3.66 (3.75) /0- (CH 2) 5 N, 2 1- 5- (2-naphthyloxy)-pentyl-pyrrolidine hydrogen oxalate 24 Cl9H25NO; 1.25 C2H204 160-163°C C: 65.12 (65.22) C (methanol) H: 7.17 (7.00) /\ n N: 3.52 (3.54) 0- (CH 2) 5-N 1. 25 (COOH) 2 N-3. 52 (3. 54) 1- 5- (1-naphthyloxy)-pentyl-pyrrolidine hydrogen oxalate 25 C15H22CINO; C2H204 131-132°C C: 56.94 (57.06) C (absolute ethanol) H: 6.67 (6.76) CL N N : 3.74 (3.91) 0- (CH 2) 5-N. (COOH) 2 Cl: 9.64 (9.91) 1- 5- (3-chlorophenoxy)-pentyl-pyrrolidine hydrogen oxalate 26 C2lH27NO; C2H204 189-190°C C: 69.16 (69.15) C (methanol) H: 7.39 (7.32) 0- (CH Z) 5 N., (COOH) 2 N: 3.39 (3.51) /-<\ "OCHN (COOH) 2' 1- 5- (4-phenylphenoxy)-pentyl-pyrrolidine hydrogen oxalate 27 Cl9H29NO; C2H204 131-132°C C: 66.73 (66.82) C (absolute ethanol) H: 8. 37 (8.28) n (COOH) 2 N : 3.68 (3.71) - (CH 2) s'f J V 1-{5- 2- (5,6,7,8-tetrahydronaphthyl)-oxy-pentyl}- pyrrolidine hydrogen oxalate 28 C2lH27NO; 1.1 C2H2°4 155-157°C C: 68.40 (68.22) C (absolute ethanol) H: 7.04 (7.21) 0- (CH 2) 5-N 1. 1 (COOH) 2 N: 3.45 (3.43) 0- (CH 2) s"N 1- 5- (3-phenylphenoxy)-pentyl-pyrrolidine hydrogen oxalate 29 C15H21NO; C2H204 140-141°C C: 63.45 (63.54) B (absolute ethanol) H: 7.26 (7.21) 0-(cl COOH) N : 4.26 (4.36) - (CH 2) 5-N, 2 V 1- (5-phenoxypentyl)-2,5-dihydropyrrole hydrogen oxalate 30 Cl9H29NO; C2H204 148-149°C C: 66.99 (66.82) C (absolute ethanol) H: 8.47 (8.28) N: 3.72 (3.71) 0- (CH Z) 5 N 1 (COOH) 2 1- {5- 1- (5,6,7,8-tetrahydronaphthyl)-oxy-pentyl}- pyrrolidine hydrogen oxalate 31 C14H21NO; C2H204 143-144°C C: 62.25 (62.12) C (absolute ethanol) H: 7.46 (7.49) 0-(cl COOH) 2 N : 4.49 (4.53) -CH Z) 4-N, 1-(4-phenoxybutyl)-pyrrolidine hydrogen(4-phenoxybutyl)-pyrrolidine hydrogen oxalate 32 C16H25NO; 1.1 C2H204 146-147°C C: 63.06 (63.10) C (absolute ethanol) H: 8.03 (7.91) aO- 2) 6rN/3 1. 1 (COOH) 2 N: 4.32 (4.04) O- (CH 2)-N r 1-(6-phenoxyhexyl)-pyrrolidine hydrogen(6-phenoxyhexyl)-pyrrolidine hydrogen oxalate 33 C I 5H23NS; 1. 1 C2H2°4 150-152°C C: 59.52 (59.29) C (absolute ethanol) H: 7.44 (7.29) /\ ""\ i i rnnn N: 4.06 (4.02) S- (CH) N., 1.1 (COOH) 2 N : 4. 06 (4. 02) 2 5 1- (5-phenylthiopentyl)-pyrrolidine hydrogen oxalate 34 C14H21NS; C2H204 114-116°C C: 59.24 (59.05) C (absolute ethanol) H: 7.16 (7.12) S- COOH) 2 N: 4.16 (4. 30) S-CH 2) 4-N,. z S: 9.79 (9.85) 1-(4-phenylthiobutyl)-pyrrolidine hydrogen(4-phenylthiobutyl)-pyrrolidine hydrogen oxalate ICI 35 C13Hl9NO; C2H204 169-170°C C: 60.98 (61.00) C (absolute ethanol) H: 7.14 (7.17) (COOH) 2 N : 4.64 (4.74) 0- (CH 2) 3-N 1- (3- henox ro 1-rrolidine h dro en oxalate 36 o2N C15H22N2o3 ; C2H2°4 130-131°C C: 55.30 (55.43) C 2 (absolute ethanol) H: 6.55 (6.57) ' (CHZ) 5N OOOH) z N: 7.49 (7.60) 1- 5- (3-nitrophenoxy)-pentyl-pyrrolidine hydrogen oxalate 37 C15H22FNO; C2H204 149-150°C C: 59.52 (59.81) C (absolute ethanol) H: 7.12 (7.09) /='1\/) (COOH) N: 4. 05 (4. 10) F - (CH 2) 5 N 1- 5- (4-fluorophenoxy)-pentyl-pyrrolidine hydrogen oxalate 38 C17H26N203 C2H204 148-149°C C: 57.32 (57.55) C (absolute ethanol) H: 7.19 (7.12) CH3 N: 6.89 (7.07) 02N</zrO-(CH 2) s-N/ (COOH) 2 1- 5- (4-nitrophenoxy)-pentyl-3-methyl-piperidine hydrogen oxalate 39 C17H2sNo2 ; C2H2°4 130-134°C C: 62.43 (62.45) D (absolute ethanol) H: 7.41 (7.45) CH COOH) N: 3.75 (3.83) 11 0 1- 5- (4-acetylphenoxy)-pentyl-pyrrolidine hydrogen oxalate 40 C15H24N20; 2. 1 C2H2°4 120-122°C C: 52.49 (52.72) E (absolute ethanol) H: 6.74 (6.50) /=\/91 2 1 (COOH) N: 6.32 (6.40) V 1- 5- (4-aminophenoxy)-pentyl-pyrrolidine di- (hydrogen oxalate) 41 C16H22N20; C2H204 119-120°C C: 61.95 (62.05) C (absolute ethanol) H: 6.88 (6.94) NC N : 8.00 (8.04) oO-(CH (CH 2) 5-N (COOH) 2 1- 5- (3-cyanophenoxy)-pentyl-pyrrolidine hydrogen oxalate 42 C13H20N2o3; C2H204 160-161°C C: 52.46 (52.63) F (absolute ethanol/H: 6.49 (6.48) u/u 0 N-CH NCH ZCH 3 z methanol N: 8.10 (8.12) \0/CH 2CH 3 1 : CH 2CH 3 1 : 1) N- 3- (4-nitrophenoxy)-propyl-diethylamine hydrogen oxalate 43 Ci4H2QN20 C2H204 148-150°C C: 59.40 (59.62) F (absolute ethanol) H: 6.82 (6.88) CH ZCH 3 NC -0- (CH2) 3-N (COOH) 2 N : 8. 60 8. 69 CH 2CH 3 N- 3- (4-cyanophenoxy)-propyl-diethylamine hydrogen oxalate 44 C22H27NO2; C2H204 141-142°C C: 67.17 (67.43) D (absolute ethanol) H: 6.80 (6.84) loch- 2) fNS (COOH) 2 N: 3.18 (3.28) 0 1- 5- (4-benzoylphenoxy)-pentyl-pyrrolidine hydrogenoxalate ~ 45 C23H29NO2 C2H204 177-178°C C: 67.77 (68.01) D (absolute ethanol) H: 7.09 (7.08) N : 3. 26 (3. 17) 0-- 0 (COOH) 2 1- {5- 4- (phenylacetyl)-phenoxy-pentyl}-pyrrolidine hydrogen oxalate 46 Ci5H23N02 ; l. lC2H204 108-110°C C: 59.30 (59.30) F (absolute ethanol) H: 7.47 (7.29) C2H5 H3CCt/tO-(CH 2) 3-NX 1.(CH 2) 3-NX 1. 1 (COOH) 2 N : 4. 18 (4. 02) C2H5 0 N-3- (4-acetylphenoxy)-propyl-diethylamine hydrogen oxalate 47 C17H26N202; C2H204 142-144°C (59.99) C (absolute ethanol) H: 7.55 (7.42) H COOH) 2 N : 7. 25 (7. 36) ICI H Cli 2) 5 N O 1- 5- (4-acetamidophenoxy)-pentyl-pyrrolidine hydrogenoxalate ~ 48 C21H27N02; C2H204 135-136°C C: 66.49 (66.49) D (absolute ethanol) H: 7.05 (7.04) \ N: 3.24 (3.37) 0- (CH 2) 5'N J (COOH) z V 1- 5- (4-phenoxyphenoxy)-pentyl-pyrrolidine hydrogen oxalate 49 C22H28N202;. 1 C2H204 176-178°C C: 64.56 (64. 38) E2 (absolute ethanol) H: 6.89 (6.74) II HH zs N N: 6.26 (6.20) 0 1.1 (COOH) 2 1- 5- (4-N-benzamidophenoxy)-pentyl-pyrrolidine h dro en oxalate 50 C17H27NO2 C2H204 102-104°C C: 61.89 (62.11) G (absolute ethanol) H: 7.94 (7.96) HsC./'\ rcoom N: 3.77 (3.81) H3C O-(CH 2) 5-N|(CH 2) 5-N| (COOH) 2 N : 3. 77 (3. 81) W HO 1- {5- 4- (1-hydroxyethyl)-phenoxy-pentyl}- pyrrolidine hydrogen oxalate 51 C16H24N20; C2H204 120-122°C C: 61.56 (61.70) H (absolute ethanol) H: 7.54 (7.48) CH 2CH 3 NC- (CH 2) 5-N ; (COOH) 2 N : 7. 87 (7. 99) CH ZCH 3 N- 5- (4-cyanophenoxy)-pentyl-diethylamine hydrogen oxalate 52 C17H24N20; C2H204 115-116°C C: 62.62 (62.97) H (absolute ethanol) H: 7.20 (7.23) COOH) 2 N : 7.76 (7.73) NC 0- (CH z) 5-N~ 1- 5- (4-cyanophenoxy)-pentyl-piperidine hydrogen oxalate 53 C14H20N2; C2H204 148-149°C C: 59.68 (59.62) H (absolute ethanol) H: 6.76 (6.88) cl 3 NC -0- (CH2) 5-\ (COOH) 2 N : 8. 57 (8. 69) cl 3 N- 5- (4-cyanophenoxy)-pentyl-dimethylamine hydrogen oxalate 54 C13Hl8N20; C2H204 124-125°C C: 58.15 (58.43) H (absolute ethanol) H: 6.30 (6.54) CH2CH3 N: 8.95 (9.09) NC -0- (CH2) 2-N (COOH) 2'' CH zCH 3 N- 2- (4-cyanophenoxy)-ethyl-diethylamine hydrogen oxalate 55 C12Hl6N20; C2H204 166-167°C C: 57.01 (57.14) H (absolute ethanol/H: 6.02 (6.16) c 3 NC 9-(CH2) 3-N (COOH) 2 meth ; nol(CH2) 3-N (COOH) 2 meth ; nol N: 9.46 (9. 52) Cl3 1 : 1) c 3 N-3- (4-cyanophenoxy)-propyl-dimethylamine hydrogen oxalate 56 C15H22N20 C2H204 143-145°C C: 60.80 (60.70) H (absolute ethanol) H: 7.11 (7.19) /==\ CH2CH3 CH2CH3 CH ZCH 3 - CH2CH3 N- 4- (4-cyanophenoxy)-butyl-diethylamine hydrogen oxalate 57 C1gH28N20; C2H204 134-136°C C: 63.38 (63.47) H (absolute ethanol) H: 8.11 (7.99) C H NC 9 C3H7 N : 7. 29 (7. 40) CHN C3H N- 5- (4-cyanophenoxy)-pentyl-dipropylamine hydrogen oxalate 58 C14Hl8N20; 1. 1 C2H2°4 5 163-165°C C: 58.95 (59.08) H (absolute ethanol) H: 6.23 (6.18) N : 8.43 (8.51) NC (CH 2) 3-N (COOH) 2 N : 8. 43 (8. 51) 1- 3- (4-cyanophenoxy)-propyl-pyrrolidine hydrogen oxalate 59 C15H2oN20 ; 1.05 C2H204 151-153°C C: 60.62 (60.61) H (absolute ethanol) H: 6.66 (6.57) Nu (CH 2) 3-No 1.05 (COOH) 2 N: 8.25 (8.27) L 1- 3- (4-cyanophenoxy)-propyl-piperidine hydrogen oxalate 60 C16H22N20; 1. 05C2H204 124-125°C C: 61.62 (61.60) H (absolute ethanol) H: 6.94 (6.88) N: 7.87 (7.94) NC (CH 2) 3-N 1.05 (COOH) 2 N-3- (4-cyanophenoxy)-propyl-hexamethyleneimine hydrogen oxalate 61 C17H26N20; C2H204 110-112°C C: 62.90 (62.62) H (absolute ethanol) H: 7.76 (7.74) NC 0- (CH)-NCH zCH 3 (2 N : 7. 61 (7. 69) CHO) CH zCH 3 N-6- (4-cyanophenoxy)-hexyl-diethylamine hydrogen oxalate 62 C16H24N20; C2H204 127-128°C C: 61.57 (61.70) H (absolute ethanol) H: 7.57 (7. 48) C3H NC 9/3 7 (COOH) N: 7.91 (7.99) C3H7 N- 3- (4-cyanophenoxy)-propyl-dipropylamine hydrogen oxalate 63 C15H25NO2; C2H204 ; 0. 5H20 33-36°C C : 58.15 (58.27) G (isopropyl alcohol) H: 8.15 (8.05) H3Cs C2H5 (COOH) 2 N: 4.21 (4.00) CH < O (CH2) 3Ns 05H2O ho 2 s N-3-4- (l-hydroxyethyl)-phenoxy-propyl- diethylamine hydrogen oxalate hemihydrate 64 C15H24N202; C2H204 99-100°C C: 57.26 (57.61) J (absolute ethanol) H: 7.47 (7.39) H3Cs/= \ C2H5 N :-7.72 (7.90) -0- (CH2) 3- (COOH) 2 HO-N 4'- (3-diethylaminopropoxy)-acetophenone-oxime hydrogen oxalate 65 C16H23No2 C2H204 159-160°C C: 61.18 (61.52) K (absolute ethanol) H: 7.11 (7.17) N: 3.96 (3.99) H3CC j-(CH2) 3-N, 2 (COOH) 2 N : 3. 96 (3 99) 0 1- 3- (4-acetylphenoxy)-propyl-piperidine hydrogen oxalate 66 Ci7H25N02 ; C2H204 143-144°C C: 62.11 (62.45) K (absolute ethanol) H: 7.41 (7.45) CH, /< N : 3.79 (3.83) 3C-2) (COOH) 2 0 1- 3- (4-acetylphenoxy)-propyl-3-methyl-piperidine hydrogen oxalate 67 C18H27No2; C2H204 171-172°C C: 63.06 (63. 31) K (absolute ethanol) H: 7.44 (7.70) /=\/7 N : 3.64 (3.69) H3C-I-- (CH 2) 3 N (COOH) 2 0 CH 3 1- 3- (4-acetylphenoxy)-propyl-3,5-trans-dimethyl- piperidine hydrogen oxalate 68 C17H25N02 ; C2H204 160-161°C C: 62.47 (62.45) K (absolute ethanol) H: 7.46 (7.45) H3CC o 9 (COOH) 2 N : 3. 77 (3. 83) //- 0 \/1-- cooH> 1-3- (4-acetylphenoxy)-propyl-4-methyl-piperidine hydrogen oxalate 69 C17H25No2; C2H204 148-149°C C: 62.54 (62.45) L (absolute ethanol) H: 7.51 (7.45) C H COO-(CH 2) 3-N2 (COOH) 2 N : 3. 79 (3. 83) /CH 2) 3 ( 0 1- 3- (4-propionylphenoxy)-propyl-piperidine hydrogen oxalate 70 C18H27No2; C2H204 174-175°C C: 63.22 (63. 31) K (absolute ethanol) H: 7.60 (7.70) CH 3 N: 3.64 (3.69) H3C-C)-(CH 2) 3-N t(CH 2) 3-N t (COOH) 2 0 CH 3 1- 3- (4-acetylphenoxy)-propyl-3,5-cis-dimethyl- piperidine hydrogen oxalate 71 Ci5H2lN02; C2H204 152-153°C C: 60.23 (60.52) L (absolute ethanol) H: 6.81 (6. 87) H-ij--fCHO. N : 4. 15 (4. 15) H I (Cti 2) 3 N') (OOH) 2 0 1- 3- (4-formylphenoxy)-propyl-piperidine hydrogen oxalate 72 C18H27No2; C2H204 121-122°C C: 63.02 (63.31) L (absolute ethanol) H: 7.73 (7.70) 3: 3.66 (3.69) CHICgt (CH 2) 37N\D H C 11-0-0 3 0 (COOH) 2 1- 3- (4-isobutyrylphenoxy)-propyl-piperidine hydrogen oxalate 73 C16H25No2; 1. 5 C2H204 118-120°C C: 57.27 (57.28) L (absolute ethanol) H: 7.00 (7.08) IC2H5 N: 3. 47 (3. 52) C2Hs ICIt/ztO (CH 2) 3 NX 15 (COOH) 2 0--'CHN 0 2Hs N- 3- (4-propionylphenoxy)-propyl-diethylamine hydrogen oxalate 74 CigH27N02 ; C2H204 138-139°C C: 63.09 (63.31) L (absolute ethanol) H: 7.78 (7.70) N: 3. 75 (3.69) C, 0 1- 3- (4-butyrylphenoxy)-propyl-piperidine hydrogen oxalate 75 Ci6H2lN02; 1. 1 C2H204 143-144°C (61.00) K (absolute ethanol) H: 6.25 (6.52) N : 4. 00 (3. 91) -CH 2) 3-N 0 1.1(COOH) 2 1- 3- (4-acetylphenoxy)-propyl-1,2,3,6- tetrahydropyridine hydrogen oxalate 76 C18H25No2 ; 1.05 C2H204 177-179°C C: 63.10 (63.21) L (absolute ethanol) H: 7.28 (7.15) -N : 3. 61 (3. 67) O (CH2) 3 N O 1.05 (COOH) 2 1- 3- (4-cyclopropanecarbonylphenoxy) propyl]- piperidine hydrogen oxalate 77 C17H25N02; 1.1 C2H204 149-151°C C: 61.72 (61.59) M (absolute ethanol) H: 7.59 (7.32) CH3 = N: 3.74 (3.74) /2/ O 1.1 (COOH) 2 1- 3- (4-acetylphenoxy)-2-R-methylpropyl piperidine hydrogen oxalate 78 C16H22N20; HCl; 0.1 H20 200-202°C C: 64.57 (64.79) N (absolute H: 8.02 (7.88) N O (CH2) 3NSCH3 ethanol/diethyl N: 9.30 (9.44) ether ether 1: 1) HCI; 0.1 H20 1- 3- (4-cyanophenoxy) propyl-4-methylpiperidine hydrochloride 79 Ci6H22N20 ; HCl 171-173°C C: 64.87 (65.18) N (absolute H: 8.01 (7.86) CH-, CH3 ethanol/diethyl (9.50) NC-O-O (CH2) 3-nez ether 1 : 1) HCI 1- 3- (4-cyanophenoxy) propyl-3-methylpiperidine h drochloride 80 C17H25N02; C2H204 148-150°C C: 62.20 (62.45) M (absolute ethanol) H: 7.46 (7.45) CH3 CH3 N : 3.73 (3.83) 0 (COOH) 2 1- 3- (4-acetylphenoxy)-2-S-methylpropyl piperidine hydrogen oxalate 81 ClgH27N02; HCl 148-150°C C: 66.10 (66.34) O (acetone) H: 8.92 (8.66) HIC: 4.16 (4.30) 0-- HUI HCI 1- {3- 4- (3-oxobutyl) phenoxy] propyl} piperidine hydrochloride 82 ClHlgFN2O; HCl; 0.25 H20 157-159°C C: 59.13 (59.40) L (absolute H: 6.60 (6.81) F ethanol/diethyl N: 8.94 (9. 24) NC O (CH2) 3-No ether 1 : 4) -b- HCI; 0.25 H20 1- 3- (4-cyano-3-fluorophenoxy) propyl] piperidine h drochloride 83 ClsH22N2o3 ; C2H2°4 172-174°C C: 55.45 (55.43) N (absolute ethanol) H: 6.53 (6.57) CH-. CH3 N : 7.58 (7.60) 02N -0 (CH2) 3-N (COOH) 2 1- 3- (4-nitrophenoxy) propyl]-3-methylpiperidine hydrogenoxalate ~ 84 C16H22N20 HCl 177-180°C C: 64.96 (65.18) N (absolute H: 7.79 (7.86) H3C ethanol/diethyl N : 9.44 (9.50) NC/O (CH2) 3-N ether 1 : 5) HCI 1- 3- (4-cyanophenoxy) propyl]-2-methylpiperidine hydrochloride 85 C15H22N203; C2H204 151-153°C C: 55.38 (55.43) N (absolute ethanol) H: 6.57 (6.57) H3 N: 7.40 (7.60) 02N (CH2) 3-N (COOH) 2 1- 3- (4-nitrophenoxy) propyl]-2-methylpiperidine hydrogen oxalate 86 C15H22N203 1. 1 C2H204 119-121°C C: 54.52 (54.74) N (absolute ethanol) H: 6.55 (6.46) /\/\ N : 7.19 (7.42) 02N (CH2) 3NDeCH3 U 1.1 (COOH) 2 1- 3- (4-nitrophenoxy) propyl]-4-methylpiperidine hydrogen oxalate 87 C16H22N20 ; 1. 4 HCl; 1.5 H20 180-1825°C C: 58.52 (58.26) N (absolute H: 8.20 (8.17) H3C ethanol/diethyl N: 7.90 (7.99) NC-/\-0 (CH2) 3-N ether 1 : 5) 1.4 HCI ; 1 5 H20 H3C 1- 3- (4-cyanophenoxy)propyl]-2,6-dimethylpiperidine hydrochloride 88 C18H27N02; C2H204 135-136°C C: 63.34 (63. 31) N (methanol/H: 7.63 (7.70) C2 absolute ethanol N: 3.65 (3.69) 1 : 1) (COOH) 2 CH3 1- 3- (4-propionylphenoxy) propyl-3-methylpiperidine hydrogen oxalate 89 Cl9H27N02; 1.8 C2H204 80-82°C C: 58.54 (58.57) L (absolute ethanol) H: 6.57 (6.65) \ N : 2. 97 (3.02) ra 0---- 1.8 (COOH) 2 1- 3- (4-cyclobutanecarbonylphenoxy) propyl] piperidine hydrogen oxalate 90 C2oH29N02; 1. 1 C2H2°4 143-145°C C: 64. 39 (64. 33) L (absolute H: 7.78 (7.59) ethanol/diethyl N : 3.36 (3.38) CHZ) 3-N ether 1 : 1) 1.1 (COOH) 2 1-3- (4-cyclopentanecarbonylphenoxy) propyl piperidine hydrogen oxalate 91 C18H26N20; 1.05 C2H204 158-159°C C: 63. 38 (63. 37) N (absolute ethanol) H: 7.19 (7.43) C2H5 N: 7.22 (7.35) Nc--o-O (CH2) 3-N 1.05 (COOH) 2 H3C 1- 3- (4-cyanophenoxy) propyl]-cis-2-methyl-5- ethylpiperidine hydrogen oxalate 92 C18H26N20; 1. 4 C2H204; 0.6 C2H50H sticky oil C: 59.89 (60.04) N (after removal of H: 7. 39 (7.42) C2H5 absolute ethanol) N: 6.31 (6. 37) < rRNC <O (CH2) 3-N 1.4 (COOH) 2; 0.6 C2H50H H3C 1- 3- (4-cyanophenoxy) propyl]-trans-2-methyl-5- ethylpiperidine hydrogen oxalate 93 C17H24N20; C2H204 161-163°C C: 62.73 (62.97) N (absolute ethanol) H: 7.28 (7.23) CH3 N: 7.64 (7.73) NC/O (CH2) 3-N (COOH) 2 CH3 1- 3- (4-cyanophenoxy) propyl]-cis-3,5- dimethylpiperidine hydrogen oxalate 94 C18H27N02; 1.1 C2H204 163-165°C C: 62.43 (62.46) N (methanol/H: 7.67 (7.58) absolute ethanol N : 3. 53 (3. 61) C2H5 1 : 1) 1 : 1) 1.1 (COOH) 2 1- 3- (4-propionylphenoxy) propyl]-4-methylpiperidine hydrogen oxalate 95 C18H27No2; C2H204 92-94°C C: 63.01 (63.31) N (methanol/H: 7.79 (7.70) absolute ethanol N: 3.61 (3.69) C2H5 O (CH2) 3-N TID-1 : 1) (COOH)2 H3C 1-3- (4-propionylphenoxy) propyl-2-methylpiperidine hydrogen oxalate 96 C18H2gNo2; C2H204 144-145°C C: 62.95 (62.97) P (methanol/H: 8.13 (8.19) absolute ethanol N: 3.54 (3.67) 1 <>-1 : 1) OH\ (COOH) 2 CH3 l- {3- 4- (l-hydroxypropyl) phenoxy] propyl}-3- meth 1 i eridine h dro en oxalate 97 C18H2gNo2; C2H204 182-183°C C: 62.64 (62.97) P (methanol/H: 8. 31 (8.19) absolute ethanol N : 3. 62 (3. 67) C2H5-CH O (CHZ) 3-N~ J-CH3 OH (COOH) 2 1-{3- 4- ( 1-hydroxypropyl) phenoxy propyl}-4- methylpiperidine hydrogen oxalate 98 C18H28N202; HCI; 0.1 H20 151-153°C C: 62.91 (63.09) J (absolute H: 8.64 (8.59) ethanol/diethyl N: 8.28 (8.17) C2H5 T CH2) 3-N ether 1 : 1) HIC H3C HCI;0.1 H20 1- 3- (4-propionylphenoxy) propyl]-2-methylpiperidine oximehydrochloride 99 Cl9H3oN202; C2H204 179-181°C C: 61.86 (61.75) Q (methanol/H: 7.81 (7.90) /5/\ absolute ethanol (6.86) C2H5 CH3 1: 1) N (OCH3) (COOH) 2 1-3- (4-propionylphenoxy) propyl-4-methylpiperidine methoxime hydrogen oxalate 100 C17H24N20; C2H204 163-165°C C: 63.04 (62.97) N (absolute ethanol) H: 7.10 (7.23) CH3 /3 N : 7.53 (7.73) Nc-ao (CH2) 3-N (COOH)2 CH3 1- 3- (4-cyanophenoxy) propyl-trans-3,5- dimethylpiperidine hydrogen oxalate 101 C20H2gNo2; C2H204 ; 0. 2H20 136-138°C C: 64.54 (64.59) N (absolute H: 7.70 (7.74) r*LJ CH3 ethanol/diethyl N: 3.44 (3.42) O (CH2) 3-N ether 1 : 1) O (COOH) 2; 0. 2 H20 CH3 1- 3- (4-cyclopropylcarbonylphenoxy) propyl]-trans- 3,5-dimethylpiperidine hydrogen oxalate 102 C20H2gNo2; 1. 1 C2H204 130-132°C C: 64.50 (64.33) N (absolute H: 7.82 (7.59) CH3 ethanol/diethyl N: 3. 33 (3.38) O(CH2) 3-N ether 1 : 1) 0 1.1 (COOH) 2 CH3 1- 3- (4-cyclopropylcarbonylphenoxy)propyl]-cis-3,5- dimethylpiperidine hydrogen oxalate 103 C16H23No3 C2H204 156-158°C C: 59.03 (58.85) L (methanol) H: 6.76 (6.86) N : 3.77 (3.81) H3C0 \/O (CH2) 3-N' 0 (COOH) 2 1- 3- (4-carbomethoxyphenoxy) propyl] piperidine hydrogen oxalate 104 CisH27NO; C7HsS03 118-120°C C: 67.26 (67.38) R (absolute H: 7.83 (7.92) ethanol/diethyl N : 3.08(3.14) H3C-- O (CH2) 3-N ether 1: 3) CH3C6H4SO3H H3C 1- 3- (4-propenylphenoxy) propyl]-2-methyl piperidine hydrogen p-toluene sulfonate 105 Cl9H3oN202 HCl 185-187°C C: 64.28 (64.30) Q (absolute H: 8.77 (8.80) ethanol/diethyl N : 7. 80 (7. 89) ether 1 : 3) ether 1: 3) N (OCH3) HCI H3C 1-3- (4-propionylphenoxy) propyl-2-methylpiperidine methoximehydrochloride 106 C2oH33N02; C7H8So3; 0.3 H20 105-107°C C: 65.25 (65.24) S (absolute H: 8.44 (8.44) ethanol/diethyl N: 2.80 (2.82) C2H5CH9\/O (CH2) 3N/ ether 1 : 3) OC2H5 H3C CH3C6H4SO3H; 0.3 H20 1- {3- 4- ( 1-ethoxypropyl) phenoxy] propyl} -2-methyl piperidine hydrogen p-toluene sulfonate 107 C18H28N202; C2H204 ; 0. 5CH30H 157-160°C C: 59.92 (59.98) J (methanol) H: 8.00 (7.86) /5 < N : 6. 74 (6. 82) CH2) 3-N rCH3 V N (OH) (COOH) 2; 0.5 CH30H -3- (4-propionylphenoxy) propyl-4-methylpiperidine oxime hydrogen oxalate 108 C14H2oBrNO; C2H204 175-177°C C: 49.52 (49.50) L (absolute ethanol) H: 5.62 (5.71) N: 3.50 (3.61) (COOH) 2 1- 3- (4-bromophenoxy) propyl piperidine hydrogen oxalate 109 C14H20N2o3; C2H204 148-151°C C: 54.14 (54.23) L (absolute ethanol) H: 6.26 (6.26) N : 7.88(7.91) (COOH) 2 (COOH) 2 1- 3- (4-nitrophenoxy) propyl] piperidine hydrogen oxalate 110 C16H26SN203; C2H204 149-153°C C: 51.58 (51.91) L (absolute ethanol) H: 6.80 (6.78) H3C i1°l N: 6.84 (6.73) N-S/O (CHZ) 3-N H3C O (COOH) 2 1-3- (4-N, N-dimethylsulfonamidophenoxy) propyIpiperidine hydrogen oxalate 111 C17H27No; C2H204 131-134°C C: 64.68 (64.93) L (absolute ethanol) H: 8.50 (8.32) H3C-N : 3.96 (3.99) O (CH2) 3-N Hic (COOH) 2 1- 3- (4-isopropylphenoxy) propyl] piperidine hydrogen oxalate 112 C18H2gNo; 1.1 C2H204 133-136°C C: 64.67 (64.79) L (absolute ethanol) H: 8.47 (8.40) \/\/\ N'3 76 C3 74) H3 N : 3. 76 (3.74) H (CH2) 3-N H3C 1.1 (COOH) 2 1- 3- (4-sec-butylphenoxy) propyl] piperidine hydrogen oxalate 113 C17H27No; C2H204; 0.5 H20 121-124°C C: 63.46 (63. 31) L (absolute ethanol) H: 8.36 (8.39) N: 3.92 (3.89) C3H7-O-O (COOH) 2; 0.5 H20 1- 3- (4-propylphenoxy) propyl] piperidine hydrogen oxalate 114 C16H25NO; C2H204; 0.5 H20 148-151°C C: 62.65 (62.41) L (absolute ethanol) H: 7.88 (8.15) \ N :. 4.42 (4.04) CZHS O (CH2) 3-N\ U (COOH) 2; 0.5 H20 1- 3- (4-ethylphenoxy) propyl] piperidine hydrogen oxalate No Structure Synthesis .. ~ No'v NoH NaH (a) (b) 116 ber OH NA NOH NaH 117 GN-o i H3C-SO, "'OH NaH (a) (b) 118D--) r) r NO S NOH NaH C'S I (a) (c) 0 119 NO''N O=C=N H GN OH (d) ~ 120 GNOH O=C=N H (d) ( ) .- 121 NO~'N~ NOH diphosgene G H, N ly (e) (d) No Structure Synthesis NH 122--,s 19, KJ H bJ H2NOO WK2CO3 KJI HxN \ K2C03 I csl tn) s cl (g) (h) N''N'v NH S=C=N H--o 0 124 W O NU W Ii) 125 cul 0 0 0 "CO 0 C) N1J G I > G' H H GNNHZ (k) o n 127 0 Br Br H K, C03 2 3 HA tm) f1 No Structure Synthesis 0 128, o \ I I KZC03 Br I/CNH ONX HO (I) (m) (n) 129 n oH ZON \/NaH (a) (b) zon ojor u Ho N cl Ber cri H (o) (p) lu) ~ ~N (q) N/NHZ CI CNX W ONV NaH W (a) (b) ce 133 H H HO N/NHz N I HO 131CN ~ NH<t 4 CN ~ NH2 Clty4N'z GN (t) (r) NOZ 134 H N02 ci H -N HO (s) (t) (r) No Structure Synthesis cul N 135 H N H HO (s) (t) (r) GNH GNH ho (t) (r) <BR> (a) toluene, 12 h, r. t.<BR> <P>(b) toluene, tetrabutylammonium iodide, 15-crown-5,12 h, 80 °C.<BR> <P>(C) THF, 12 h, reflux.<BR> <P>(d) acetonitrile, 4 h, 80 °C.<BR> <P>(e) ethyl acetate, 3 h, 60 °C.<BR> <P>(f) diethyl ether, 2 h, r. t.<BR> <P>(g) H2O/EtOH, 2 h, reflux.<BR> <P>(h) Kl, EtOH, 2 d, reflux.<BR> <P>(i) dioxane/H20 (1+1), 4 h, 0 OC.<BR> <P>(k) acetonitrile, 5 min, r. t.<BR> <P>(I) acetone/DMF (10: 1), 10 min, r. t.<BR> <P>(m) 12 h, r. t.<BR> <P>(n) 1 h, reflux.<BR> <P>(o) triethylamine, acetone, 8 h, 50 °C.<BR> <P>(p) Na, MeOH, DMF, 6 h, 80 °C.<BR> <P>(q) triethylamine, MeOH, 24 h, 50 °C.<BR> <P>(r) K2CO3, KI, EtOH, 6 h, reflux.<BR> <P>(S) triethylamine, Kl, EtOH, 12 h, reflux.<BR> <P>(t) thionyl chloride, THF, 2 h, 0 °C. No Structure Synthesis GNH ber K, CO, ou HO ( 19) O 0 /' KZC03 Br/NH cis HO (g) (e) ( (9) (el 0 139 KZCO3 Br/NH trans HO Br 139 I Br , trans HO (g) (e) 140 0 0 ber 141 I w I GNH I \ O I \ OH N F/ NA 0 0 /HO Ia) ( con nu 141 OH N F hot HO (c) (d) (e) No Structure Synthesis 0 0 143 GNH 143 1 1 < : YH HO (a) (c) (d) (e) 144 H, C-0, S H (b) (e) (e) -nu 145 145 0 cis 146 (c) (e) j N YNH trans ( 147 NO I NH 147 NOi) . r-NH V H, C-03S HOOH N-a'- (b) (c) (e) 148 GNO \ HaC-sS I GNH HOOH N (b) (c) (e) No Structure Synthesis 149 0 H, C-0, S H I/CI N \ CI Ho oh ( 'NH 150 H, C-0, S Cl cil ci t cis > () ( 'NH I51N I H3C OgS HOOH C. (c) CI Cl (c) (e) 1S2 N N I//NH G. N G N OH ci 153 (d) (e) N\ 153 N ci H NN HZN OH------- I) H N 154 N nazi GNH CL (I) (d) (e) ( No Structure Synthesis N cri 155 / GNH CI HzNH C---.-- CI (1) (d) (e) I//GNH 156 Cl /H2NOH CI (I) (d) $ N N \ O C ZON G. N, ~ (y wGwi (I) (d) (e) (h) (e) () (r) 56 C ci N N ci cl CI Br C'Br (h) (e) (,) (r) H h) 159 N 0 ci N ONH I59CN'>\z so t\-N0N<NHCNHßCI Y/° \== (h) (e) (i) (r) No Structure Synthesis ci N ci 160 H N ci C, on N H, N ci OH (e) (o) N cri cri N I-a C, CI Cri v ~oh (h) lo) 0 OU 162 N02 SCI GNH ci NO'v I/ (d) (e) ~-~~. 163 NN N 164 ci (d) (e) No Structure Synthesis 165 NX VNH2 02N) H N''N'CI H (d) (e) (q) 166 N OH l68 CS c 1 N ifs H2N C1 SX HZN ~ OH ;"HN C U ci (d) (e) CLIN 168 N N S I HZN s------------ (h) (d) (e) 0 169 N NHZ L" bu O Br- 170 C-0, S 170 HO"--'OH a) THF, 10 h, r. t. k) ether, 2 h, r. t.<BR> b) THF, 10 h, reflux 1) ethanol, KI, triethylamine, 12 h, reflux<BR> c) THF, tetrabutylammonium iodide, 15-crown-5,24 h, reflux m) nitrobenzol, A1C13, 3 d, r. t.<BR> d) thionyl chloride, 3h, 0°C-70°C n) DMF, KI, K2CO3,22 h, reflux<BR> e) acetone, KI, 12 h, reflux o) acetone, KI, K2CO3,22 h, reflux<BR> acetone, 10 min., r. t. p) ethanol, KI, 6 d, reflux<BR> g) acetone, 12 h, reflux<BR> q) THF, Pd/C, 1 bar, 12 h<BR> h) acetone, KI, 3 d, reflux r) phenol, KI, 12 h, 150 °C<BR> i) 6N HCI, 12 h, reflux

The following compounds can be prepared according to the synthesis schemes: ~ No. Structure Synthesis scheme 7 N- (3- (N, N-Diethylamino) propyl) N'-phenylurea scheme 7 N-Cyclohexylmethyl-N'- (3-piperidinopropyl) guanidine scheme 12 N- (4-Bromobenzyl)-N'- (4-piperidinobutyl) sulphamide scheme 12 3-Chloro-N- (4-piperidinobutyl)-N-methyl-benzene sulphonamide scheme 11 N- (4-Chlorobenzyl)-2- (4-piperidinomethyl) phenyl) ethan amidine scheme 9 1- (5-Cyclohexylpentanoyl)-1, 4-bipiperidine

cis-1- (6-Cyclohexyl-3-hexen-1-yl) piperidine trans-1- (6-Cyclohexyl-3-hexen-1-yl) piperidine 1- (6-Cyclohexyl-3-hexin-1-yl) piperidine scheme 14 1- (2- (5, 5-Dimethyl-1-hexin-1-yl) cyclopropyl) piperidine (u) potassium tert. butanolate, THF, 24h, 0-50 °C; (v) chromatographic separation; (w) NH3 (fl.), MeOH,-78-0 °C.

Compounds 1 to 114 are prepared according to the following procedures: METHOD A: A solution of 1-bromo-5-phenoxypentane (1.4 to 3.5 mmol) in ten equivalents of the suitable secondary amine was heated to reflux temperature with stirring for 48 hours (compds. 1,3 and 4), 24 hours (compd. 2) or 4 hours (compd. 5). After cooling, the excess base was removed under reduced pressure and the residue diluted with aqueous sodium hydroxide. The product was extracted with diethyl ether, the organic extracts washed with water, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The remaining oil was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. The precipitate formed was washed with diethyl ether and recrystallised from absolute ethanol.

METHOD B: A solution of 1-bromo-5-phenoxypentane (0.9 to 1.7 mmol) and an excess of the suitable secondary amine (2.3 to 10 equivalents) in 10 ml absolute ethanol was heated to reflux temperature with stirring for 48 hours (compd. 6) or 24 hours (compds. 7,8,9,10,11,12&13,14,15,16,17 and 29). After cooling, the solvent was removed under reduced pressure and the residue diluted with aqueous sodium hydroxide. The product was extracted with diethyl ether, the organic extracts washed with water, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The cis and trans isomers 12 and 13 were separated by column chromatography on silica gel eluting with a solvent mixture of petroleum spirit (bp 60-80°C), diethyl ether and triethylamine in the ratio 66: 33: 1, and the eluent was removed under reduced pressure to leave an oil. Compounds 14 and 16 were purified by column chromatography on silica gel eluting with diethyl ether and triethylamine in the ratio 99: 1, and the eluent was removed under reduced pressure to leave an oil. The oil was converted to oxalate salt (compds. 17 and 29) by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents of oxalic acid in absolute ethanol. If no precipitate appeared, diethyl ether was

added to form a precipitate. The solid was washed with diethyl ether and recrystallised from isopropyl alcohol (compds. 6,7,10,13 and 16), absolute ethanol (compds. 8,9,11,12,15 and 29) or methanol (compd. 17). The oil was converted to hydrochloride salt (compd. 14) by adding 2N HCI. The precipitate was formed in a mixture of chloroform and diethyl ether (1: 1) and recrystallised from acetone.

METHOD C: A solution of the suitable cc-bromo-co-aryloxy alkane (0.4 to 1.4 mmol) or co- bromoalkyl phenyl sulphide (1 mmol, compds. 33 and 34) and an excess of pyrrolidine (10 to 15 equivalents) or 3-methylpiperidine (10 equivalents, compd.

38) in 10 ml absolute ethanol was heated to reflux temperature with stirring for 24 hours or 16 hours (compd. 47). After cooling, the solvent was removed under reduced pressure and the residue diluted with aqueous sodium hydroxide. The product was extracted with diethyl ether, the organic extracts washed with water, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The remaining oil was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. If no precipitate appeared, diethyl ether was added to form a precipitate. The solid was washed with diethyl ether and recrystallised from absolute ethanol.

METHOD D: A solution of the suitable 4'- (5-bromopentoxy) phenyl ketone (0.7 to 1 mmol, compds. 39,44 and 45) or 1-bromo, 5- (4-phenoxyphenoxy) pentane (0.6 mmol, compd. 48) and an excess of pyrrolidine (10 to 15 equivalents) in 10 ml absolute ethanol was heated to reflux temperature with stirring for 16 hours (compds. 39,44 and 48) or 24 hours (compd. 45). After cooling, the solvent was removed under reduced pressure and the residue diluted with aqueous sodium hydroxide. The product was extracted with chloroform (compds. 39,45 and 48) or dichloromethane (compd. 44), the organic extracts dried over magnesium sulphate, filtered and concentrated under reduced pressure. The remaining oil was converted to oxalate salt by dissolving in a small amount of absolute

ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol.

The precipitate was washed with diethyl ether and recrystallised from absolute ethanol (recrystallised twice from absolute ethanol in the case of compd. 39).

METHOD E: 1. The oxalate 18 was prepared according to method C. A solution of compound 18 (0.57 mmol) in 10 mi methanol and 10 ml absolute ethanol was placed with 100 mg of palladium (5%) on carbon catalyst in a two-neck round- bottom flask fitted with a balloon filled with hydrogen. The mixture was stirred vigorously at room temperature and the flask was purged of air and filled with hydrogen. After 3 hours, the catalyst was filtered off on celite and the solvent removed under reduced pressure. The residual solid was converted to oxalate salt by dissolving in methanol and adding a solution of oxalic acid (2 equivalents) in absolute ethanol. Diethyl ether was added to form a precipitate.

The product was recrystallised from absolute ethanol.

2. To a solution of compound 40 (0.35 mmol) in pyridine vigorously stirred at 0°C was added dropwise a slight excess of benzoyl chloride (0.4 mmol). The stirring was allowed to continue 20 minutes after the end of the addition after which the mixture was placed in the refrigerator overnight (16 hours). The solvent was removed under reduced pressure and the residue diluted with aqueous sodium hydroxide. The product was extracted with chloroform, the organic extracts dried over magnesium sulphate, filtered and concentrated under reduced pressure. The remaining oil was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. The precipitate was dissolved in methanol, filtered, and concentrated under reduced pressure. the solid was recrystallised from absolute ethanol METHOD F: In a three-neck flask kept under nitrogen was placed a solution of the suitable phenol (1.6 mmol), 3- (diethylamino) propanol (1.5 mmol), and triphenyl phosphine (1.9 mmol) in 10 ml freshly distille tetrahydrofuran. The mixture was stirred and cooled to 0°C with an ice and salt bath. A solution of diisopropyl

azodicarboxylate (2 mmol) in 10 ml tetrahydrofuran was added very slowly (typically over 40 minutes) and the mixture was allowed to warm to room temperature after which it was stirred overnight at room temperature (16 hours).

The solvent was then removed under reduced pressure, the residue dissolved in ethyl acetate (20 ml) and the product extracted with 2N HCI (2x10 ml). The aqueous solution was neutralised with sodium hydroxide and the product extracted with dichloromethane. After drying over magnesium sulphate and filtration, the solvent was removed under reduced pressure. The residue was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. If no precipitate appeared, diethyl ether was added to form a precipitate. The solid was washed with diethyl ether and recrystallised from absolute ethanol (compds. 43 and 46) or from a 1: 1 mixture of methanol and absolute ethanol (compd. 42).

METHOD G: A solution of the free base of compound 39 (0.6 mmol) or compound 46 (0.8 mmol) in 20 ml dry diethyl ether was added dropwise to a stirred suspension of lithium aluminium hydride (0.6 or 0.8 mmol) in 20 ml dry diethyl ether kept under nitrogen. The mixture was stirred at room temperature under nitrogen for two hours. Ice-cold water was carefully added and the organic layer decanted. The aqueous phase was extracted with diethyl ether. The combined organic solutions were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The oil was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. The precipitate was washed with diethyl ether and recrystallised from absolute ethanol (compd 50) or from isopropyl alcohol, giving a very hygroscopic solid (compd. 63).

METHODH : A solution of the suitable a-bromo-co- (4-cyanophenoxy) alkane (0.5 to 0.7 mmol) and an excess of the suitable secondary amine (8 to 12 equivalents) in 10 ml absolute ethanol was heated to reflux temperature with stirring for 24 hours

(compds. 54,55,57 and 60), 20 hours (compd. 52), 16 hours (compds. 56,58, 59 and 61) or 8 hours (compd. 51) or was stirred at room temperature for 48 hours (compd. 53) or 24 hours (compd. 60). After cooling, the solvent was removed under reduced pressure and the residue diluted with aqueous sodium hydroxide. The product was extracted with diethyl ether, the organic extracts washed with water, dried over magnesium sulphate, filtered and concentrated under reduced pressure. Compound 62 was purified by column chromatography on silica gel eluting with ethyl acetate, and concentrated under reduced pressure. For all the compounds of method H, the remaining oil was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. If no precipitate appeared, diethyl ether was added to form a precipitate. The solid was washed with diethyl ether and recrystallised from absolute ethanol (two recrystallisations were required for compds. 58 and 59) or from a 1: 1 mixture of methanol and absolute ethanol (compd. 55).

METHOD J: A solution of compound 46 (1 mmol) in 10 ml methanol was stirred at room temperature and a solution of hydroxylamine hydrochloride (2 equivalents) in 2 ml water was added. The mixture was stirred at 50-70°C in a water bath for 20 minutes. Methanol was removed under reduced pressure. The residue diluted with aqueous sodium hydroxide. The product was extracted with diethyl ether, the organic extracts washed with water, dried over magnesium sulphate, filtered and concentrated under reduced pressure. Compound 64 was purified by column chromatography on silica gel eluting with ethyl acetate, and concentrated under reduced pressure. The remaining oil was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. Diethyl ether was added to form a precipitate. The solid was washed with diethyl ether and recrystallised from absolute ethanol.

For example 98, the product was converted to the hydrochloride salt by addition of 2N HCI. The salt was recrystallised from absolute ethanol/diethyl ether (1: 1).

METHOD K: A solution of 4'- (3-bromopropoxy) acetophenone (0.8 to 1.9 mmol) and an excess of the suitable piperidine (3 to 10 equivalents) in 10 ml absolute ethanol was heated to reflux temperature with stirring for 16 hours. After cooling, the solvent was removed under reduced pressure and the residue diluted with aqueous sodium hydroxide. The product was extracted with diethyl ether, the organic extracts washed with water, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The cis and trans isomers 67 and 70 were separated by column chromatography on silica gel eluting with a solvent mixture of diethyl ether, petroleum spirits (bp 60-80°C) and triethylamine in the ratio 66: 33: 1, and the eluent was removed under reduced pressure to leave an oil. Compound 75 was purified by column chromatography on silica gel eluting with chloroform and methanol (1: 1), and concentrated under reduced pressure.

The remaining oil was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents of oxalic acid in absolute ethanol. If no precipitate appeared, diethyl ether was added to form a precipitate. The solid was washed with diethyl ether and recrystallised from absolute ethanol.

METHOD L: In a three-neck flask kept under nitrogen was placed a solution of the suitable 4'-hydroxyphenyl ketone (0.9 to 3 mmol), 3- (1-piperidinyl) propanol (0.9 to 3 mmol), and triphenyl phosphine (1 to 3.5 mmol) in 10 ml freshly distille tetrahydrofuran. The mixture was stirred and cooled to 0°C with an ice and salt bath. A solution of diethyl azodicarboxylate (1 to 3.6 mmol) in 10 ml tetrahydrofuran was added very slowly (typically over 40 minutes) and the mixture was allowed to warm to room temperature after which it was stirred overnight at room temperature (16 hours). The solvent was then removed under reduced pressure, the residue dissolved in ethyl acetate (20 ml) and the product extracted with 2N HCI (2x10 mi). The aqueous solution was neutralised with sodium hydroxide and the product extracted with dichloromethane. After drying over magnesium sulphate and filtration, the solvent was removed under reduced pressure. The crude product was purified by column chromatography

on silica gel eluting with diethyl ether containing 1 % triethylamine, and concentrated under reduced pressure. The residue was converted to oxalate salt by dissolving in a small amount of absolute ethanol and adding a solution of two equivalents oxalic acid in absolute ethanol. If no precipitate appeared, diethyl ether was added to form a precipitate. The solid was washed with diethyl ether and recrystallised from absolute ethanol.

For example 82, the amine was converted to the hydrochloride salt by addition of 2N HCI. The salt was recrystallised from absolute ethanol/diethyl ether (1: 14).

Method M: A solution of 3- (4-acetylphenoxy)-2- (R or S)-methylpropyl para-toluene sulfonate (0.55 to 0.66 mmol) and piperidine (5 to 6 mmol) in 10 ml absolute ethanol was stirred and heated under reflux for 2 hours. After cooling, the solvent was removed under reduced pressure, the residue diluted with aqueous NaOH (10 ml) and the oil was extracted with diethyl ether (3 x 10 ml). The combined extracts were dried over magnesium sulfate, and the solvent removed under reduced pressure. The yellow oil was purified by column chromatography on silica gel eluting with a 1: 1 mixture of chloroform and absolute ethanol (example 80). After concentration, the oil was dissolved in about 2 ml absolute ethanol and a solution of oxalic acid (1 to 1.1 mmol) in 2 ml absolute ethanol was added. The precipitate was recrystallised from absolute ethanol.

Method N: A solution of 1-bromo-3- (4-substitutedphenoxy) propane (0.4 to 2 mmol) and the suitably substituted piperidine (2.5 to 8 mmol) in 10 ml absolute ethanol was stirred and heated under reflux for 6 to 24 hours. After cooling, the solvent was removed under reduced pressure, the residue diluted with aqueous NaOH (10 ml) and the oil was extracted with diethyl ether (3 x 10 ml). The combined extracts were dried over magnesium sulfate, and the solvent removed under

reduced pressure. The residual oil was dissolved in about 5 ml diethyl ether and a solution of HCI in 10 ml diethyl ether was added. The-precipitate was recrystallised from a 1: 1 or 1: 5 mixture of absolute ethanol and diethyl ether (examples 78,79,84,87). The oil was purified by column chromatography on silica gel eluting with a mixture of 33% petroleum ether (60-80°C), 66% diethyl ether and 1% triethylamine (examples 101 and 102) or with 99% diethyl ether and 1 % triethylamine (examples 88,94 and 95) and concentrated. The residual oil was dissolved in about 5 ml absolute ethanol and a solution of oxalic acid (1 to 1.6 mmol) in 5 ml absolute ethanol was added. The precipitate was recrystallised from absolute ethanol or from a 1: 1 mixture of methanol and absolute ethanol (examples 83,85,86,91,93,100,101 and 102). The product was obtained as a sticky oil after removal of absolute ethanol (example 92).

Method O: A mixture of 4- (4-hydroxyphenyl)-2-butanone (200 mg, 1.2 mmol), 3- chloropropyl piperidine hydrochloride (200 mg, 1 mmol) and potassium carbonate (830 mg, 6 mmol) in 10 mi absolute ethanol was stirred and heated under reflux for 8 hours. After cooling, the reaction mixture was filtered and concentrated under reduced pressure. The residue was diluted with aqueous sodium hydroxide and extracted with diethyl ether (3 x 10 ml). The combined extracts were dried over magnesium sulfate, and the solvent removed under reduced pressure. The free base was dissolved in diethyl ether and a solution of HCI in diethyl ether was added. The precipitate was recrystallised from acetone.

Method P: A solution of the ketone (0.4 mmol) in 10 ml methanol was stirred at 0°C in an ice-bath. To this solution was added portionwise NaBH4 (1 mmol). The mixture was left to stir at room temperature for 16 hours. The solvent was removed, water (10 ml) was added to the residue and the product was extracted with chloroform (4 x 10 ml). The combined extracts were dried over magnesium sulfate, and the solvent removed under reduced pressure. The free base was

dissolved in absolute ethanol (5 ml) and a solution of oxalic acid (1 mmol) in 5 ml absolute ethanol was added. The precipitate was recrystallised from absolute ethanol.

Method Q: Similar to method J using methoxylamine in place of hydroxylamine. For example 105, the product was converted to the hydrochloride salt by addition of 2N HCI. The salt was recrystallised from absolute ethanol/diethyl ether (1: 3).

Method R: Similar to method P. The reduced product was converted to the hydrochloride salt by addition of 2N HCI. Then, the product was converted to the free base by addition of 10% aqueous NaOH. Then, the product was converted to the para- toluene sulfonate by addition of a solution of para-toluene sulfonic acid (1 mmol) in 5 mi absolute ethanol. The precipitate was recrystallised from absolute ethanol/diethyl ether (1: 3).

Method S: Similar to method P. The reduced product was converted to the para-toluene sulfonate by addition of a solution of para-toluene sulfonic acid (1 mmol) in 5 ml absolute ethanol. The precipitate was recrystallised from absolute ethanol/diethyl ether (1: 3).

Intermediates: (4-hydroxyphenyl) cyclopropyl ketone, intermediate for examples 76,101 and 102.

S. N. Rastogi et al. J. Med. Chem. 15,286-291 (1972)

4'- (3-hydroxy-2- (R)-methylpropoxy) acetophenone and 4'- (3-hydroxy-2- (S)- methylpropoxy) acetophenone, intermediates for examples 77 and 80.

A mixture of 4'-hydroxyacetophenone (1.3 to 2.8 mmol), 3-bromo-2- (R or S)- methyl-1-propanol (1.3 to 2.6 mmol) and potassium carbonate (1.7 to 3.6 mmol) in acetone (20 ml) was stirred and heated under reflux for 24 hours. The suspension was filtered hot and the solvent removed under reduced pressure to leave an oil that was purified by column chromatography on silica gel eluting with a mixture of diethyl ether and petroleum ether (60-80 °C). After concentration, a colourless oil was obtained.

NMR: 7.91 (m, 2H); 6.92 (m, 2H); 4.01 (m, 2H); 3.71 (br, 2H); 2.54 (s, 3H); 2.21 (m, 1H); 2.10 (br, 1H); 1.06 (d, 3H) NMR: 7.91 (m, 2H); 6.93 (m, 2H); 4.01 (m, 2H); 3.71 (br, 2H); 2.55 (s, 3H); 2.23 (m, 1 H); 2.09 (br, 1 H); 1.06 (d, 3H) 3- (4-acetylphenoxy)-2- (S)-methylpropyl para-toluene sulfonate and 3- (4- acetylphenoxy)-2- (R)-methylpropyl para-toluene sulfonate, intermediates for examples 77 and 80.

A solution of 4'- (3-hydroxy-2- (R or S)-methylpropoxy) acetophenone (0.7 to 1.2 mmol) in pyridine (5 ml) was stirred at 0 °C and para-toluene sulfonyl chloride (1 to 1.6 mmol) was added portionwise. The mixture was subsequently placed in the refrigerator overnight. The solvent was then removed under reduced pressure and the residue purified by column chromatography on silica gel eluting with a mixture of 50% diethyl ether and 50% petroleum ether 60-80 °C.

After concentration, a colourless oil was obtained. In the case of the R-isomer, the oil formed a white solid that was recrystallised from absolute ethanol.

NMR: 7.91 (m, 2H); 7.74 (m, 2H); 7.23 (m, 2H); 6.79 (m, 2H); 4.11 (m, 2H); 3.87 (m, 2H); 2.57 (s, 3H); 2.38 (s, 3H); 2.33 (m, 1 H); 1.07 (d, 3H) NMR: 7.88 (m, 2H); 7.71 (m, 2H); 7.21 (m, 2H); 6.75 (m, 2H); 4.07 (m, 2H); 3.83 (m, 2H); 2.53 (s, 3H); 2.34 (s, 3H); 2.30 (m, 1 H); 1.04 (d, 3H)

1-bromo-3- (4-nitrophenoxy) propane, intermediate for examples 83,85 and 86.

J. N. Ashley et al. J. Chem. Soc. 3298-3304 (1958) 1-bromo-3- (4-propionylphenoxy) propane, intermediate for examples 88,94 and 95.

To a stirred and heated mixture of 1,3-dibromopropane (80 mmol) and potassium carbonate (50 mmol) in acetone (200 mi) was added dropwise a solution of the hydroxy ketone (40 mmol) in acetone (80 ml). The reaction was allowed to continue overnight. The mixture was filtered hot and the solvent removed under reduced pressure to leave an oil that was dissolved in ethyl acetate. Addition of petroleum spirit (60-80°C) formed a precipitate. The solid was filtered and dried under reduced pressure.

NMR: 7.96 (m, 2H); 6.93 (m, 2H); 4.18 (t, 2H); 3.62 (t, 2H); 2.96 (q, 2H); 2.34 (m, 2H); 1.22 (t, 3H) (4-hydroxyphenyl) cyclobutyl ketone and (4-hydroxyphenyl) cyclopentyl ketone, intermediates for examples 89 and 90.

A mixture of cyclobutylcarbonyl chloride (5 mmol) or cyclopentylcarbonyl chloride (7 mmol) and aluminium chloride (15 mmol) in dry dichloromethane (40 ml) was stirred at 0 °C and a solution of phenol (8 mmol) in dry dichloromethane (20 ml) was added dropwise. the mixture was then stirred and heated under reflux for 3 hours. After cooling to 0 °C, water was added with vigorous stirring.

The organic layer was decanted off, dried over magnesium sulfate and concentrated. The crude product was purified by column chromatography on silica gel eluting with petroleum ether/diethyl ether (2: 1).

NMR: 7.72 (m, 2H); 6.80 (m, 2H); 3.95 (m, 1H); 2.45 (m, 2H); 2.15 (m, 4H) NMR: 7.92 (m, 2H); 7.25 (s, 1 H); 6.92 (m, 2H); 3.70 (m, 1 H); 2.00 (m, 4H); 1.75 (m, 4H) 1-bromo-3- (4-cyclopropanecarbonylphenoxy) propane, intermediate for examples 101 and 102.

To a stirred and heated mixture of 1,3-dibromopropane (5 mmol) and potassium carbonate (3.4 mmol) in acetone (40 ml) was added dropwise a solution of 4- cyclopropanecarbonylphenol (5 mmol) in acetone (20 ml). The reaction was allowed to continue overnight. The mixture was filtered hot and the solvent removed under reduced pressure to leave an oil. The oil was purified by column chromatography on silica gel eluting with petroleum ether/ethyi acetate (15: 1).

4- (N, N-dimethylsulfonamido) phenol, intermediate for example 110.

N. Eliel J. Org. Chem. 20,1657-1660 (1955) Compounds 115 to 170 are prepared according to the following procedures : Example 115 3,3-Dimethylbutyl 3-piperidinopropyl ether Sodium 3-piperidinopropanolate (5 mmol), 5 mmol of 3, 3-dimethylbutyl chloride, a catalytic amount of tetrabutylammonium iodide, and 0.5 mmol of 15-crown-5 in 10 ml of dry dimethyl sulfoxide were refluxed for 12 hours. Water was added, and it was extracted with diethyl ether. The organic layer was purified by column chromatography on silica gel (eluent: methylene chloride/methanol (90/10), ammonia atmosphere). The solvent was removed under reduced pressure and the residue crystallized with oxalic acid from diethyl ether/ethanol.

SF: C14H29NO x 1.1 C2H204 (326.4) mp: 143 °C CHN analysis calculated: C 59.6 H 9.63 N 4.29 found: C 59.7 H 9.61 N 4.30 Example 116 3-Phenylpropyl 3-piperidinopropyl ether Sodium 3-piperidinopropanolate (20 mmol), 20 mmol of 3-phenylpropyl bromide, and 0.5 mmol of 15-crown-5 in 30 ml of dry toluene were refluxed for 4

hours. The solvent was evaporated and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol/aqueous ammonia (90/10/0.5)). After removing the solvent under reduced pressure the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C17H27NO x C2H204 (351.4) mp: 125 °C CHN analysis calculated: C 64.9 H 8.32 N 3.99 found: C 64.9 H 8.13 N 4.02 Example117 3- (4-Chlorophenyl) propyl 3-piperidinopropyl ether Sodium 3-piperidinopropanolate (20 mmol), 7 mmol of 3- (4-chlorophenyl) propyl- mesylate, and 0.5 mmol of 15-crown-5 in 30 ml of dry toluene were refluxed for 4 hours. The solvent was evaporated and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol (90/10)).

After removing the solvent under reduced pressure the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C17H26NOCl x C2H204 (385.9) mp: 147 °C CHN analysis calculated: C 59.1 H 7.31 N 3.63 found: C 59.0 H 7.34 N 3.60 Example118 2-Benzothiazolyl 3-piperidinopropyl ether Sodium 3-piperidinopropanolate (5 mmol) and 5 mmol of 2-chlorobenzothiazole in 20 ml of dry tetrahydrofurane were refluxed for 12 hours. The suspension was filtered and the solvent evaporated under reduced pressure. The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C15H20N2OS x C2H204 (366.4) mp: 178.2-178.8 °C CHN analysis calculated: C 55.7 H 6.05 N 7.64 found: C 55.6 H 6.03 N 7.51 Example 119 N-Phenyl-3-piperidinopropyl carbamate 3-Piperidinopropanol hydrochloride (10 mmol) and 10 mmol of phenyl isocyanate in 40 ml of dry acetonitrile were refluxed for 3 hours. The solvent was evaporated, and then the residue was recrystallized in dry ethanol.

SF: C15H22N202 x HCI x 0.1 H20 (300.6) mp: 169-170 °C CHN analysis calculated: C 59.9 H 7.78 N 9.32 found: C 59.9 H 7.64 N 9.05 Example 120 N-Pentyl-3-piperidinopropyl carbamate 3-Piperidinopropanol hydrochloride (4 mmol) and 4 mmol of pentyl isocyanate in 20 ml of dry acetonitrile were refluxed for 3 hours. The solvent was evaporated and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol/aqueous ammonia (90/10/0.5)). After removing the solvent under reduced pressure the residue was crystallized with hydrochloric acid in 2-propanol.

SF: C14H28N202 x HCI x 0.5 H20 (301.9) mp: 88-89 °C CHN analysis calculated: C 55.7 H 10.0 N 9.28 found: C 55.7 H 9.84 N 9.18

Example 121 (S)- (+)-N- 2- (3, 3-Dimethyl) butyl-3-piperidinopropyl carbamate 3-Piperidinopropanol hydrochloride (5 mmol) and 5 mmol of (S)-2- (3,3- dimethyl) butyl isocyanate in 10 ml of dry acetonitrile were refluxed for 12 hours.

The solvent was evaporated and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol (90/10), ammonia atmosphere). The solvent was removed and the residue crystallized with oxalic acid from diethyl ether/ethanol.

SF: C15H30N202 x C2H204 x 0.25 H20 (365.0) mp: 148 °C a 2D = +10. 4° (c = 0.495, Methanol) CHN analysis calculated: C 56.0 H 8.98 N 7.68 found: C 56.0 H 9.01 N 7.64 Example 122 N- (4-Chlorobenzyl)-S- (3-piperidinopropyl) isothiourea 4-Chlorobenzylamine (10 mmol) was added dropwise to 10 mmol of benzoylisothiocyanate dissolved in 20 mi of dry ether followed by stirring for 2 hours. The precipitated product was filtered off and crystallized from ethyl acetate (Yield: 60%). Potassium carbonate (10 mmol) in 30 ml of water was added dropwise to 5 mmol of the product in 20 ml of ethanol and refluxed for 2 hours. The precipitated product was filtered off and crystallized from ethyl acetate/petroleum ether (Yield: 65%). 3-Piperidinopropyl chloride hydrochloride (3 mmol), 3 mmol of the product, and a catalytic amount of potassium iodide were refluxed in 20 ml of ethanol for 2 days. Subsequently the ethanol was evaporated and the residue purified by column chromatography using methanol/ethyl acetate (2/8) as eluent. After evaporation of the solvent, the product was crystallized with hydrochloric acid from diethyl ether/ethanol.

SF: C16H24CIN3S x 2 HCI x H20 (416.8) mp: 104-107.5 °C CHN analysis calculated: C 46.1 H 6.77 N 10.1 found: C 45.9 H 6.87 N 9.69 Example 123 N'-Cyclohexylthiocarbamoyl-N-1, 4'-bipiperidine 1,4'-Bipiperidine (5 mmol) in 10 ml of dry ether was added dropwise to 5 mmol of cyclohexyl isothiocyanate in 30 ml of dry ether followed by stirring for 2 hours.

Filtration gave a residue, which was dissolved in ethanol and crystallized with oxalic acid. Recrystallization resulted in the pure product.

SF: C, 7H31N3S x H2C204 x 0.25 H20 (404.1) mp: 225-226 °C CHN analysis calculated: C 56.5 H 8.35 N 10.39 found: C 56.2 H 8.25 N 10.33 Example 124 N-Heptanoyl-1, 4'-bipiperidine 1,4'-Bipiperidine (10 mmol) in 5 ml of water was added dropwise to a solution of 5 mmol of n-heptanoyl chloride in 20 ml of dioxane. After stirring for 15 minutes the solvent was evaporated under reduced pressure and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol/aqueous ammonia (90/10/0.5)). The solvent was removed under reduced pressure, and the residue was crystallized with oxalic acid.

SF: C17H32N20 x H2C204 (370 : 5) mp: 131-132 °C CHN analysis calculated: C 61.6 H 9.25 N 7.56 found: C 61.6 H 9.36 N 7.50

Examgie 125 3-Cyclopentyl-N- (3- (1-pyrrolidinyl) propyl) propanamide 3-Cyclopentyl propionylchloride (5 mmol) in 10 ml of dioxane was added dropwise to a solution of 10 mmol of 1- (3-aminopropyl) pyrrolidine in water. After stirring for 4 hours the solvent was evaporated under reduced pressure and the residue purified by column chromatography on silica gel (eluent: methylene chloride/ methanol/aqueous ammonia (90/10/1)). The solvent was removed under reduced pressure and the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C17H28N2O x H2C204 x 0.5 H20 (351.2) mp: 89.5 °C CHN analysis calculated: C 58.1 H 8.83 N 7.97 found: C 58.1 H 8.76 N 7.87 Example 126 N-Cyclohexyl-N'- (1-pyrrolidinyl-3-propyl) urea In an argon atmosphere 10 mmol of cyclohexylisocyanate was added slowly to 10 mmol of 1- (3-aminopropyl) pyrrolidine in 10 ml of acetonitrile. The product preci-pitated instantly as a pure white solid. The solvent was removed under reduced pressure and the product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C14H27N3O x C2H204 x 0.25 H20 (347.7) Yield: 83% mp: 113.3 °C CHN analysis calculated: C 56.0 H 8.45 N 12.2 found: C 55.6 H 8.27 N 12.0

Example 127 a- (4-Acetylphenoxy)-a'-piperidino p-xylol Hydroxyacetophenone (2 mmol) and 5 mmol of K2CO3 were stirred in 20 ml of acetone with 2 ml of DMF for 10 minutes. After addition of 3.5 mmol of a, a'- dibromoxylol the reaction was stirred at ambient temperature for 12 hours and after addition of 7 mmol of piperidine for 1 hour under reflux. The solvent was evaporated under reduced pressure. The residue was suspended in water, extracted with methylene chloride. The combined organic extracts were crystallized with oxalic acid. Recrystallization resulted in the pure product.

SF: C21H25N02 x C2H204 (413.5) mp: 136-137 °C CHN analysis calculated: C 66.8 H 6.58 N 3.39 found: C 66.7 H 6.70 N 3.40 Example 128 a-(4-Acetylphenoxy)-a'- (1-pyrrolidinyl) p-xylol Hydroxyacetophenone (2 mmol) and 5 mmol of K2CO3 were stirred in 20 ml of acetone with 2 ml of DMF for 10 minutes. After addition of 3.5 mmol of a, a'- dibromoxylol the reaction was stirred at ambient temperature for 12 hours and after addition of 7 mmol of pyrrolidine for 1 hour under reflux. The solvent was evaporated under reduced pressure. The residue was suspended in water, extracted with methylene chloride. The combined organic extracts were crystallized with oxalic acid. Recrystallization resulted in the pure product.

SF: C20H23NO2 x C2H204 x 0.25 H20 (404.0) mp: 136-137 °C CHN analysis calculated: C. 65.4 H 6.36 N 3.47 found: C 65.6 H 6.29 N 3.47

Example 129 a- (3-Phenylpropoxy)-a'-piperidino p-xylol 4- (Piperidinomethyl) benzoic acid methyl ester (22 mmol) in dry tetrahydrofurane was added dropwise to a suspension of 44 mmol of lithium aluminium hydride in 30 mi of dry tetrahydrofurane at 0 °C. After refluxing for 2 hours a saturated solution of ammonium chloride in water was added dropwise. After stirring for 12 hours at ambient temperature the organic layer was isolated and the aqueous layer extracted with methylene chloride. The organic extracts were combined and the solvent was evaporated under reduced pressure. The residue was crystallized with maleic acid from diethyl ether/2-propanol (Yield: 91%). Sodium 4- (piperidinomethyl) benzyl alcoholate (5 mmol) and 6 mmol of 3- phenylpropyl bromide in 10 mi of dry toluene were refluxed for 6 hours. The solvent was evaporated under reduced pressure. The residue was purified by rotatory chromatography on silica gel using methylene chloride/ammonia atmosphere as eluent. The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C22H29NO x C2H204 x 0.5 H20 (422.5) mp: 104-105 °C CHN analysis calculated: C 68.2 H 7.63 N 3.32 found: C 68.3 H 7.26 N 3.36 Example 130 3- (4-Chlorobenzyl)-5- (2-piperidinoethyl)-1,2,4-oxadiazole Hydroxylamine hydrochloride (20 mmol) was added dropwise to a solution of 20 mmol of sodium in 50 ml of methanol at 0 °C. After stirring for 30 minutes at ambient temperature 10 mmol of 4-chlorobenzyl cyanide was added dropwise at 0 °C. After refluxing for 6 hours the suspension was filtered and the solvent evaporated under reduced pressure. The residue was crystallized from diethyl ether (Yield: 41%). To a solution of 4 mmol of the product and 6 mmol of 3- piperidinopropionic acid methyl ester in 15 ml of dry methanol 5 mmol of sodium

in 20 ml of methanol was added dropwise at 0 °C. After stirring for 1 hour under argon atmosphere followed by refluxing for 18 hours-the solvent was evaporated under reduced pressure. The residue was suspended in DMF and stirred for 6 hours at 80 °C. The solvent was evaporated under reduced pressure. The residue was suspended in water and extracted with methylene chloride. The residue of the organic layer was purified by rotatory chromatography on silica gel using methylene chloride/ammonia atmosphere as eluent. The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C16H20CIN30 x C2H204 (395.8) mp: 152-154 °C CHN analysis calculated: C 54.6 H 5.60 N 10.6 found: C 54.3 H 5.60 N 10.5 Example 131 2-((2-Piperidinoethyl)((2-Piperidinoethyl) amino) benzothiazole 2-Chlorobenzothiazole (10 mmol), 10 mmol of 2-piperidinoethanamine, and 30 mmol of triethylamine in 50 mi of dry ethanol were refluxed for 6 hours. The product was crystallized with hydrochloric acid in 2-propanol and recrystallized in methanol.

SF: C14H19N3S x 2 HCI x 0.25 H20 (338.8) Yield: 95% mp: 225 °C CHN analysis calculated: C 49.6 H 6.40 N 12.4 found: C 49.5 H 6.49 N 12.3 Example 132 5-Piperidinopentylamine 5-Chlorovaleronitrile (10 mmol), 20 mmol of piperidine, 20 mmol of potassium carbonate and a catalytic amount of potassium iodide in 50 ml of ethanol were refluxed for 6 hours. The solvent was removed under reduced pressure, the residue suspended in water and extracted with methylene chloride. The organic layer was purified by column chromatography on silica gel using methylene chloride/methanol/aqueous ammonia (90/10/1) as eluent (Yield: 59%). The

product was added dropwise to a suspension of 25 mmol of lithium aluminium hydride in 25 ml of dry tetrahydrofurane at 0 °C. After refluxing for 1 hour 10 ml of a saturated solution of sodium/potassium tartrate in water was added dropwise. The residue was filtered off and the filtrate purified by column chromatography on silica gel using methylene chloride/methanol/aqueous ammonia (90/10/1) as eluent. The residue was crystallized with hydrochloric acid from diethyl ether/2-propanol.

SF: Cl oH22N2 x 2 HCI x 0.5 H20 (252.2) mp: 187 °C CHN analysis calculated: C 47.6 H 9.99 N 11.1 found: C 47.8 H 9.70 N 11.0 Example 133 5-Nitro-2- (6-piperidinohexyl) pyridine 6-Aminohexanol (15 mmol), 15 mmol of 2-chloro-5-nitropyridine, 5 ml of triethyl- amine, and a catalytic amount of potassium iodide were refluxed in 30 ml of ethanol for 12 hours. The solvent was evaporated, and the residue was purified by column chromatography on silica gel (eluent: methylene chloride/methanol (95/5), ammonia atmosphere). The solvent was removed under reduced pressure (Yield: 66%). The product (5 mmol) was dissolved in tetrahydrofurane, stirred at 0 °C and 10 mmol of thionyl chloride was added dropwise. After 1 hour at ambient temperature the mixture was warmed to 60 °C for 2 hours. The solvent and the excess of thionyl chloride were evaporated. The oily residue was crystallized with hydrochloric acid from diethyl ether/ethanol (Yield: 95%).

The product (5 mmol), 10 mmol of piperidine, 15 mmol of potassium carbonate, and a catalytic amount of potassium iodide were refluxed in 30 ml of ethanol for 12 hours. The solvent was evaporated and the residue purified by column chromatography (eluent: methylene chloride/methanol (95/5), ammonia atmosphere). The solvent was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C16H26N402 x C2H204 (396.4) mp: 118.6-119 ; 7 °C CHN analysis calculated: C 54.5 H 7.12 N 14.1 found: C 54.4 H 7.18 N 14.2 Example 134 3-Nitro-2- (6-piperidinohexylamino) pyridine 6-Aminohexanol (15 mmol), 15 mmol of 2-chloro-3-nitropyridine, 5 ml of triethylamine and a catalytic amount of potassium iodide were refluxed in 30 ml of ethanol for 12 hours. The solvent was evaporated and the residue was purified by column chromatography on silica gel (eluent: methylene chloride/methanol (98/2), ammonia atmosphere). The solvent was removed under reduced pressure (Yield: 55%). The product (5 mmol) was dissolved in tetrahydrofurane, stirred at 0 °C and 10 mmol of thionyl chloride was added dropwise. After 1 hour at ambient temperature the mixture was warmed to 60 °C for 2 hours. The solvent and the excess of thionyl chloride were evaporated.

The oily residue was crystallized with hydrochloric acid from diethyl ether/ethanol (Yield: 95%). The product (5 mmol), 10 mmol of piperidine, 15 mmol of potassium carbonate, and a catalytic amount of potassium iodide were refluxed in 30 ml of ethanol for 12 hours. The solvent was evaporated and the residue purified by column chromatography (eluent: methylene chloride/methanol (95/5), ammonia atmosphere). The solvent was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethylether/ethanol SF: C16H26N402 x C2H204 (396.4) mp: 130.3-130.7 °C CHN analysis calculated: C 54.5 H 7.12 N 14.1 found: C 54.3 H 7.14 N 13.9

Example 135 2- (6-Piperidinohexylamino) pyrimidine 6-Aminohexanol (15 mmol), 15 mmol of 2-chloropyrimidine, 5 ml of triethylamine, and a catalytic amount of potassium iodide were refluxed in 30 ml of ethanol for 12 hours. The solvent was evaporated, and the residue was purified by column chromatography on silica gel (eluent: methylene chloride/methanol (98/2), ammonia atmosphere). The solvent was removed under reduced pressure (Yield: 40%). The product (5 mmol) was dissolved in tetrahydrofurane, stirred at 0 °C and 10 mmol of thionyl chloride was added dropwise. After 1 hour at ambient temperature the mixture was warmed to 60 °C for 2 hours. The solvent and the excess of thionyl chloride were evaporated.

The oily residue was crystallized with hydrochloric acid from diethyl ether/ethanol (Yield: 95%). The product (5 mmol), 10 mmol of piperidine, 15 mmol of potassium carbonate, and a catalytic amount of potassium iodide were refluxed in 30 mi of ethanol for 12 hours. The solvent was evaporated and the residue purified by column chromatography (eluent: methylene chloride/methanol (95/5), ammonia atmosphere). The solvent was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethylether/ethanol.

SF: C15H26N4 x C2H204 (352.4) mp: 150.3-150.9 °C CHN analysis calculated: C 57.9 H 8.00 N 15.9 found: C 58.0 H 8.14 N 15.8 Example 136 N- (6-Phenylhexyl) piperidine 6-Phenylhexanol (5 mmol) was stirred at 0 °C, and thionyl chloride (10 mmol) was added dropwise. After 1 hour at ambient temp. the mixture was warmed to 60 °C for 2 hours. The excess of thionyl chloride was evaporated. The oily residue was purified by column chromatography on silica gel (eluent: methylene

chloride) (Yield: 98%). The product was dissolved in 50 ml of ethanol, and 10 mmol of K2CO3,1 mmol of KI, and 10 mmol of piperidine were added. After refluxing for 6 hours the solvent was evaporated under reduced pressure. The residue was suspended in water and extracted with methylene chloride. The organic extracts were combined, dried with MgS04 and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol/aqueous ammonia (90/10/1)). The residue was crystallized with oxalic acid from diethyl ether/methanol.

SF: C17H27N x C2H204 (335.5) mp: 152 °C CHN analysis calculated: C 68.0 H 8.71 N 4.18 found: C 68.0 H 8.67 N 4.05 Example 137 u.- (4-Acetylphenoxy)-cc'- (4-methylpiperidino) p-xylol a, a'-Dibromo-para-xylene (30 mmol), 4-hydroxyacetophenone (20 mmol), and potassium carbonate (50 mmol) were refluxed in 50 ml of acetone for 12 hours.

The solvent was removed under reduced pressure and the residue purified by column chromatography on silica gel (eluent: methylene chloride/petroleum ether/methanol (60/38/2)).

The product (2 mmol), 4-methylpiperidine (6 mmol), potassium carbonate (8 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. The solvent was evaporated. The residue was washed with water and extracted with ethyl acetate. The solvent was removed under reduced pressure.

The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C22H27NO2 x C2H204 x 0.75 H20 (440.7) mp: 145 °C CHN analysis calculated : C 65.41 H 6.92 N 3.18 found: C 65.12 H 6.69 N 3.17

Example 138 a- (4-Acetylphenoxy)-a'- (3, 5-cis-dimethylpiperidino) p-xylol Following the procedure described in example 137, the ether obtained (2 mmol), 3,5-dimethylpiperidine (mixture of cis and trans, 8 mmol), potassium carbonate (8 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel and thereby separated from the corresponding diastereomer (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C23H29NO2 x C2H204 x 0.5 H20 (450.2) mp: 148 °C CHN analysis calculated: C 66.69 H 7.11 N 3.11 found: C 66.95 H 7.30 N 3.20 Example 139 a- (4-Acetylphenoxy)-a'- (3, 5-trans-dimethylpiperidino) p-xylol Following the procedure described in example 137, the ether obtained (2 mmol), 3,5-dimethylpiperidine (mixture of cis and trans, 8 mmol), potassium carbonate (8 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel and thereby separated from the corresponding diastereomer (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C23H29NO2 x C2H204 x 0.5 H20 (450.2) mp: 141 °C CHN analysis calculated: C 66.69 H 7.11 N 3.11 found: C 66.94 H 7.17 N 3.19

Example 140 a- (4-Acetylphenoxy)-a'- (2-methylpyrrolidino) p-xylol Following the procedure described in example 137, the ether obtained (2 mmol), 2-methylpyrrolidine (6 mmol), potassium carbonate (8 mmol) and catalytic amounts of potassium iodide were refluxed-in acetone for 12 hours.

The solvent was evaporated. The residue was washed with water and extracted with ethyl acetate. The solvent was removed under reduced pressure. The product was crystallized with hydrochloric acid from diethyl ether/ethanol.

Recrystallization resulted in the pure product.

SF: C21H25NO2 x HCI x 0.25 H20 (361.1) mp: 324 °C CHN analysis calculated: C 69.26 H 7.00 N 3.85 found: C 69.52 H 7.12 N 3.85 Example 141 a-phenoxy)-a'-piperid ino-p-xylol A solution containing 1,4-benzenedimethanol (30 mmol), sodium hydride (25 mmol), catalytic amounts of tetrabutylammonium iodide, and 15-crown-5 (0.5 mmol) in tetrahyrofuran was stirred for 10 minutes. Cyclopropyl-4- fluorophenylketone (20 mmol) was added dropwise, and the solution was refluxed for 24 hours. The solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: methylene chloride/methanol (98/2)).

At 0 °C the product (4 mmol) was added to thionyl chloride (8 mmol). The temperature was raised to 70°C for three hours. Excess thionyl chloride was evaporated and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol (95/5)). The product (2 mmol), piperidine (4 mmol), catalytic amounts of potassium iodide, and potassium carbonate (6 mmol) dissolved in acetone were refluxed for 12 hours. The solvent was evaporated. The crude product was washed with water and extracted with ethyl

acetate. The organic layer was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C23H27NO2 x C2H204 (439.2) mp: 194 °C CHN analysis calculated: C 68.33 H 6.61 N 3.19 found: C 68.38 H 6.78 N 3.29 Example 142 a- (4-Cyclopropylcarbonylphenoxy)-a'- (4-methylpiperidino) p-xylol Following the procedure described in example 141, the chloride obtained (2 mmol), 4-methylpiperidine (4 mmol), potassium carbonate (6 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours.

The solvent was evaporated. The crude product was washed with water and extracted with ethyl acetate. The organic layer was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C24H29NO2 x C2H204 x 0.75 H20 (466. 7) mp: 169-170 °C CHN analysis calculated: C 66.91 H 6.96 N 2.99 found: C 66.85 H 6.83 N 2.96 Example 143 a- (4-Cyclopropylcarbonylphenoxy)-a'-pyrrolidino-p-xylol Following the procedure described in example 141, the chloride obtained (2 mmol), pyrrolidine (4 mmol), catalytic amounts of potassium iodide, and potassium carbonate (6 mmol) were refluxed in acetone for 12 hours. The solvent was evaporated. The crude product was washed with water and extracted with ethyl acetate. The organic layer was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C22H25NO2 x C2H204 x 0.5 H20 (434.2) mp: 179 °C

CHN analysis calculated: C 66.38 H 6.45 N 3.22 found: C 66.61 H 6.45 N 3.22 Example 144 3-Phenylpropyl 3- (4-methylpiperidino) propyl ether 3-Phenylpropylmesilate (18 mmol), catalytic amounts of tetrabutylammonium iodide, and 15-crown-5 (0.5 mmol) were added under argon atmosphere to a solution of 1,3-propanediol (25 mmol) and sodium hydride (25 mmol) in tetrahydrofuran which had been stirred over night. The mixture was refluxed for 24 hours. The solvent was evaporated and the oily residue purified by column chromatography (eluent: methylene chloride/methanol (95/5)). At 0 °C the product (8 mmol) was added to thionyl chloride (16 mmol). The temperature was raised to 70 °C for three hours. Excess thionyl chloride was evaporated.

The residue was purified by column chromatography on silica gel (eluent: methylene chloride), and the solvent was evaporated under reduced pressure.

The chloride obtained (5 mmol), 4-methyipiperidine (10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)) and crystallized with oxalic acid from diethyl ether/ethanol.

SF: C18H29NO x C2H204 (365.4) mp: 119-120 °C CHN analysis calculated: C 65.73 H 8.55 N 3.83 found: C 65.44 H 8.83 N 3.79 Example 145 3-Phenylpropyl 3- (3, 5-cis-dimethylpiperidino) propyl ether Following the procedure described in example 144 the chloride obtained (5 mmol), 3,5-dimethylpiperidine (mixture of cis and trans, 10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved

in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel and thereby separated from the corresponding diastereomer (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: Cl9H3, NO X C2H204 (379.5) mp: 107-108 °C CHN analysis calculated: C 66.46 H 8.76 N 3.69 found: C 66.42 H 8.54 N 3.67 Example 146 3-Phenylpropyl 3- (3, 5-trans-dimethylpiperidino) propyl ether Following the procedure described in example 143 the chloride obtained (5 mmol), 3,5-dimethylpiperidine (mixture of cis and trans, 10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel and thereby separated from the corresponding diastereomer (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: CgH3NO x C2H204 379.5) mp: 123.5 °C CHN analysis calculated: C 66.46 H 8.76 N 3.69 found: C 66.35 H 8.72 N 3.75 Example 147 3-Phenylpropyl 3- (3-methylpiperidino) propyl ether Following the procedure described in example 143 the chloride obtained (5 mmol), 3-methylpiperidine (10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel (eluent: diethyl ether/petroleum ether/triethylamine

(66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C18H2gNO x C2H204 (365.4) mp: 123 °C CHN analysis calculated: C 65.73 H 8.55 N 3.83 found: C 65.39 H 8.72 N 3.79 Example 148 3-Phenylpropyl 3-pyrrolidinopropyl ether Following the procedure described in example 143 the chloride obtained (5 mmol), pyrrolidine (10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C15H25N0 x C2H204 (337.4) mp: 105.5 °C CHN analysis calculated: C 64.07 H 8.07 N 4.15 found: C 63.85 H 7.84 N 4.13 Example 149 3- (4-Chlorophenyl) propyl 3- (4-methylpiperidino) propyl ether 3- (4-Chlorophenyl) propylmesilate (18 mmol), catalytic amounts of tetrabutyl- ammonium iodide, and 15-crown-5 (0.5 mmol) were added under argon atmosphere to a solution of 1,3-propanediol (25 mmol) and sodium hydride (25 mmol) in tetrahydrofuran which had been stirred over night. The mixture was refluxed for 24 hours. The solvent was evaporated and the oily residue purified by column chromatography (eluent: methylene chloride/methanol (95/5)). At 0 °C the product (8 mmol) was added to thionyl chloride (16 mmol). The temperature was raised to 70 °C for three hours. Excess thionyl chloride was evaporated. The residue was purified by column chromatography on silica gel

(eluent: methylene chloride) and the solvent was evaporated under reduced pressure. The chloride obtained (5 mmol), 4-methylpiperidine (10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)) and crystallized with oxalic acid from diethyl ether/ethanol.

SF: C18H28NOCI x C2H204 (399.9) mp: 116 °C CHN analysis calculated: C 60.08 H 7.56 N 3.50 found: C 59.78 H 7.33 N 3.49 Example 150 3- (4-Chlorophenyl) propyl 3- (3, 5-cis-dimethylpiperidino) propyl ether Following the procedure described in example 149 the chloride obtained (5 mmol), 3,5-dimethylpiperidine (mixture of cis and trans, 10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel and thereby separated from the corresponding diastereomer (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C19H3oNOCI x C2H204 x 0.25 H20 (418.5) mp: 117.5 °C CHN analysis calculated: C 66.46 H 8.76 N 3.69 found: C 66.42 H 8.54 N 3.67 Example 151 3- (4-Chlorophenyl) propyl 3- (3, 5-trans-dimethylpiperidino) propyl ether Following the procedure described in example 149 the chloride obtained (5 mmol), 3,5-dimethylpiperidine (mixture of cis and trans, 10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved

in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel and thereby separated from the corresponding diastereomer (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C19H30NOCI x C2H204 (413.4) mp: 150 °C CHN analysis calculated: C 60.93 H 7.79 N 3.38 found: C 60.95 H 7.39 N 3.34 Example152 4- (6-Piperidinohexylamino) quinoline 6-Aminohexanol (15 mmol), 4-chloroquinoline (15 mmol), 5 mi of triethylamine and catalytic amounts of potassium iodide were refluxed in ethanol for 12 hours. The solvent was evaporated and the residue was purified by flash chromatography on silica gel (eluent: methylene chloride/methanol (98/2), ammonia atmosphere). The solvent was removed under reduced pressure. At 0 °C the product (5 mmol) was added to thionyl chloride (10 mmol). The temperature was raised to 70 °C for three hours. Excess thionyl chloride was evaporated. The residue was recrystallized from diethyl ether/ethanol. The product (5 mmol), piperidine (10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours.

The solvent was evaporated and the residue purified by flash chromatography (eluent: ethyl acetate/methanol/triethylamine (95/5/2)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C2oH29N3 x 2 C2H204 x 0.5 H20 (500.6) mp: 167.3-168.1 °C CHN analysis calculated: C 57.6 H 6.85 N 8.39 found: C 57.7 H 6.55 N 8.42

Example 153 2-Methyl 4- (3-piperidinopropylamino) quinoline Synthesis and purification were performed according to the procedure stated in example 152 using reagents 3-aminopropanol (15 mmol), 4-chloro-2- methylquinoline (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The final product was purified by flash chromatography (eluent: ethyl acetate/triethylamine (95/5)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C18H25N3 x 2 C2H204 (463.5) mp: 185.5-186.3 °C CHN analysis calculated: C 57.0 H 6.31 N 9.07 found: C 56.9 H 6.19 N 8.98 Example 154 2-Methyl 4- (6-piperidinohexylamino) quinoline Synthesis and purification were performed according to the procedure stated in example 152 using reagents 6-aminohexanol (15 mmol), 4-chloro-2- methylquinoline (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The final product was purified by column chromatography (eluent: ethyl acetate/triethylamine (95/5)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C21H31N3 x 2 C2H204 x 0.75 H20 (519.1) mp: 193.6-194.0 °C CHN analysis calculated: C 57.9 H 7.09 N 8.10 found: C 57.8 H 7.08 N 7.85

Example 155 7-Chloro-4- (3-piperidinopropylamino) quinoline Synthesis and purification were performed according to the procedure stated in example 152 using reagents 3-aminohexanol (15 mmol), 4,7-dichloroquinoline (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The final product was purified by column chromatography (eluent: ethyl acetate/triethylamine (90/10)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol SF: C17H22CIN3 x 2 C2H204 (483.9) mp: 202.9-204.0 °C CHN analysis calculated: C 52.1 H 5.42 N 8.68 found: C 51.9 H 5.25 N 8.65 Example 156 7-Chloro-4- (4-piperidinobutylamino) quinoline Synthesis and purification were performed according to the procedure stated in example 152 using reagents 3-aminobutanol (15 mmol), 4,7-dichloroquinoline (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The final product was purified by column chromatography (eluent: ethyl acetate/triethylamine (90/10)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C18H24CIN3 x 2 C2H204 x 0.5 H20 (506.9) mp: 162.6-163.5 °C CHN analysis calculated: C 52.1 H 5.76 N 8.28 found: C 52.2 H 5.64 N 8.15

Example 157 7-Chloro-4- (8-piperidinooctylamino) quinoline 1,8-Dibromooctane (30 mmol), potassium phthalimide (15 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 3 days. The solvent was evaporated, and the residue was purified by flash chromatography on silica gel (eluent: methylene chloride/petroleum ether (60/40)). The solvent was removed under reduced pressure. The product (12,5 mmol), piperidine (50 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. Solvent and piperidine were evaporated. The residue was treated with hydrochloric acid (2N), with potassium carbonate solution and was then extracted with methylene chloride. The solvent was removed under reduced pressure, and the residue was refluxed in hydrochloric acid (6N) for 12 hours.

The solution was neutralized with potassium carbonate solution and extracted with methylene chloride. The organic layer was evaporated and the product was purified by flash chromatography on silica gel (eluent: methylene chloride/triethylamine/methanol (90/10/2)). The product (5 mmol), 4,7- dichloroquinoline (5 mmol), and catalytic amounts of potassium iodide were melted with 10 g of phenole for 12 hours. The residue was purified by flash chromatography (eluent: ethyl acetate/triethylamine (95/5)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C22H32CIN3 x 2 C2H204 (554.0) mp: 150.7-150.9 °C CHN analysis calculated: C 56.4 H 6.55 N 7.58 found: C 56.2 H 6.48 N 7.42 Example 158 7-Chloro-4- (10-piperidinodecylamino) quinoline Synthesis and purification were performed according to the procedure described in example 157 using reagents 1,10-dibromodecane (30 mmol), potassium phthalimide (15 mmol), and catalytic amounts of potassium iodide in

the first step. The final product was purified by column chromatography (eluent: ethyl acetate/triethylamine 95/5). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C24H36CIN3 x 2 C2H204 (582.1) mp: 151.2-151.5 °C CHN analysis calculated: C 57.8 H 6.93 N 7.22 found: C 57.4 H 6-. 81 N 7.07 Example 159 7-Chloro-4- (12-piperidinododecylamino) quinoline Synthesis and purification were performed according to the procedure described in example 157 using regents 1,12-dibromododecane (30 mmol), potassium phthalimide (15 mmol), and catalytic amounts of potassium iodide in the first step. The residue was purified by flash chromatography (eluent: ethyl acetate/triethylamine (95/5)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C26H40CIN3 x 2 C2H204 (610.2) mp: 141.6-142.9°C CHN analysis calculated: C 59.1 H 7.27 N 6.89 found: C 58.7 H 7.30 N 6.78 Example 160 7-Chloro-4- (4- (3-piperidinopropoxy) phenylamino) quinoline 4-Hydroxyaniline (11 mmol), 4,7-dichloroquinoline (10 mmol), 1 ml of 2N hydrochloric acid, and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. The product was filtered. The product (5 mmol), 3- piperidinopropylchloride hydrochloride (5 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 22 hours. The product was filtered and purified by flash chromatography (eluent: methylene chloride/petroleum ether/triethyiamine (95/25/5)). The

solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C23H26CIN30 x 2 C2H204 x 0.25 H20 (580. 5) mp: 189.8-190.3 °C CHN analysis calculated: C 55.9 H 5.29 N 7.23 found: C 55.7 H 5.43 N 7.14 Example 161 7-Chloro-4- (2- (4- (3-piperidinopropoxy) phenyl) ethylamino) quinoline Tyramine (10 mmol), 4,7-dichloroquinoline, and catalytic amounts of potassium iodide were melted in 10 g of phenol at 150 °C for 12 hours. The residue was crystallized with hydrochloric acid from ethyl acetate/water. The product (5 mmol), 3-piperidinopropylchloride hydrochloride (5 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were refluxed in N, N- dimethylformamide for 22 hours. The solvent was evaporated and the residue purified by flash chromatography (eluent: ethyl acetate/petroleum ether/triethylamine (95/50/5)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C25H30CIN30 x 2 C2H204 x H20 (622.1) mp: 149.8-150.2 °C CHN analysis calculated: C 56.0 H 5.83 N 6.75 found: C 55.7 H 5.77 N 6.46 Example 162 4- (6-Piperidinohexanoyl) phenyl 3-piperidinopropyl ether 3-Phenoxypropylbromide (10 mmol), piperidine (20 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. The solvent was evaporated. The residue was treated with ethyl acetate. The solvent was removed under reduced pressure, and the product was crystallized with hydrochloric acid from isopropanol/diethyl ether. The product (5 mmol) was added to a solution of 6-bromohexanoylchloride (7.5 mmol) and

aluminiumtrichloride (22.5 mmol) in 10 ml of nitrobenzol. The mixture was stirred at room temperature for 3 days. Ethyl acetate was added, and the mixture was extracted with hydrochloric acid (6N). The solution was neutralized with potassium carbonate solution and extracted with methylene chloride. The solvent was removed under reduced pressure. The product (2.5 mmol), piperidine (5 mmol), potassium carbonate (7.5 mmol), and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. The solvent was evaporated, and the residue was purified by flash chromatography (eluent: methylene chloride/petroleum ether/methanol (96/3/3)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C25H4oN202 x 2 C2H204 (580.7) mp: 149.1-149.5 °C CHN analysis calculated: C 60.0 H 7.64 N 4.82 found: C 59.9 H 7.59 N 4.81 Example 163 5-Nitro-2- (5-piperidinopentylamino) pyridine Synthesis and purification were performed according to the procedure stated in example 152 using reagents 5-aminopentanol (15 mmol), 2-chloro-5- nitropyridine (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The final product was purified by column chromatography (eluent: ethyl acetate/triethylamine (90/10)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C15H24N402 x C2H204 (382.4) mp: 95.7-96.0 °C CHN analysis calculated: C 53.4 H 6.85 N 14.65 found: C 53.6 H 7.00 N 14.55

Example 164 3-Nitro-2- (6-piperidinopentylamino) pyridine Synthesis and purification were performed according to the procedure stated in example 152 using reagents 5-aminopentanol (15 mmol), 2-chloro-3- nitropyridine (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step, The final product was purified by column chromatography (eluent: ethyl acetate/triethylamine (95/5), ammonia atmosphere). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C15H24N402 x C2H204 x 0.25 H20 (386.9) mp: 148.5-149.2 °C CHN analysis calculated: C 52.8 H 6.90 N 14.48 found: C 52.8 H 6.80 N 14.51 Example 165 5-Amino-2- (6-piperidinopentylamino) pyridine Synthesis and purification were performed according to the procedure stated in example 152 using reagents 5-aminopentanol (15 mmol), 2-chloro-5- nitropyridine (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The product was purified by column chromatography on silica gel (eluent: methylene chloride/methanol (95/5), ammonia atmosphere) and dissolved in 20 mi of tetrahydrofuran. 100 mg of palladium/active charcoal (10%) was added, and the mixture was hydrogenated at 1 bar H2 for 12 hours. The solvent was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C15H26N4 x 2 C2H204 (442.5) mp: 85.7-87.3 °C CHN analysis calculated: C 51.6 H 6.83 N 12.66 found: C 51.4 H 6.81 N 12.83

Example 166 2- (6-Piperidinohexylamino) quinoline Synthesis and purification were performed according to the procedure stated in example 152 using reagents 6-aminohexanol (15 mmol), 2-chloroquinolin (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The final product was purified by flash chromatography (eluent: ethyl acetate/triethylamine (95/5)). The solvent was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C2oH29N3X 2 C2H204 x 0.75 H20 (505. 1) mp: 90.7-91.5 °C CHN analysis calculated: C 57.1 H 6.88 N 8.32 found: C 57.1 H 6.54 N 8.17 Example 167 N- (4-Chlorobenzyl)-NV-cyclohexyl-3-piperidinopropyl isothiourea Cyclohexylamine (10 mmol) was added dropwise to 4-chlorobenzylisothio- cyanate (10 mmol) dissolved in 20 ml of dry ether. The solution was stirred for 2 hours at room temperature. The precipitated product was filtered off and crystallized from ethyl acetate. 3-Piperidinopropyl chloride hydrochloride (3 mmol), the product (3 mmol), and ca-talytic amounts of potassium iodide were refluxed in ethanol for 6 days. Sub-sequently, ethanol was evaporated, and the residue was purified by column chromato-graphy (eluent: methylene chloride/methanol (95/5)). After evaporation of the solvent the product was crystallized with hydrochloric acid from diethyl ether/ethanol.

SF: C22H34CIN3S x 2 HCI x H20 (499.0) mp: 103.0-107.0 °C CHN analysis calculated: C 53.0 H 7.68 N 8.42 found: C 52.6 H 7.88 N 8.24

Example 168 2- (6-Piperidinohexylamino) benzothiazole Synthesis and purification were performed according to the procedure stated in example 152 using reagents 6-aminohexanol (15 mmol), 2-chlorobenzothiazole (15 mmol), 5 ml of triethylamine, and catalytic amounts of potassium iodide in the first step. The final product was purified by flash chromatography (eluent: methylene chloride/methanol (95/5), ammonia atmosphere). The solvent was removed under reduced pressure, and the residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C18H27N3S x 1.9 C2H204 (488.6) mp: 98.5-101.8 °C CHN analysis calculated: C 53.6 H 6.35 N 8.60 found: C 54.0 H 6.43 N 8.33 Example 169 10-Piperidinodecylamine The synthesis was performed according to the procedure described in example 157 using reagents 1,10-dibromodecane (30 mmol), potassium phthalimide (15 mmol), and catalytic amounts of potassium iodide in the first step. The product (12.5 mmol), piperidine (50 mmol) and catalytic amounts of potassium iodide were refluxed in acetone for 12 hours. Solvent and piperidine were evaporated.

The residue was treated with hydrochloric acid (2N), with potassium carbonate solution and then extracted with methylene chloride. The solvent was removed under reduced pressure, and the residue was refluxed in hydrochloric acid (6N) for 12 hours. The solution was neutralized with potassium carbonate solution and extracted with methylene chloride. The organic layer was evaporated, and the final product purified by flash chromatography (eluent: methylene chloride/triethylamine/methanol (90/10/2)). The solvent was removed under reduced pressure. The residue was crystallized with oxalic acid from diethyl ether/ethanol.

SF: Ci5Hs2N2 x 2 C2H204 x 0.75 H20 (434.0) mp: 116.1-117.2 °C

CHN analysis calculated: C 52.6 H 8.71 N 6.45 found: C 52.5 H 8.70 N 6.35 Example 170 3-Phenylpropyl 3-(N, N-diethylamino) propyl(N, N-diethylamino) propyl ether Following the procedure described in example 144 the chloride obtained (5mmol), diethylamine (10 mmol), potassium carbonate (15 mmol), and catalytic amounts of potassium iodide were dissolved in acetone and refluxed for 12 hours. After evaporating the solvent the product was purified by column chromatography on silica gel (eluent: diethyl ether/petroleum ether/triethylamine (66/33/1)). The product was crystallized with oxalic acid from diethyl ether/ethanol.

SF: C16H27NO x C2H204 (340.3) mp: 80 °C CHN analysis calculated: C 63.69 H 8.61 N 4.13 found: C 63.52 H 8.40 N 4.06 Pharmacological stud Interaction of compounds with the H3 receptor are evidenced in vitro by the measurement of the release of neosynthesized tritiated histamine from rat cerebral cortex synaptosomes preincubated with tritiated histidine (Garbarg et al., J. Pharmacol. Exp. Ther., 1992,263: 304-310). The H3 potency of agonists is measured by the inhibition of tritiated histamine release and that of antagonists by the progressive reversal of release inhibition by the selective H3 agonist (R) a-methylhistamine (Arrang et al., Nature, 1987,327: 117-123).

Interaction of compounds with the H3 receptor are evidenced in vitro on guinea-pig ileum by the procedure described by Ligneau et al., J.

Pharmacol. Exp. Ther. 271,452-459 (1994).

Briefly, longitudinal muscle strips from guinea-pig small intestine were dissected out and incubated in a gassed 02/C02 (95 %/5 %) modified Krebs-Ringer's bicarbonate medium at +37°C in presence of 1 uM mepyramine

to block the H1 receptor. After equilibration, contractile activity under stimulation (rectangular pulses of 15 V, 0,5 msec, 0,1 Hz) was recorded.

Concentration-response curves of the effect of (R) a- Methylhistamine alone or together with the antagonist were established.

The effects of agonists and antagonists were estimated in vivo by the measurement of the tele-methylhistamine level variations in the brain of mice (Garbarg et al., J. Neurochem., 1989,53: 1724-1730). At various time after p. o. administration of the compounds, the effect of agonists and antagonists are evidenced by the decrease and increase respectively in telemethylhistamine level induced.

The changes are compared to those induced by reference compounds given in high dosage and this allows the calculation of the ED50 value for each compound which correspond to the dose responsible for an half maximal effect.

The results are listed here-below or reported in the following tables II and III: -example mg/kg -example 74 1- 3- (4-buyrylphenoxy) propyl piperidine, ED50=0.21 mg/kg -example 76 : 1- [3- (4-cyclopropa neca rbo nyl phe noxy) propyl pipe rid i ne, ED50=0.18 mg/kg -example 88 1- 3- (4-propionylphenoxy) propyl-3-methylpiperidine, ED5o=0.14 mg/kg -example 101: 1- 3- (4-cyclopropane carbonyl phenoxy) propyl-trans-3,5 dimethylpiperidine, ED50=0. 17 mg/kg TABLE II: ExXnRFF? Ki (nM) ED50 No. (ns=1) (mg/kg/p. o.) 1805-(CH2)4-P-N0239111i 4303Et.Etp-CN9528050 4603Et.Etp-CHsCO207(L44 50 O 5 -(CH2)4-p-CH3CH(OH) 28 7 1.0 5604Et,Etp-CN62151 5903-(CH2)5-p-CN112(L20 6003-(CH2)e-p-CN8.(CH2)e-p-CN8. 7 2. 1 0. 64 63 O 3 Et, Etp-CH3CH(OH) 60 18 0.45 64 O 3 Et, Etp-CH3C=N(OH) 2.7 0. 9cl8 6603-(3-Me)-(CH2)5-p-CHaCO3.(3-Me)-(CH2)5-p-CHaCO3. 7 0. 5 0. 3 6803-(4-Me)-(CH2)5-p-CHgCO4.(4-Me)-(CH2)5-p-CHgCO4. 6 2. 0 0. 5 69 O 3-(CH2) s-p-C2H5CO 4.(CH2) s-p-C2H5CO 4. 7 0. 8 0. 6

TABLE lil: Example H3-receptor antagonist activity No. pA2 (guinea-pig ileum) 06*3 1246.4 1307.2 1316.6 136 6.5 All the above compounds were find to be H3-antagonists.

Comparative data concerning the activity of imidazole derivatives and of the non-imidazole analogues according to the invention, are reported below in Table IV: TABLE IV: Imidazole derivative Non-imidazole analogue according to j the invention ex 59: (C H2) 3-0- O C-N fi O- (CH2) 3-N' HN N..,//N Ki=12nM Ki=11 nM ED50 = 0.54 mg/kg ED50 = 0,20 mg/kg ex 43: C H2C H3 NC O- (C Hz) 3-N \CH2CH3 Ki = 95 nM ED50 = 0.50 mg/kg ex 58: NC-0-0- (CH2) 3-N :) Ki = 20 nM ex 60: NCC O- (C H2) 3- Ki = 9 nM ex 116: (C H2) 3-0- (C H2) 3 H N O Ki = 17 nM Ki 15 nM